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Chapter 1                                                                                                    General Introduction 
A brief history of antimicrobial resistance 
 
Alexander Fleming discovered the first antimicrobial agent, penicillin (a β-lactam), in 
1928 in the mold Penicillium notatum. Penicillin was initially found to be active against 
staphylococcal strains, which at that time were a major source of infectious diseases. Indeed, 
the mortality rate of individuals with severe Staphylococcus aureus infection in the early 
1940’s was about 80% [1]. The discovery of penicillin gave clinicians an effective means to 
combat fatal microbial infections for the first time. Since that time, many different types of 
antimicrobial agents have been discovered, including aminoglycosides, macrolides and 
cephalosporins to name but a few. Further, current advances in biochemistry and engineering 
now mean that novel antimicrobial agents can be produced by 1) synthetically altering the 
structure of known antimicrobial agents, or by 2) high throughput screening strategies. 
However, even as new antibiotics are being discovered, bacteria are acquiring mechanisms to 
neutralise their effect. 
 Even at the time that penicillin was being commercially made available in 1945, 
reports of enzymes possessing β-lactamase activity had already been published by Abraham 
and Chain [2], and we now know that antimicrobial resistance mechanisms have been around 
for many millions of years, even before the large-scale use of antibiotic therapy in human 
populations began. For example, ampicillin (a derivative of penicillin) resistant bacteria 
estimated to be approximately 2000 years old have been recovered from glacial samples 
obtained from the Canadian Arctic Archipelago, while a more recent study detected TEM-
type β-lactamases from a metagenomic library of cold seep deep-sea segments estimated to 
be approximately 10,000 years old [3, 4]. In fact, it is now known that many environmental 
organisms produce antimicrobial compounds in order to limit competition for nutrients or 
chemically alternative niches in defined niches. However, in response, bacteria have evolved 
(and are continuing to evolve) mechanisms to counteract these lethal antimicrobial 
compounds, in order to protect themselves from attack. It is these mechanisms that eventually 
create problems with respect to antimicrobial resistance and human health. 
During the period after Alexander Fleming’s discovery of penicillin, academia and the 
pharmaceutical industry discovered and developed many new antimicrobial agents. However, 
after each new class of antimicrobial agent was brought to market, new resistance 
mechanisms appeared that reduced the efficacy of the new antibiotics, seriously limiting 
patient treatment options. For example, one new class of antimicrobial agents discovered 
were broad-spectrum β-lactam antibiotics, the cephalosporins. These antibiotics have an 
extended-spectrum of action against both Gram-positive and Gram-negative bacteria and 
were originally extensively used for the treatment of serious infections caused by Gram-
negative bacteria in the 1980s [5]. However, resistance to cephalosporins rapidly developed, 
creating new problems for the treatment of infectious diseases. This race between the 
introduction of new antimicrobial agents and the appearance of associated resistance 
mechanisms in microorganisms is still a major problem globally, limiting the successful 
treatment of infectious diseases by health care professionals. It is essential therefore to 
monitor the spread of existing, new, and emerging antimicrobial mechanisms in the world. 
The goal of this thesis is to provide further data that will help monitor existing antimicrobial 
resistances in order to add information to global antimicrobial resistance monitoring 
campaigns, whilst also helping to predict future trends. 
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Overview of antimicrobial resistance in microorganisms of major clinical importance 
 
Both Gram-negative and Gram-positive microorganisms are associated with 
antimicrobial resistance in the clinical (and nosocomial) environments. 
 
A. Gram-negative microorganisms:  
 
Currently, the most important clinically relevant antimicrobial resistances among 
Gram-negative bacteria are associated with the enterobacteriaceae, namely:  
1. Extended-spectrum β-lactam resistance in Klebseilla pneumoniae, Escherichia 
coli and Salmonella species.    
2.  Fluoroquinolone resistance in Salmonella species.  
 
1. β-lactam resistance in E. coli was first identified in the early 1920’s. Subsequent studies 
showed that β-lactam resistance among enterobacteriaceae was caused by the so-called TEM-
1 and SHV-1 β-lactamases, which possess an amino-acid similarity of 68%. As the discovery 
of new antibiotics quickened, a new class of antibiotics, the broad-spectrum β-lactam 
antibiotics (cephalosporins), were introduced due to their improved spectrum of activity 
against both Gram-negative and Gram-positive bacteria. Coincidently, β-lactam resistant 
strains of enterobacteriaceae were also found to be susceptible to these broad-spectrum 
antibiotics. However, soon after the introduction of the cephalosporins, resistant 
enterobacterial isolates began to emerge. The mechanism facilitating this particular resistance 
was found to be a mutation in either TEM or SHV β-lactamase genes, which lead to changes 
in the relevant β-lactamase amino-acid sequence, giving rise to different phenotypic variants 
that possessed “extended” β-lactamase activities. The fact that the new TEM and SHV type 
β-lactamases possessed  “extended” activity against β-lactam antibiotics, meant that they 
were named “extended-spectrum β-lactamases” or ESBLs [6]. The first ESBL (SHV-type) 
reported to cause the inactivation of extended spectrum β-lactam antibiotics was reported in 
Germany in 1983 [7]. However, since 1995, the rate of dissemination and reporting of ESBLs 
among different bacterial isolates has  increased rapidly in most parts of the world [8-10]. In 
fact, the increased frequency of microbial isolates carrying these mutation events most 
probably occurred via an increase in “selection pressure” after the introduction and large-
scale use of cephalosporins, which removed cephalosporin sensitive bacterial isolates from 
the clinical environment, thereby allowing cephalosporin resistant isolates to take advantage 
of the newly available niches [11-14]. 
Untill the 1990’s, ESBLs found in clinical isolates of bacteria were mostly identified 
as TEM and SHV-type enzymes. However, a different class of ESBL enzymes (called CTX-
M) began to emerge after this date. CTX-M enzymes are a new class of β-lactamase that have 
become increasingly prevalent in the clinical and nosocomial environments, affecting all 
populated continents. Indeed, since first being reported in Germany in 1990 [15], several 
different classes of CTX-M enzyme groups have emerged, with CTX-M carrying 
enterobacterial isolates having quickly become the most widespread and clinically relevant 
group of ESBL enzymes. To illustrate this point, to date, more than 50 different CTX-M 
enzymes have been reported, which are grouped into five main subgroups (CTX-M-1, CTX-
M-2, CTX-M-8, CTX-M-9 and CTX-M-25) based on their amino acid sequence similarities 
[10].  
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2. Fluoroquinolone resistance within the enterobacteriaceae (and in particular within the 
Salmonella species) is also of great economic and nosocomial importance. Fluoroquinolone 
antibiotics have been available since the 1960s, when nalidixic acid was introduced. 
Subsequent structural modifications to the quinolone molecule led to the development of 
newer compounds such as ciprofloxacin and norfloxacin, which provided better results in the 
treatment of severe (enterobacterial) infections. However, microorganisms including 
salmonellae rapidly developed resistance to these fluoroquinolone compounds, mainly due to 
binding-site mutations in the DNA gyrase (the enzyme affected by fluoroquinolones that is 
required for correct DNA synthesis) and due to active efflux system. Fluoroquinolone resista- 
ance in enterobacteriaceae is currently one of the main concerns associated with the 
developing world.  
The major aspect causing concern with respect to treatment failures in Gram-negative 
bacterial infections currently, is the in-vivo acquisition of both extended-spectrum β-
lactamase (ESBL) AND fluoroquinolone resistance genes. This characteristic has now been 
well-established in isolates from several countries [16-18], especially in countries where 
"over-the-counter" antibiotics are available without a general practitioner’s prescription. In 
India, this problem tends to be particularly associated with (non-typhoidal) salmonellae 
isolates [19].   
 
B. Gram-positive microorganisms: 
 
The most important clinically relevant antimicrobial resistances in Gram-positive 
bacteria are: 
1. Methicillin resistance in Staphylococcus aureus.  
2. Vancomycin resistance in Staphylococcus aureus and Enterococcus faecium. 
3. High-level gentamicin resistance (HLGR) in Enterococcus faecalis.  
 
1. Among Gram-positive bacteria probably the most important and worrying aspect of 
antimicrobial resistance relates to the development of resistance in Staphylococcus aureus. S. 
aureus lives as the part of the normal skin flora in the nose or on the skin, and is considered 
to be a major pathogen capable of causing relatively mild infections such as furuncles, post-
operative wound infections up to life-threatening invasive infections such as sepsis and 
endocarditis [20]. As previously mentioned, infections with S. aureus were a major cause of 
morbidity and mortality in the 1930s and 1940s, though the introduction of penicillin initially 
greatly decreased the mortality rate. However, by the 1950s penicillinase-producing hospital 
strains of S. aureus (that were coincidently also resistant to other commonly available 
antimicrobials of the time) were becoming a major problem, responsible for significant 
numbers of infections [21]. Further, though the introduction of new antimicrobial agents such 
as methicillin, and the synthetic penicillins, cloxacillin and flucloxacillin, initially helped 
combat the problems conferred by penicillinase positive S. aureus [22], resistance to these 
new antibiotics was quickly reported, with methicillin resistance being reported in S. aureus 
(MRSA) isolates from England as early as 1960 [23]. 
 
2. In subsequent decades, nosocomial infections caused by methicillin resistant S. aureus 
(MRSA) continued to increase and an intense search was made for new antibiotics that were 
effective against MRSA isolates. In this respect, vancomycin, a glycopeptide antimicrobial 
agent was introduced to combat the treatment problems associated with MRSA. Again, 
though initially successful, intermediate vancomycin resistant S. aureus isolates were soon 
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reported worldwide [23], with the fear that transfer of high-level vancomycin resistance, via 
the vanA gene complex of glycopeptide-resistant enterococci into S. aureus, would occur.  
This fear became a reality when small numbers of clinical isolates of vancomycin resistant S. 
aureus (VRSA), carrying the vanA gene complex, were reported from the USA between 2002 
and 2007. Other high-level VRSA isolates were subsequently reported in India [24-26], with 
the vanA gene complex found to be carried on transposon Tn1546 [24], a transposon reported 
in vanA positive E. faecium [27]. In fact, the treatment of nosocomial VRSA infections 
remains problematic, with the wide scale use of antibiotics effective against VRSA most 
probably leading to the acquisition of new resistance phenotypes.   
Vancomycin resistance is also a problem often associated with nosocomial infections 
by enterococci. Enterococci are prevalent in environmental, human and nosocomial settings,  
being found as commensals of the gastrointestinal tract of both humans and animals [28-31], 
and generally exhibiting only low virulence. Nevertheless, colonization followed by infection 
can readily occur in immuno-compromised patients and those with serious injuries within the 
nosocomial environment, particularly if the patient has previously been treated with 
antibiotics (for example in an attempt to treat an infection caused by an unrelated bacterial 
species). Among the genus Enterococcus, Enterococcus faecalis and Enterococcus faecium 
are the species most commonly found to be associated with human nosocomial infection [32], 
with E. faecalis accounting for approximately 75% of all enterococcal infections, and E. 
faecium accounting for the majority of the remainder [33]. These are particularly associated 
with infections such as urinary tract infections, bacteremia, intra-abdominal infections, skin 
and soft tissue infections and endocarditis [34-37]. The most important aspect of clinically 
relevant antimicrobial resistance among enterococci was the appearance of vancomycin-
resistant Enterococcus faecium in 1986, which lead to clonal expansion of this highly 
resistant and potentially difficult-to-treat pathogen across the world [38]. Further, the spread 
of nosocomial vancomycin resistant enterococci has been promoted via the extensive use of 
vancomycin within hospitals [39, 40], as well as the use of the animal growth promoter 
avoparcin in Europe. With respect to phenotype, enterococci may actually exhibit intrinsic 
(VanC) or acquired resistance to vancomycin, with 6 acquired vancomycin resistance 
genotypes reported namely vanA, vanB, vanD, vanE, vanG and vanL [41, 42] ]. Of these 
subtypes, the vanA genotype (VanA phenotype) is the most common type of acquired 
glycopeptide resistance found in vancomycin resistant enterococci within hospitals. Further, 
it is generally accepted that a single focal group of vanA-type VRE (clonal complex 17 or 
CC17) is particularly associated with nosocomial infections [43].  
 
3. High-level gentamicin resistant Enterococcus faecalis (HLGRE) were first reported in 
1979 in France [44]. Subsequently, HLGRE were described from clinical samples of 
hospitalized patients in several countries [45, 46]. High-level aminoglycoside resistance in 
enterococci is mediated by aminoglycoside-modifying enzymes (AMEs) and may be 
facilitated by several related AMEs that are expressed from a series of aminoglycoside 
resistance genes, usually carried on transposons. HLGRE is mediated by the AME aac (6’)-
Ie-aph (2”)-Ia, aph (2”)-Ib, aph (2”)-Ic, and aph (2”)-Id [47, 48]. E. faecalis is capable of 
acquiring and mobilizing transposon-related drug resistance determinants from, and into, 
other bacterial species [49, 50]. Clinically, it is particularly important to investigate the 
mechanism and prevalences of high-level aminoglycoside resistance in E. faecalis, as 
aminoglycosides are important antimicrobial agents when administered in combination with 
other cell wall-active agents such as β-lactams, this produces a synergistic bactericidal effect 
especially useful in nosocomial infections associated with bacteremia and endocarditis. 
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“Biological” mechanisms of antimicrobial resistance 
 
Generally, microorganisms exhibit two types of antimicrobial resistance mechanisms 
i.e. intrinsic and acquired resistance: intrinsic resistance is a natural phenomenon that is 
exhibited by many microorganisms and is conferred by the analogous genetic make-up of a 
particular species. Acquired resistance is the result of active or passive acquisition of genes 
that encode antimicrobial proteins, which then protect the host bacterium from the effects of 
antibiotics. In some cases of acquired resistance, the genes involved in antibiotic resistance 
arise by mutation of a regulatory gene and in others, they are acquired from bacteria co-
habitating within their environment that are already resistant to antibiotics [51].  
There are 6 “biological” mechanisms associated with intrinsic and acquired 
antimicrobial resistance (Figure 1).   
These are: a) altered target sites, b) bypass pathways, c) decreased uptake, d) active 
efflux system, e) enzymatic inactivation or modification, and f) overproduction of target [52]. 
 
a) Alteration in antibiotic target sites are usually brought about by point mutations at the 
regions of a gene necessary for antibiotic activity, resulting in lowered binding affinity 
between the antibiotic and its target. For example, point mutations in the gene encoding DNA 
gyrase can alter the binding efficiency of quinolone antibiotics, thereby reducing their 
efficacy. In addition, not only single mutations, but multiple point mutations may also occur, 
eventually leading to higher levels of resistance, as observed for the quinolone resistance-
determining region (QRDR) of DNA topoisomerase genes (gyrA, gyrB, and parC), where 
multiple mutations lead to higher minimum inhibitory concentrations (MICs) and therefore 
decreased susceptibility to quinolone antimicrobial agents [53]. 
  
b) Bypass pathways play an important role in developing antimicrobial resistance as they 
allow bacterial cells to protect themselves by the production of an alternative target (usually 
an enzyme) that is resistant to inhibition by a particular antibiotic, while still continuing to 
produce the original sensitive target. One well-known example of this particular mechanism 
is vancomycin resistance in enterococci, which are normally susceptible to vancomycin. The 
normal target of vancomycin is a cell wall precursor that contains a pentapeptide that has a 
D-alanine-D-alanine terminus to which the vancomycin binds, thereby preventing cell wall 
synthesis. When an enterococcus acquires the vanA gene cluster, it generates an alternative 
cell wall precursor ending in D-alanine-D-lactate, to which vancomycin can not bind [54]. 
 
c) A decreased uptake of antimicrobial agents across the bacterial cell membrane is usually 
caused by lowered cell permeability; in a bacterial cell, outer membrane proteins (OMPs) 
provide channels of entry for molecules to the cell membrane (including antimicrobial 
agents) based on charge, shape, and size of the entering molecule. Loss of function of one of 
these porins due to a mutation event can cause loss of function of that particular porin, 
possibly leading to antibiotic resistance [55-57]. For example, loss of the D2 porin due to 
mutation causes imipenem resistance in Pseudomonas aeruginosa [58].  
 
d) Enzymatic inactivation or modification of antimicrobial agents is a common mechanism of 
resistance that reduces or eliminates antimicrobial activity. One of the most common 
mechanisms involved in enzymatic modification of antimicrobial agents is acetylation. One 
classical example of such modification involves aminoglycoside acetyltransferase, that 
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acetylates and inactivates aminoglycosides such as gentamicin [59]. In addition, this 
mechanism is also involved in the chloramphenicol resistance [60].   
 
e) The overproduction of an antibiotic binding target protein. One example of such type of 
antimicrobial resistance is β-lactam resistance in enterococci. Enterococci can overproduce 
low-affinity penicillin-binding proteins, leading to high-level resistance to β-lactam 
antibiotics. 
 
f) The active efflux of antimicrobial agents is associated with enzymes that possess the ability 
to bind to antimicrobial agents and pump them out of the bacterial cell before they can reach 
their site of action. Examples of active efflux mediated antimicrobial resistance include, 
resistance to tetracycline and fluoroquinolones in enterobacteriaceae and high intrinsic 
resistance to penem antibiotics in Pseudomonas aeruginosa due to the composition of the 
cellular membrane and an active efflux system [61, 62]. 
 
 
 
 
f  Active efflux
 
Figure 1. Different mechanisms involved in antimicrobial resistance. (Adapted with 
permission from: Coates A, Hu Y, Bax R et al. The future challenges facing the development 
of new antimicrobial drugs. Nat Rev Drug Discov 2002; 1:895-910). 
 
Types of mobile genetic elements involved in antimicrobial resistance 
 
Several different “molecular platforms” facilitate the spread of antimicrobial 
resistance genes among microorganisms. The different platforms associated with the 
transmission of antimicrobial resistances in both Gram-negative and Gram-positive bacteria 
are described briefly below: 
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Plasmids:  
 
Plasmids are extra-chromosomal, circular, double-stranded units of DNA, that are 
transferable and capable of autonomous replication within a suitable host [63, 64]. They have 
proven to be the ideal vehicle for the dissemination of genes responsible for antimicrobial 
resistance. Plasmids usually do not contain any of the core genes needed by a bacterial cell 
for basic growth and multiplication, instead they tend to carry genes that enable the cell to 
circumvent particular unfavorable environmental conditions, for example when in the 
presence of a potentially lethal antibiotics or heavy metals. Basically, there are many types of 
plasmids, which are widespread in all bacterial populations studied, and which may generally 
be divided, into five main classes: 
a) Fertility or F-plasmids, are capable of conjugation i.e. transfer of genetic material between 
bacteria via a conjugation tube. An F-plasmid contains tra (for "transfer") genes and a 
number of other genes responsible for compatibility and replication. 
b) Resistance or R-plasmids contain genes that code for resistance to antibiotics. R-plasmids 
tend to harbour a variety of genes encoding not only resistance to a wide spectrum of 
antimicrobial agents, but also resistance to heavy metals, mutagenic agents such as ethidium 
bromide, and disinfectant agents including formaldehyde [65, 66]. Some examples of R-
plasmid mediated antimicrobial resistance include those that mediate resitance to 
cephalosporins, fluoroquinolones, glycopeptides and aminoglycosides. For instance, A/C and 
FIA plasmids harbour genes responsible for extended-spectrum β-lactam antibiotics in 
enterobacteriaceae [67], whilst, pMG252 is responsible for carrying qnr genes, which are 
involved in fluoroquinolone resistance in enterobacteriaceae [68]. Additionally, pLRM19 
carries vanB resistance genes in enterococci [69], and pRE25 harbours resistance genes 
against 12 antibiotics including aminoglycosides [70].  
c) Col-plasmids contain genes that code for bacteriocins, i.e. bacterial proteins that possess 
the capacity to kill bacteria of different species.  
d) Degradative plasmids enable the digestion of unusual aromatic substances e.g. toluene or 
salicylic acid. 
e) Virulence plasmids enable bacteria to increase their pathogenic potential. 
However, this division of plasmids into functional classes has tended to be replaced 
by a system relying on different Inc groups, involving characterization of plasmid-associated 
recombinases (Rec) and relaxases (Rel). More recent plasmid classification systems include 
factors relating to copy number (cop) and maintenance (toxin-antitoxin, or post segregational 
killing (PSK), systems) [71]. 
Figure 2. shows the typical structure of the simple resistance plasmid R100 from E. coli. 
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Plasmid 
R100
IS1
mer
sul
str
cat
IS1
IS10IS10
rep
ori T
tra
REPLICATION
FUNCTIONS
Streptomycin resistance gene 
Sulphonamide resistance gene 
Chloramphenicol resistance gene 
Insertion sequences  
Mercury ion resistance gene 
 
  
 Figure 2. Typical structure of a simple antibiotic resistance plasmid R100 
 
 
Transposons: 
 
Transposons were discovered by Barbara McClintock in the 1940s [72], she was 
subsequently awarded a Nobel prize in 1983. Transposons belong to the set of mobile genetic 
elements called transposable elements. In bacteria, transposons can “jump” from 
chromosomal DNA to plasmid DNA and back, allowing the transfer and permanent addition 
of accessory genes, such as those encoding antimicrobial resistance, between bacterial 
species. This process may lead to the development of multi-antimicrobial resistant bacterial 
strains. Bacterial transposons can be divided in to four classes, Class I (composite 
transposons). The mobility of these transposons is associated with plasmids or phages. 
Common examples of Class I transposons are, Tn5, Tn1525 and Tn10. Class II transposons 
are more frequently found in enterobacteriaceae, but are not directly transmissible. The 
typical example is Tn3. Class III transposons (Transposons of the family Tn5090-Tn7) are 
phage-associated. One typical example is Tn552 from S. aureus. Fourth group of transposons 
are also called as  “conjugative transposons”, or ICEs (integrative and conjugative elements) 
or CONSTINs (conjugal self-transmissible, integrating elements), to stress its frequent 
interaction with the bacterial chromosome. Typical example is Tn916.  
Class I mobile genetic elements or retrotransposons are first transcribed to RNA, and 
then reverse transcribed back to DNA by reverse transcriptase, before being inserted at 
another position in the genome. Class II transposons move directly from one position to 
another using a transposase to "cut and paste" themselves within the genome. Class II 
transposon are directly transmissible between bacteria, particularly between Gram-negatives. 
Class III transposons consist of bacteriophage Mu and related temperate phages. The entire 
phage genome functions as a transposon, and replication of the phage DNA during vegetative 
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growth occurs by replicative transposition facilitated by a transposase. Example of a Class II 
transposon, Tn3 is shown in Figure 3. Tn3 contains terminal inverted repeats, a transposase, a 
resolvase and ampicillin resistance genes. The inverted repeat sequences are recognised by 
the transposase and act as recognition sequences for transposase digestion. The transposase 
enzyme is responsible for the excision and re-integration of transposed DNA. Resolvase 
enzyme is involved in the separation of transposons into their component replicons during 
copying, cutting and pasting. 
 
 
 
Resolvase Transposase 
(ampicillin resistance)
Ap
Inverted repeats  
 
 
Figure 3. Tn3 transposon found in enterobacteriaceae 
 
Integrons: 
 
The number of platforms involved in antibiotic resistance dissemination was further 
expanded by the discovery of a novel genetic system for the movement of antibiotic 
resistance genes called the “integron” [73]. Integrons are mobile DNA elements with a 
specific structure consisting of two conserved segments flanking a central region in which 
antimicrobial resistance “gene cassettes” are integrated [73, 74]. The important components 
of an integron include, an int gene which codes for a site-specific recombinase (involved in 
recombination), an adjacent recognition site for integrase called attI (also acts as a receptor 
site for the gene cassettes), and a promoter required for expression of the gene cassette. The 
gene cassettes are mobile elements that usually carry an antibiotic resistance gene, and an 
integrase-specific recombination site, a 59-base element [75]. There are four classes of 
integrons currently described that encode antibiotic resistance genes. The majority of 
integrons described belong to class 1 (Figure 4), and are associated with sulI gene conferring 
resistance to sulphonamides) [75]. The most important epidemiological feature of class 1 
integrons is their association with Tn3 transposons. Class 2 integrons are associated with 
Tn7-family of transposons. Class 3 integrons are similar to class 2, and are associated with 
conjugative plasmids. An example of a Class 3 integron consists of an intI3 integrase gene, 
two (Pc and Pint) promoter regions, an attI3 recombination site, a blaGES-1 gene cassette, and 
a fused blaOXA-10-type/aac (6’)-Ib gene cassette [76]. Class 4 integrons are part of the SXT 
element encoding antibiotic-resistance in Vibrio cholerae [77]. 
Integrons are widespread versatile genetic elements, their ability to integrate gene 
cassettes (and especially gene cassettes encoding resistance to antimicrobial agents) makes 
them key elements in the dissemination of antibiotic resistance. Since many integrons possess 
multiple resistance genes, selection for one antimicrobial resistance determinant (via 
antibiotic treatment), may actually select for a range of antibiotic resistances.  
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sulIintlI
Pant
5’-conserved segment 3’-conserved segment
Gene cassettes
59-base element
 
 
Figure 4. Schematic representation of sulI associated integron. Adapted from: Hall RM and 
Collis CM. Mobile gene cassettes and integrons: capture and spread of genes by site-specific 
recombination. Mol Microbiol 1995; 15:593-600 [75]. 
 
Chromosomes:    
 
Antibiotic resistance genes present on chromosomes may transfer to other bacterial 
isolates via a process called transformation, in which naked DNA of a lysed bacterium is 
taken up across the cell membrane of another “competent” bacterial cell. This new DNA may 
then be incorporated into the chromosome at regions of sequence homology via a process 
called “homologous recombination”. Antibiotic resistant genes present on bacterial 
chromosomes are usually mutated versions of normal, chromosomal bacterial genes. For 
example, a mutation may alter the ribosomal structure and hence alter the active site of action 
for an antimicrobial agent such as erythromycin making this particular antimicrobial agent no 
longer effective. Additionally, resistance to β-lactam antibiotics in some naturally 
transformable bacterial pathogens has arisen by inter-species recombinational events that 
have generated hybrid penicillin-binding proteins with reduced affinity for β-lactam 
antibiotics. This type of resistance is of particular concern in pneumococci, with resistance to 
β-lactam antibiotics rapidly increasing worldwide [78]. However, chromosomally resistant 
mutants are typically resistant to only a single type of antibiotic.  
 
Modes of antimicrobial resistance transfer and dispersal  
 
 The dissemination of mobile genetic element platforms (plasmids, transposons, and 
integrons) has significantly contributed to the rapid spread of antimicrobial resistance. These 
platforms utilize 3 different modes of transmission to facilitate their dispersal, namely i) 
transformation, ii) conjugation and iii) transduction [79]. These modes of dispersal are shown 
in Figure 5. 
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Transduction Conjugation
Transformation    
 
 
Figure 5. Different modes of antimicrobial resistance transfer (Adapted with permission 
from: Levy SB and Marshall B. Antibacterial resistance worldwide: causes, challenges and 
responses. Nat Med 2004; 10:S122-129). 
 
i) Bacterial transformation involves a stable genetic change brought about by the 
uptake of naked DNA (DNA without associated cells or proteins). In the transformation 
process, so called “competent” bacteria acquire and incorporate DNA segments from bacteria 
that have died, lysed, and released their DNA into the environment ready for uptake. 
Clinically important examples of transformation-mediated antibiotic resistance include the 
acquisition of penicillin and quinolone resistance genes by pneumococci [80, 81]. 
 
ii) During conjugation, a bacterium may transfer plasmid DNA to an adjacent 
bacterium, via an elongated proteinaceous structure termed a “conjugation tube”, which is 
attached to, and couples together two separate bacterial cells [82]. Conjugation among Gram-
positive bacteria is usually initiated by production of sex pheromones, which facilitate the 
clumping of donor and recipient organisms, as well as conjugation tube attachment. 
Examples of conjugation-mediated antimicrobial resistance in Gram-negative bacteria 
include extended-spectrum β-lactam resistance [83], and in Gram-positive bacteria, high level 
vancomycin resistance, which is carried by F-plasmids in  both enterococci and staphylococci 
[84]. 
iii) During transduction, genes are transferred from one bacterium to another via a 
bacteriophage (bacterial virus), though this is now thought to be a relatively rare event. 
Genetic exchange via transduction involves bacteriophage infection of a bacterium, phage 
replication, and packaging of some of the bacterial DNA (including antibiotic resistance 
determinants) within the phage DNA. This is followed by lysis of the bacterium and infection 
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of subsequent bacteria by new phages, with subsequent transfer of antibiotic resistance genes 
to newly infected bacteria [85].  
 
Causes of antimicrobial resistance  
 
  Antimicrobial resistance is a natural biological phenomenon that can be accelerated 
by repeated exposure to antibiotics, with several studies having confirmed that increased 
human and veterinary antibiotic consumption has led to the emergence of antibiotic resistance 
worldwide [5, 6, 86-91]. Repeated exposure to antibiotics, results in the selection of pre-
existing resistant variants that ultimately become fixed in the population. In addition, 
antibiotic pressure may also select for bacteria with an increased frequency of mutation 
(hypermutators) [92], that tend to possess an increased frequency of recombination. 
Hypermutation has only an increased frequency of homologous recombination (among not 
too distant sequences). Probably the fact that in most cases, hypermutation is due to defects in 
the MMR (methyl-mismatch-repair system). Hypermutators are selected by antibiotic 
exposure by “hitch-hiking”, that is, hypermutators have more frequently mutations leading to 
antibiotic-resistance [92-96]. This selection occurs because “mutator clones” have a higher 
probability of producing mutants that survive the strong selection pressure of antibiotic 
administration. This allows their frequency to increase during treatment, which is particularly 
important in chronic infections when repeated antibiotic administrations are required [92, 94, 
95]. In addition to antibiotic prescription policies, factors contributing to the emergence of 
resistance include dose and duration of antibiotic therapy and cross-selection between 
different antibiotic classes [97].When antimicrobial agents are used incorrectly, for too short 
a time, at too low a dose, at inadequate potency, or for the wrong diagnosis,  the likelihood 
that bacteria will adapt and replicate, rather than be killed, is greatly enhanced. In fact, the 
World Health Organization (WHO) estimates that 50 percent of all medicines are 
inappropriately prescribed, dispensed, or sold, and that 50 percent of all patients fail to take 
their medicine properly [98]. Other major factors identified by WHO in initiating and 
promoting antimicrobial resistance include: 
a) The unnecessary use of antibiotics by humans 
b) The misuse of antibiotics by health professionals  
c) Over-the-counter availability of antibiotics in many countries  
d) Patient failure to follow the prescribed course of treatment  
e) The use of antibiotics in animal feeds as growth hormones 
 
Consequences of antimicrobial resistance 
 
The consequences of antimicrobial resistance not only have a profound impact on 
healthcare systems as a whole, but also on patients, society and the general economy. 
 The major problem associated with the development of antimicrobial resistance is 
treatment failure which in turn leads to increased patient morbidity, mortality and cost of 
therapy [99, 100]. Treatment failure delays the successful response to antibiotics, and results 
in longer length of disease, increased patient morbidity as well as costs. It has been shown 
that the primary cause of initial treatment failure is suboptimal dosing [101], often 
compounded by treatment failure due to inappropriate choice of antibiotic therapy. For 
example, if a hospital pharmacy only offers a limited range of antimicrobial agents to 
clinicians for treatment, subsequent treatment failures may occur due to the lack of (more 
expensive) appropriate antibiotics. Thus healthcare policies and directives may influence 
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antimicrobial treatment options if they prefer older and more selective antimicrobial agents in 
order to reduce the cost of therapy. These economical and selective antimicrobial agents may 
be effective against non-resistant microorganisms [102], but may not be effective against 
existing or newer and emerging resistant strains.  
Another consequence of antimicrobial resistance is that those infected with resistant 
bacterial isolates may have a prolonged illness with longer periods of infection, increasing 
exposure of others to drug-resistant strains of the disease. One of the best examples is 
tuberculosis (TB). While drug-susceptible TB can be cured within six months by the use of 
standard antimicrobial agents such as isoniazid, rifampicin and ethambutol, drug-resistant TB 
requires extensive chemotherapy for as long as two years [103]. Not only are increased costs 
associated with prolonged care, but patients are also at an increased risk of dying due to 
treatment failure. A patient infected with multi-drug-resistant TB can be expected to receive 
additional expensive diagnostic evaluation including extra cultures and laboratory studies, 
and will likely require a more potent, and usually more expensive, antimicrobial treatment 
regimen. For example, the drugs that are needed to treat multidrug-resistant forms of 
tuberculosis (streptomycin, isonicotinyl hydrazine, rifampin, ethambutol, pyrazinamide, 
moxifloxacin and cycloserine) are over 100 times more expensive than the first-line drugs 
that are used to treat the non-resistant forms of TB. In addition, if appropriate, ICU and 
overall hospital length-of-stay will almost certainly be extended [104, 105] if resistant TB is 
diagnosed. In fact, in many developing countries including Russia, the high cost of such 
replacement drugs is unaffordable, with the result that some diseases can no longer be treated 
in areas where resistance to first-line drugs is widespread.  
  
 Surveillance studies  
 
Epidemiological surveillance is the systematic collection, analysis and dissemination 
of health data for the planning, implementation and evaluation of public health programmes. 
In this respect, antimicrobial resistance surveillance studies are one of the main means of 
gathering important information about: 
 
 
a) Existing trends in pathogen incidence and antimicrobial resistance mechanisms. 
 
b) The appearance of novel resistance types. 
 
c) The prediction of future trends in antimicrobial resistance. 
 
To be most effective, surveillance studies should be conducted at local, national and 
international levels. Local surveillance studies are the most important studies for clinicians 
needing guidance for empirical therapy and in the management of antimicrobial resistance in 
the nosocomial environment. Global surveillance of antibiotic resistance on the other hand is 
necessary, since antimicrobial resistance genes are able to cross both national and 
international boundaries. For example, the spread of drug-resistant tuberculosis, penicillin-
resistant pneumococci and ESBLs are just a few examples of this phenomenon.  
Currently, several international surveillance studies have been established. These 
include:  
1) European Antimicrobial Resistance Surveillance System (EARSS): EARSS is the 
first publicly funded monitoring system for antimicrobial resistance in the European region 
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established in January 1999. EARSS is a European surveillance and information system that 
provides validated data on the prevalence and spread of major disease-causing bacteria with 
resistance to one or more antibiotics. Antimicrobial resistance is monitored by a network of 
national centres in 31 European countries. These countries sytematically collect data from 
clinical laboratories in their own countries. The national centres send this data to the EARSS 
Management Team at National Institute for Public Health and the Environment (RIVM), The 
Netherlands, who check them for consistency and publish, approved results. The guidelines 
set for EARSS were published in 2001 [106].  
2) The Alexander project, established in 1992 to examine antimicrobial susceptibilities 
in bacterial isolates from community-acquired infections of the lower respiratory tract. 
Isolates of S. pneumoniae, H. influenzae and M. catarrhalis were collected from 
geographically separated areas in countries in the European Union and various states in the 
USA, Mexico, Brazil, Saudi Arabia, South Africa and Hong Kong. Testing of a range of 
compounds was undertaken in a central laboratory funded by the pharmaceutical company 
“GlaxoSmithKline Beecham”.  
3) The PROTEKT study, a longitudinal, global, multicenter surveillance study 
involving 69 centers from 29 countries, which was started in 1999. Antimicrobial resistance 
profiles were determined in microorganisms involved in community-acquired respiratory 
tract infections. The different classes of antimicrobial agents were used to determine 
antibiotic susceptibility profiles, among them the β-lactams, cephalosporins, quinolones and 
glycopeptides. The PROTEKT surveillance study is funded by Aventis pharma [107]. 
Examples of national surveillance studies include: 
1) The Danish Integrated Antimicrobial Resistance Monitoring and Research Program 
(DANMAP). 
2) NETHMAP (The Netherlands antimicrobial surveillance program). 
 
With respect to this particular thesis, a surveillance program exclusively concentrating 
on the molecular mechanisms and epidemiology involved in the spread of antimicrobial 
resistance in clinically important bacteria was started in 2006. This surveillance program, 
called DRESP2 for “Drug Resistance Spread 2” was funded by a European Union grant 
(FP6), and involves 10 academic research institutions and 1 small medium enterprise (SME) 
across the European Union. The main objective of the project was to provide information on 
the mechanisms and “signatures” associated with the molecular mechanisms (platforms) 
responsible for the spread of antimicrobial resistance. This information was then to be used in 
predicting future trends in antimicrobial resistance. 
 
Aim and outline of this thesis 
 
The aim of the research performed in this thesis is to increase our current knowledge 
regarding the molecular mechanisms involved in the spread of antimicrobial resistance. The 
focus of the research was fixed on the characterization of antimicrobial resistance in 
clinically relevant Gram-negative and Gram-positive bacteria, in order to identify new 
molecular “signatures” and antibiotic resistance profiles that could provide information on 
the future impact of antibiotic resistances. Geographical regions were particularly targeted, 
where information on the molecular mechanisms and fingerprints of existing antimicrobial 
resistances is currently limited. The Medical Microbiology and Infectious Diseases 
department of the Erasmus University Medical Center was one of the partners in the 
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collaboration. This thesis forms part of the results obtained by the DRESP2 consortium 
(http:// www.dresp2.com/). 
 
  The following topics were specifically addressed in this thesis.   
 
• β-lactamase MIC distribution and correlation to other antibiotic resistances in 
Moraxella catarrhalis isolates. 
In this study we investigated correlation of different antibiotics in 1440 global M. catarrhalis 
isolates obtained from 7 world regions (chapter 2). 
• Production of extended-spectrum β-lactamses (ESBLs) in enterobacteriaceae from 
Paraguay and India. 
We characterized ESBL types in E. coli and K. pneumoniae from Paraguay (chapter 3), as 
well as the prevelance and characterization of ESBLs among, K. peumoniae and non-
typhoidal salmonellae from India (chapter 4, 5 and 6). 
• High-level vancomycin resistance in Enterococcus faecium isolates from Saudi 
Arabia and Paraguay. 
High-level vancomycin resistant E. faecium (vanA type), isolates from Saudi Arabia and 
Paraguay (chapter 7 and 8) were studied. 
• High-level aminoglycoside resistance in Enterococcus faecalis from patients 
attending a Dutch hospital. 
High-level gentamicin resistance among E. faecalis isolates obtained from patients during 
and after hospitalization in a Dutch teaching hospital were studied (chapter 9). 
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Abstract  
 
Objectives: To compare and contrast the geographic and demographic distribution of bro β-
lactamase and antibiotic MIC50/90 for 1440 global Moraxella catarrhalis isolates obtained 
from children and adults between 2001 and 2002. 
 
Methods: One thousand four hundred and forty M. catarrhalis isolates originating from seven 
world regions were investigated. The isolates were recovered from 411 children <5 years of 
age and 1029 adults >20 years of age. PCR-restriction fragment length polymorphism 
(RFLP) was performed to determine bro prevalence and to distinguish between bro types. 
MIC values of 12 different antibiotics were determined using the CLSI (formerly NCCLS) 
broth microdilution method. 
 
Results: Of the 1440 isolates, 1313 (91%) possessed the bro-1 gene and 64 (4%) possessed 
the bro-2 gene. Additionally, the prevalence of bro positivity between the child and adult age 
groups was significantly different (P<0.0001), though bro-1 and bro-2 prevalences within age 
groups were not significantly different. Consistently higher β-lactam MICs were observed for 
M. catarrhalis isolates originating in the Far East. Significant correlations in MICs were 
observed for several antibiotic combinations, including all five β-lactams with each other, and 
among the two quinolones. 
 
Conclusions: The worldwide prevalence of bro gene carriage in clinical isolates of M. 
catarrhalis is now approaching 95%, with children significantly more likely to harbour bro-
positive isolates than adults. Further, statistically significant differences in the distribution of 
β-lactam MICs were observed between different world regions, particularly with respect to 
the Far East. 
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Introduction 
 
Moraxella catarrhalis is a Gram-negative diplococcal commensal of the respiratory 
tract of humans that is also frequently implicated as a pathogen in human disease [1, 2]. The 
species is frequently associated with respiratory tract infections, including acute and chronic 
otitis media, sinusitis, acute bronchitis and pneumonia [3]. However, a general division tends 
to exist between the frequency of M. catarrhalis isolation in upper and lower respiratory tract 
infection between children and adults, e.g. otitis media predominates in children compared 
with exacerbations of chronic obstructive pulmonary disease (COPD) in adults [4]. 
The first β-lactamase-producing M. catarrhalis isolate was reported from Sweden in 
1976, and in the last 30 years there has been a dramatic increase in the percentage of β-
lactamase positive M. catarrhalis clinical isolates. Indeed, although M. catarrhalis is still 
susceptible to the majority of antimicrobial agents, >95% of global clinical isolates are now 
resistant to penicillin [5-8]. In addition, M. catarrhalis resistance to cefaclor and cefuroxime 
has recently been reported, with 80% of M. catarrhalis isolates tested from the UK and 
Ireland showing resistance to cefaclor and 5% showing resistance to cefuroxime [9]. 
In 1977, it was reported that M. catarrhalis produces a single β-lactamase, designated 
BRO, which was subsequently found to be located on the bacterial chromosome [10]. Later 
research indicated the presence of two BRO types, named BRO-1 and BRO-2, encoded by 
bro-1 and bro-2 genes. The two BRO enzymes are distinguishable by their level of β-
lactamase production, and different isoelectric focusing patterns (resulting from a single 
amino acid substitution). The bro-2 gene has a 21 bp deletion in its promoter region 
compared with bro-1 [3, 10, 11]. Further genetic analysis of the bro gene indicated that it 
may have a Gram-positive origin, due to the fact that there is no significant sequence 
similarity between bro and the β-lactamase genes of other Gram-negative bacteria, and that 
the gene possesses an LPXTG signal sequence motif, characteristic for Gram-positive 
bacteria [12, 13]. This finding, coupled with the relatively conserved nature of the immediate 
sequences flanking the bro gene, suggests that the gene may have been fortuitously acquired 
by M. catarrhalis via interspecies gene transfer, with ‘promoter-up’ mutations leading to the 
appearance and eventual dissemination of the bro-1 variant [12]. However, this interpretation 
of the appearance and spread of the bro genes is still open to debate [14].  
At the clinical level, β-lactamase production by M. catarrhalis has been reported to 
indirectly benefit other bacterial species present in mixed bacterial infections (e.g. 
Streptococcus pneumoniae and Haemophilus influenzae), by virtue of production of a β-
lactamase whose activity allows susceptible isolates to evade antibiotic therapy with β-lactam 
antibiotics (specifically penicillin), possibly facilitating treatment failure [15, 16]. 
The aim of this study was to determine the distribution of antibiotic MIC50/90 in a 
cross-sectional population of global M. catarrhalis isolates obtained from children and adults 
between 2001 and 2002. Special emphasis was placed on β-lactam antibiotic resistance 
phenotypes and bro β-lactamase genetic variation due to the clinical importance of β-
lactamase resistance within this species. Antimicrobial MICs of 12 different antibiotics for a 
set of 1440 global M. catarrhalis isolates were obtained. Information was also collected 
regarding age (of patients from which the specimen was obtained), world region and 
specimen type. 
 
Materials and methods 
 
Bacterial strains 
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A total of 1440 M. catarrhalis isolates were used in the analysis, comprising 411 
isolates obtained from children (<5 years of age) and 1029 isolates obtained from adults (>20 
years of age) during the years 2001–2002 (see Table 1). Samples were collected 
consecutively within countries, but collection times were not globally uniform; thus, the 
study shares characteristics with a global ‘point prevalence’ study where the ‘point’ is 1–2 
years. The isolates originated from a total of 30 countries, namely Argentina (34), Australia 
(36), Austria (9), Belgium (40), Brazil (25), Canada (160), China (8), Ecuador (15), Eire (45), 
France (36), Germany (158), Hong Kong (24), Hungary (15), Italy (70), Japan (224), the 
Netherlands (18), Peru (7), Poland (19), Portugal (20), Russia (1), South Africa (115), South 
Korea (12), Spain (127), Sweden (23), Switzerland (23), Taiwan (44), Turkey (3), the UK 
(32), the USA (86) and Venezuela (11), where the numbers in parentheses represent the 
number of isolates. With respect to specimen type, the isolates were cultured from 
bronchiolar lavages (125), blood (9), ear swabs (48), middle ear fluids (17), nasopharyngeal 
swabs (199), sinus fluids (68), sputa (950) and throat swabs (20). Four isolates were cultured 
from unknown specimen types. Isolates were received and tested at a central laboratory. All 
isolates were collected as part of the PROTEKT study using sampling and identification 
methods as published by Felmingham [17]. There was a significant difference in sample type 
(lower respiratory tract versus upper respiratory tract) between the age groups (Fisher’s exact 
test P<0.0001), which reflected the difference in disease states associated with M. catarrhalis 
between the two age groups. 
 
 bro gene PCR-restriction fragment length polymorphism (RFLP) screening and β-lactamase 
testing  
 
To differentiate between bro-1 and bro-2 isolates, a PCR was first performed using 
primer pair BROF 50-TRGTGAAGTGATTTT KRRMTTG-30 and BROR 50-
GCAATTTATTAACTGGATGTA-30, which yielded amplicons differing in size by 21 bp 
(bro-1 165 bp and bro-2 144 bp). The PCR thermocycler parameters used were 94ºC for 5 
min, followed by 94ºC for 30 s, 51ºC for 30 s and 72ºC for 30 s for 35 cycles, and then 72ºC 
for 7 min. To confirm bro-1 or bro-2, 5 µL of PCR product was digested using 2.5 U of the 
restriction enzyme Tsp509i (New England Biolabs, MA, USA) for 30 min at 65ºC. 
Electrophoresis was performed on the enzyme digests using 3.5% agarose at 6 V/cm for 25 
min. Tsp509i cleaved the bro-1 region of interest into two visible fragments of 55 and 91 bp, 
while bro-2 was left with a visible fragment of 91 bp. The agarose gel was stained with 
ethidium bromide and visualized on a UV transilluminator. All isolates (including bro-
negative isolates) were investigated for the presence of β-lactamase production using the 
nitrocefin disc test (Oxoid, Basingstoke, UK). 
 
 Antibiotic resistance testing  
 
MIC values were determined using the CLSI (formerly NCCLS) broth microdilution 
method with lyophilized microtitre plates (Sensititre system, Trek Diagnostics) with an 
inoculum of 3-7x104 cfu in 100 µL of medium [17, 18]. 
 
Statistical methods  
 
The Pearson correlation coefficient was used to assess associations of log2 MICs 
among antibiotics. Differences in frequencies were assessed using the Fisher’s exact or x2 
tests. Multiway analysis of variance (ANOVA) was performed in a linear regression 
framework to test the contribution of potential predictor variables to ampicillin MICs. β-
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lactamase-positive isolates were included in the analysis (n=1377). The analysis was based 
on log2-transformed MICs using the General Linear Model procedure in SAS version 9.1. 
Four main factors were included in the model: age; source; infection type; and region. First, 
an analysis was carried out on a model that included all main effects, the nested effect of 
countries within regions, and all two- three- and four-way interactions. As none of the three- 
or four-way interactions was significant, they were removed from subsequent analyses. For 
countries with samples sizes of ≥25 isolates, separate ANOVAs were conducted to compare 
differences among countries within regions followed by the Student–Newman–Keuls a 
posteriori test to compare means. 
 
Results 
 
Distribution of bro β-lactamase types 
 
The results of PCR-RFLP screening of 1440 global M. catarrhalis isolates revealed 
that 1377 (96%) isolates contained the bro β-lactamase gene, whilst 63 (4%) isolates were 
PCR and β-lactamase negative (Table 1). Among the 1377 bro-positive isolates, 1313 (95%) 
isolates were found to carry the bro-1 gene and 64 (5%) isolates were found to carry the bro-
2 gene. With respect to age, the prevalence of bro-1, bro-2 and bro-negative isolates in the 
child group was 96% (396/411), 3% (12/411) and 1% (3/411), respectively; whilst for the 
adult group the prevalence was 89% (917/1029), 5% (52/1029) and 6% (60/1029). The 
prevalence of bro positivity between the two age groups was significantly different (x2 
P<0.0001), with a relatively increased number of bro-2 and bro-negative isolates being found 
in isolates cultured from the adult group. However, the prevalence of bro-1 and bro-2 alone 
between the age groups was not significant (Fisher’s exact test P = 0.067). All isolates found 
to be bro PCR positive were also found to produce β-lactamase enzyme using the nitrocefin 
disc test. All nitrocefin disc test positive isolates were found to be bro PCR positive. 
 
Individual antimicrobial MICs 
 
The MIC50 and MIC90 values obtained for 1440 M. catarrhalis isolates from seven 
world regions using 12 antibiotics, and divided into bro-1, bro-2 and bro-negative types, are 
shown in Tables 2, S1 and S2 [Tables S1 and S2 are available as Supplementary data at JAC 
Online (http://jac.oxfordjournals.org/)], respectively. For antibiotics with more than minimal 
variation in MICs, isolates from the Far East had consistently higher 50% and 90% MICs of 
β-lactam antibiotics compared with the rest of the world. This was particularly pronounced 
for cefaclor where the 90% MIC was 32 mg/L in the Far East, but only 4 mg/L in all other 
regions tested. Unlike β-lactams, no difference was observed in non-β-lactam antibiotic 
MIC50/90 ranges in any geographical region, except for the 90% MICs of tetracycline 
observed in Eastern European isolates and 90% MICs of telithromycin observed in Far East 
and South African isolates. Though relatively few isolates were tested from Eastern European 
countries (which could have influenced the statistical validity of the results), Eastern 
European MICs of the remaining 12 antibiotics tested were similar to those observed for the 
majority of other regions tested.  
 
Inter-relationships between antibiotics  
 
Significant correlations were observed between: (i) all five of the β-lactam antibiotics 
(all 15 pairs of antibiotic combinations in both children and adults at P<0.0001); (ii) the 
quinolones ciprofloxacin and levofloxacin (P<0.0001) in both child and adult age groups; 
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(iii) all five β-lactams and erythromycin, tetracycline, chloramphenicol and 
sulfamethoxazole/trimethoprim (all at P<0.01 in children and adults); (iv) tetracycline, 
chloramphenicol and sulfamethoxazole/trimethoprim (all at P<0.05) with each other; and (v) 
sulfamethoxazole/trimethoprim and telithromycin (P=0.01). With particular respect to 
worldwide patterns, log2 MICs of ampicillin were significantly correlated with: (i) 
tetracycline (r=0.12), erythromycin (r=0.18) and sulfamethoxazole/trimethoprim (r=0.14) in 
the Far East; (ii) chloramphenicol (r=0.21), erythromycin (r=0.17) and sulfamethoxazole/ 
trimethoprim (r=0.20) in North America; (iii) sulfamethoxazole/ trimethoprim (r=0.23) and 
telithromycin (r=0.20) in Latin America; (iv) tetracycline (r=0.46) and chloramphenicol 
(r=0.37) in Eastern Europe; and (iv) erythromycin (r=0.13) and 
sulfamethoxazole/trimethoprim (r=0.09) in Western Europe, where, interestingly, there was 
significant (P<0.01) negative correlation between log2 ampicillin MICs and telithromycin 
(r=20.11) as well as the quinolones, ciprofloxacin (r=20.10) and levofloxacin (r=-0.15).  
With regard to ampicillin MICs, there were significant differences among regions 
(P=0.04), among countries within regions (P<0.0001) as well as ‘age x source’ (P<0.01) and 
‘age x region’ (P=0.03) interactions. The ‘age x source’ interaction reflects differences 
between children and adults in carriage sites for M. catarrhalis; children are more likely to 
have M. catarrhalis associated with the inner ear compared with the more prevalent 
colonization of the lower respiratory tract observed in adults. The ‘age x region’ interaction 
was caused by a higher proportion of the South African isolates being derived from children 
(66%), compared with isolates from all other regions (18%–36%). 
 The Far East region had significantly higher ampicillin MICs than all other regions 
(1.67 mg/L versus 0.28–0.83 mg/L). Significant differences among countries within regions 
were present in the Far East (P<0.01) where Hong Kong had the lowest MICs, North 
America (P<0.001) where MICs were significantly higher in the USA compared with 
Canada, and Latin America where MICs were significantly higher in Brazil compared with 
Argentina (P<0.05). 
For non-β-lactam antibiotics, differences among countries within regions were present 
in: the Far East where there were significantly higher MICs in Taiwan of 
sulfamethoxazole/trimethoprim (P<0.0001), tetracycline (P<0.0001) and the quinolones 
(P<0.001), and Hong Kong had significantly lower MICs of chloramphenicol (P<0.0001) and 
the cephalosporins cefaclor P<0.01), cefpodoxime (P<0.0001) and cefuroxime P<0.0001); 
Western Europe where MICs of sulfamethoxazole/trimethoprim (P=0.001), levofloxacin 
(P=0.02), cefazolin (P=0.001) and tetracycline (P=0.03) were lowest in France; and in Latin 
America where Argentina had higher MICs of tetracycline (P<0.001) and levofloxacin 
(P=0.01) compared with Brazil. 
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Table 1. Distribution of bro-1, bro-2 and bro-negative isolates in 1440 M. catarrhalis 
isolates obtained from children and adults in seven world regions during the years 2001 and 
2002 
 
Children  Adults   
Region   bro-1   bro-2 bro-neg          total bro-1   bro-2 bro-neg          total
Australia 12 - - 12 24 - - 24
Eastern Europe 6 1 - 7 24 4 3 31
Far East 111 2 - 113 176 12 11 199
Latin America 28 1 - 29 55 6 2 63
North America 51 1 1 53 176 5 12 193
South Africa 74 2 - 76 31 8 - 39
Western Europe 114 5 2 121 431 17 32 480
Total    396 12 3 411 917 52 60 1029
 
 
Children=isolates from children < 5 years of age. 
Adults=isolates from adults > 20 years of age. 
The prevalence of bro types between age groups was significantly different (P<0.0001). 
 
Discussion 
 
There has been a rapid rise in the prevalence of worldwide β-lactamase-resistant M. 
catarrhalis isolates (which now approaches 90%–99% of all clinical isolates), since the first 
reports appeared in the late 1970s. This is considered to be the fastest dissemination of any 
known bacterial β-lactamase [13]. In the current analysis, >90% of isolates were found to be 
β-lactamase and bro gene positive, with the great majority of isolates carrying the bro-1 type 
(increased β-lactamase production compared with bro-2), a finding consistent with previous 
studies. However, when taking account of demographics, a significant difference in the 
distribution of bro types was observed, with adults being more likely to be colonized by bro-
2 or bro-negative isolates. This observation may reflect increased global β-lactam use in 
children compared with adults, or indicate that different genotypes (associated with particular 
bro phenotypes) circulate within child and adult populations. However, previous studies have 
reported no linkage between M. catarrhalis genotypes and bro type, with at least one study 
reporting ampicillin MIC variation in apparently identical M. catarrhalis isolates cultured 
from an otitis media patient in Japan [19]. Further, a recent global survey of 195 M. 
catarrhalis isolates revealed no association between M. catarrhalis genotypes and child or 
adult age groups [4]. Perhaps differences in the global prescribing of β-lactam antibiotics 
between child and adult age groups are responsible for the difference in bro type carriage 
observed in this study. 
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The statistical interpretation of our results must be viewed cautiously because the 
sample isolates were not randomly selected. While use of convenience samples in 
surveillance studies is not uncommon, its impact is most probably greatest within countries of 
small geographical extent and those with minimal socioeconomic differentiation where 
residents have equal access to healthcare. With geographic and cultural homogeneity, clonal 
outbreaks are more likely to dominate a convenience sample. Conversely, the timing of 
outbreaks and the underlying genotypes involved are much less likely to be coincident across 
large regions and, thus, regional patterns of differentiation should be viewed with more 
confidence. With respect to geographical region, it is obvious from this study that 
consistently increased bro-1 β-lactam MICs are observed in M. catarrhalis isolates 
 40
Chapter 2                                                                                                          BRO β-lactamase 
originating from the Far East, and especially Japan (which provided the majority of isolates 
collected from the Far East in this study). Though some of these results have been published 
separately by Inoue et al. [20] and Canton [21], we are the first to show in detail that bro-1-
positive M. catarrhalis isolates from the Far East represent a phenotypically distinct subset of 
global isolates.  
Mechanisms not associated with the bro gene per se may be involved in the increased 
β-lactamase resistance observed in isolates from the Far East carrying the bro-1 gene. To 
support this hypothesis, a study of 818 M. catarrhalis isolates from five European countries 
and the USA, collected between 1992 and 1993, indicated 8% penicillin and 4% amoxicillin 
resistance in β-lactamase-negative M. catarrhalis isolates, though this activity was limited to 
isolates from Europe alone [22]. Another study of 90 M. catarrhalis isolates from Turkey and 
published in 2007 found a single BRO-negative isolate (1/5) that exhibited penicillin 
resistance [23]. A third study reported that 16% of BRO negative isolates collected from a 
single hospital over a 10 year period (1984–1994) in Tennessee, USA, exhibited reduced 
susceptibility to penicillin [14]. Finally, Jetter et al. [24] recently published evidence linking 
the M. catarrhalis outer membrane porin M35 to aminopenicillin susceptibility. Taken 
together, these results indicate that non-bro-related mechanisms of β-lactamase resistance 
exist within some isolates of the M. catarrhalis species, and that these mechanisms may be 
associated with geographical and/or temporal factors.  
The question remains as to whether regional differences in β-lactam MICs are actually 
clinically relevant. In this respect, it has been reported that bro-positive M. catarrhalis 
isolates may protect penicillin-susceptible Streptococcus pneumoniae isolates from antibiotic 
therapy [15]. Therefore, It would be interesting to investigate whether the prevalence of S. 
pneumoniae β-lactam treatment failures in the Far East could be related to co-colonization 
between S. pneumoniae and bro-positive M. catarrhalis isolates, and whether any increased 
prevalence in treatment failure was due to increased β-lactam MICs in the Far East. 
Interestingly, studies have indicated an increase in MICs of both cefuroxime and 
cefaclor, as well as an overall decrease in susceptibility to cephems [20, 22, 25-28], though in 
our study this effect was observed for Far East isolates only. Based on past experience, with 
respect to the rapid dissemination of penicillin resistance in M. catarrhalis, it seems logical 
that the global monitoring of these antibiotic resistances in M. catarrhalis should continue.  
The majority of global M. catarrhalis isolates circulating during the years 2001–2002 
were susceptible to most non-β-lactam antibiotics. These results are consistent with previous 
studies investigating antimicrobial susceptibility from M. catarrhalis isolates cultured in 
1999–2000 and 1999–2007 [9, 20, 29]. Occasionally, resistance to tetracycline, erythromycin, 
streptomycin and fluoroquinolones has been reported [30], though in this study the only 
exception to non-β-lactam antibiotic susceptibility appeared to be a relative 8-fold increase in 
tetracycline MICs to 4 mg/L (intermediate resistance) at the 90% inhibition level, for isolates 
recovered from Eastern Europe. However, the number of isolates tested from Eastern Europe 
was relatively low, which could have affected the statistical reliability of our results. In this 
respect it is worthwhile noting that the MICs obtained for all other antibiotics (including β-
lactam antibiotics) in this region matched the MICs obtained for the majority of other 
geographical regions. Further analysis of interregional differences revealed that 30% (6/20) 
of isolates from Poland possessed tetracycline MICs of 4 mg/L, with neither Hungary nor 
Turkey (the other countries included in this global region) possessing tetracycline MICs >1 
mg/L. Further research is therefore necessary to determine whether tetracycline use in Poland 
is particularly high compared with the rest of the world, or whether our finding represents a 
statistical anomaly, perhaps resulting from a sample with over-representation of a single 
clone. 
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 Not unexpectedly, strong correlations in MICs were found among functionally related 
antibiotics, i.e. β-lactams or quinolones. MIC correlations for antibiotics with a shared 
mechanism action are most probably caused by a specific resistance determinant. Thus, the 
action of a β-lactamase is the likely explanation for worldwide correlations among the five β-
lactam agents. Similarly, several known resistance factors can account for the correlations 
between the two quinolones. While correlations in MICs were stronger among antibiotics 
with shared mechanisms of action, significant correlations were prevalent even among 
functionally and structurally unrelated antibiotics. An association of susceptibility phenotypes 
for antibiotics whose modes of action have no evident relationship is more likely to be caused 
by genetic linkage of resistance determinants it may derive from a non-specific resistance 
mechanism, such changes in efflux pumps or membrane permeability. Either may explain the 
correlations between β-lactam agents and four antibiotics possessing diverse mechanisms of 
action. However, M. catarrhalis, resistance to non-β-lactam antibiotics is rare, and plasmids, 
particularly multidrug resistance plasmids, are uncommon. Thus, the significant correlations 
involving non-β-lactam agents most probably represent small differences in susceptibility to 
the non-β-lactam agents. Such incremental differences that influence susceptibility to 
multiple agents may be caused by genetic mutations whose individual phenotypic effects may 
be small but that in concert with other factors may bring about marked reductions in 
susceptibility. Again, these multifactorial effects may arise from changes in the efficiency 
and specificity of efflux pumps and membrane permeability. 
 In this study, significant correlations were observed between tetracycline, 
chloramphenicol, sulfamethoxazole/trimethoprim and telithromycin, as well as β-lactam 
MICs. These significant correlations may reflect the preferred antibiotic prescribing practices 
associated with the treatment of M. catarrhalis infections in different world regions, or 
possibly the preferred antibiotic prescribing policies for infections where M. catarrhalis is a 
co-colonizing bacterium. In any case, β-lactam antibiotics, with or without the inclusion of a 
β-lactamase inhibitor (e.g. amoxicillin/clavulanate), remain the antimicrobial drugs of choice 
for treating M. catarrhalis infections [31]. 
 Finally, it would be interesting to know whether differences in β-lactam prescribing 
policies in the Far East (compared with the rest of the world) are providing the selection 
pressure towards increased β-lactam MICs in this world region, as β-lactams are commonly 
used for the empirical treatment of community-acquired respiratory tract infections in the Far 
East [32]. If this is indeed the case, then changes in antibiotic prescribing policy in the Far 
East may be warranted. 
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Table S1. Antibiotic MICs obtained for 64 bro-2-positive M. catarrhalis isolates originating from seven world regions during the years 2001 and 2002 
 
MIC (mg/L) 
 Country (number of isolates) MIC50 MIC90 range 
Australia (0)     
AMP - - - 
AMC - - - 
CXM - - - 
CEC - - - 
CPD - - - 
ERY - - - 
CIP - - - 
LVX - - - 
TET - - - 
CHL - - - 
SXT - - - 
TEL - - - 
    
Eastern Europe (5)    
AMP 2 8 1-8 
AMC 0.12 0.12 0.12-0.12 
CXM 0.5 0.5 0.5-0.5 
CEC 1 2 0.5-1 
CPD 0.25 0.25 0.12-0.25 
ERY 0.25 0.5 0.25-0.5 
CIP 0.03 0.06 0.03-0.06 
LVX 0.03 0.06 0.015-0.06 
TET 0.5 1 0.25-1 
CHL 0.5 1 0.5-1 
SXT 0.5 4 0.25-4 
TEL 0.06 0.12 0.06-0.12 
    
Far East (14)    
AMP 2 4 0.5-4 
AMC 0.12 0.25 0.12-0.25 
CXM 0.5 2 0.25-2 
CEC 1 2 0.5-8 
CPD 0.25 0.5 0.06-0,05 
ERY 0.25 0.25 0.25-0.25 
CIP 0.03 0.06 0.015-0.5 
LVX 0.03 0.06 0.015-1 
TET 0.25 0.5 0.25-0.5 
CHL 0.5 0.5 0.5-0.5 
SXT 0.12 0.25 0.03-0.25 
TEL 0.06 0.06 0.06-0.12 
    
Latin America (7)    
AMP 1 8 0.5-8 
AMC 0.12 0.25 0.12-0.25 
CXM 0.5 1 0.25-1 
CEC 1 2 0.5-2 
CPD 0.12 0.25 0.12-0.25 
ERY 0.25 0.25 0.25-0.5 
CIP 0.03 0.03 0.015-0.03 
LVX 0.03 0.06 0.03-0.06 
TET 0.25 1 0.25-1 
CHL 0.5 0.5 0.5-0.5 
SXT 0.25 4 0.12-4 
TEL 0.06 0.12 0.03-0.12 
    
North America (6)    
AMP 0.5 4 0.25-4 
AMC 0.12 0.25 0.12-0.25 
CXM 0.5 1 0.25-1 
CEC 0.5 1 0.5-1 
CPD 0.12 0.25 0.12-0.25 
ERY 0.25 0.25 0.25-0.5 
CIP 0.03 0.06 0.015-0.06 
LVX 0.03 0.06 0.03-0.06 
TET 0.25 0.5 0.25-0.5 
CHL 0.5 0.5 0.25-0.5 
SXT 0.12 0.25 0.12-0.25 
TEL 0.06 0.06 0.03-0.6 
    
South Africa (10)    
AMP 1 2 0.25-4 
AMC 0.12 0.12 0.12-0.25 
CXM 0.5 0.5 0.25-1 
CEC 1 2 0.5-2 
CPD 0.12 0.25 0.12-0.5 
ERY 0.25 0.25 0.25-0.25 
CIP 0.03 0.03 0.015-0.03 
LVX 0.03 0.03 0.015-0.06 
TET 0.25 0.5 0.25-0.5 
CHL 0.5 0.5 0.5-0.5 
SXT 0.25 0.25 0.12-1 
TEL 0.06 0.06 0.03-0.12 
    
Western Europe (22)    
AMP 1 2 0.25-4 
AMC 0.12 0.12 0.12-0.25 
CXM 0.5 1 0.25-2 
CEC 1 2 0.5-2 
CPD 0.12 0.5 0.12-0.5 
ERY 0.25 0.25 0.25-0.25 
CIP 0.03 0.06 0.03-0.06 
LVX 0.03 0.06 0.03-0.06 
TET 0.25 1 0.25-1 
CHL 0.5 1 0.25-1 
SXT 0.25 0.5 0.06-1 
TEL 0.06 0.12 0.03-0.12 
  
AMP, ampicillin; AMC, amoxicillin/clavulanate; CXM, cefuroxime; CEC, cefaclor; CPD, cefpodoxime; ERY, erythromycin; CIP, ciprofloxacin; LVX, levofloxacin; TET, tetracycline; 
CHL, chloramphenicol; SXT, sulfamethoxazole/trimethoprim; TEL, telithromycin.  
MIC50 = MIC where 50% of the isolates were inhibited. 
MIC90 = MIC where 90% of the isolates were inhibited.  
Range = range of MICs. 
 
 
 
 
Table S2. Antibiotic MICs obtained for 63 bro-negative M. catarrhalis isolates originating from seven world regions during the years 2001 and 2002 
 
MIC (mg/L) 
Country (number of isolates) MIC50 MIC90 range 
Australia (0)     
AMP - - - 
AMC - - - 
CXM - - - 
CEC - - - 
CPD - - - 
ERY - - - 
CIP - - - 
LVX - - - 
TET - - - 
CHL - - - 
SXT - - - 
TEL - - - 
    
Eastern Europe (3)    
AMP 0.12 0.12 0.12-0.12 
AMC 0.12 0.12 0.12-0.25 
CXM 0.25 0.5 0.25-0.5 
CEC 0.5 0.5 0.5-0.5 
CPD 0.12 0.12 0.06-0.12 
ERY 0.25 0.25 0.25-0.25 
CIP 0.03 0.06 0.03-0.06 
LVX 0.03 0.06 0.03-0.06 
TET 0.25 0.25 0.25-0.25 
CHL 0.5 0.5 0.25-0.5 
SXT 0.12 0.25 0.06-0.25 
TEL 0.015 0.03 0.008-0.03 
    
Far East (11)    
AMP 0.12 0.12 0.12-0.12 
AMC 0.12 0.12 0.12-0.12 
CXM 0.5 0.5 0.25-0.5 
CEC 0.5 1 0.5-1 
CPD 0.12 0.12 0.06-0,12 
ERY 0.25 0.25 0.25-0.25 
CIP 0.03 0.03 0.015-0.03 
LVX 0.03 0.06 0.03-0.06 
TET 0.25 0.25 0.12-0.5 
CHL 0.5 0.5 0.5-0.5 
SXT 0.12 0.12 0.06-0.25 
TEL 0.06 0.06 0.06-0.12 
    
Latin America (2)    
AMP 0.12 0.12 0.12-0.12 
AMC 0.12 0.12 0.12-0.12 
CXM 0.5 0.5 0.5-0.5 
CEC 0.5 1 0.5-1 
CPD 0.12 0.12 0.06-0,12 
ERY 0.25 0.25 0.25-0.25 
CIP 0.03 0.03 0.03-0.03 
LVX 0.03 0.06 0.015-0.06 
TET 0.25 0.5 0.25-0.5 
CHL 0.5 0.5 0.5-0.5 
SXT 0.06 0.12 0.06-0.12 
TEL 0.06 0.06 0.06-0.06 
    
North America (13)    
AMP 0.12 0.12 0.12-0.12 
AMC 0.12 0.12 0.12-0.12 
CXM 0.25 0.5 0.25-0.5 
CEC 0.5 1 0.5-2 
CPD 0.12 0.25 0.12-0.25 
ERY 0.25 0.25 0.25-0.25 
CIP 0.03 0.03 0.015-0.03 
LVX 0.03 0.06 0.015-0.06 
TET 0.25 0.5 0.25-0.5 
CHL 0.5 0.5 0.25-0.5 
SXT 0.12 0.25 0.06-0.5 
TEL 0.06 0.06 0.04-0.06 
    
South Africa (0)    
AMP - - - 
AMC - - - 
CXM - - - 
CEC - - - 
CPD - - - 
ERY - - - 
CIP - - - 
LVX - - - 
TET - - - 
CHL - - - 
SXT - - - 
TEL - - - 
    
Western Europe (34)    
AMP 0.12 0.12 0.12-0.12 
AMC 0.12 0.12 0.12-0.12 
CXM 0.5 0.5 0.12-2 
CEC 0.5 1 0.5-1 
CPD 0.12 0.25 0.06-0.5 
ERY 0.25 0.25 0.25-0.25 
CIP 0.03 0.06 0.015-0.06 
LVX 0.03 0.06 0.03-0.06 
TET 0.25 0.5 0.12-1 
CHL 0.5 1 0.25-1 
SXT 0.12 0.25 0.06-01 
TEL 0.06 0.12 0.04-0.12 
 
AMP, ampicillin; AMC, amoxicillin/clavulanate; CXM, cefuroxime; CEC, cefaclor; CPD, cefpodoxime; ERY, erythromycin; CIP, ciprofloxacin; LVX, levofloxacin; TET, tetracycline; 
CHL, chloramphenicol; SXT, sulfamethoxazole/trimethoprim; TEL, telithromycin.  
MIC50 = MIC where 50% of the isolates were inhibited. 
MIC90 = MIC where 90% of the isolates were inhibited.  
Range = range of MICs. 
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Chapter 3                                                                      Dominance of CTX-M-2 and CTX-M-56 
Sir, 
Extended-spectrum β-lactamases (ESBLs) have been reported from all the continents 
of the world including South America [1, 2]. However, there is currently a lack of knowledge 
regarding ESBL carriage in many South American countries, including Paraguay. Therefore, 
the aim of this study was to investigate the molecular characteristics and clonality of ESBL-
positive Klebsiella pneumoniae and Escherichia coli isolates from Asunción, Paraguay.   
One hundred and eight clinically relevant ESBL-positive K. pneumoniae (83) and E. 
coli (25) isolates, obtained from a total of 1006 K. pneumoniae (428) and E. coli (578), were 
collected during an 8 week period from April to June 2005 from 12 collaborating laboratories 
representing different major semi-public and private hospitals in the region of Asunción.  
Isolates were initially tested for resistance to ceftazidime and cefotaxime using CLSI 
guidelines [3], and antibiotic susceptibility profiling was performed using the VITEK 2 
system (bioMérieux, Marcy l’Éetoile, France). Among the 83 K. pneumoniae isolates tested, 
the proportions resistant to gentamicin, ciprofloxacin, piperacillin/tazobactam and co-
trimoxazole were 75%, 72%, 99% and 55%, respectively. Among the 25 ESBL-positive E. 
coli, the proportions resistant to the same antibiotics were 72%, 68%, 96% and 56%. As well 
as resistance to ceftazidime and cefotaxime, 58% (48/83) of the Paraguayan ESBL-positive 
K. pneumoniae and 44% (11/25) of E. coli isolates were found to be resistant to both 
ciprofloxacin and gentamicin. Multidrug resistance (i.e. expression of both fluoroquinolone 
and aminoglycoside resistance) among ESBL-positive K. pneumoniae and E. coli is already 
well documented [4]. All of the ESBL-positive isolates tested were susceptible to imipenem.  
Genotyping by PFGE revealed a lack of clonality, and a high degree of genotypic 
diversity in both K. pneumoniae and E. coli isolates, with no association between genotype 
and hospital of isolation, type of ESBL or associated antibiotic resistance profile (Figure 1).  
PCR screening and sequencing of β-lactamase genes of the ESBL-positive isolates 
were performed using standard methods and primers [Table S1, available as Supplementary 
data at JAC Online (http://jac.oxfordjournals.org/)] [5]. With respect to the 83 ESBL-positive 
K. pneumoniae isolates, 83% produced CTX-M-2 and 11% produced CTX-M-56. 
Interestingly, both CTX-M-2 and CTX-M-56 belong to the same group of β-lactamase gene 
variants, the ‘CTX-M-2 group’. Among the CTX-M-2 isolates, 88% also produced SHV-1 
while 32% were positive for TEM-1, while 56% of the isolates producing CTX-M-56 were 
also positive for SHV-1 and TEM-1. Five (6%) ESBL-positive K. pneumoniae isolates lacked 
genes encoding CTX-M enzymes but were positive for SHV-2. Among the 25 isolates of 
ESBL-positive E. coli, 16 (64%) produced CTX-M-2 (10 of which also produced TEM-1) 
and 9 (36%) produced CTX-M-56, of which 8-produced TEM-1. These data show that 100% 
of clinical ESBL E. coli and 94% of clinical ESBL K. pneumoniae isolates cultured in 
Asunción, Paraguay carried CTX-M-2 group ESBL enzymes, which is higher than the 
previously published data from Brazil, Bolivia and Peru [1, 6, 7]. 
Plasmids were characterized using the method of Carattoli et al. [8]. Primer pairs used 
to detect A/C, FIA, I1, F1B and F11s replicons are listed in Table S1. Plasmid analysis 
revealed that 48% of K. pneumoniae isolates carried A/C plasmids, with 52%, 24% and 12% 
of E. coli isolates carrying A/C, FIA and both A/C and FIA plasmids, respectively. In this 
study, 44% of CTX-M-2-positive isolates and 78% of CTX-M-56-positive isolates were 
associated with possession of an A/C type plasmid. The association between CTX-M-56 (but 
not CTX-M-2) and A/C plasmid carriage was significant (Fisher’s exact test P=0.01 versus 
P=0.1, respectively). To our knowledge, this is the first report associating CTX-M-56 ESBL 
resistance with A/C replicon type plasmid carriage. This study highlights the important role 
played by CTX-M enzymes in ESBL phenotype Enterobacteriaceae within Paraguayan 
hospitals.  
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Figure 1. PFGE patterns obtained from 83 ESBL-positive K. pnumoniae (lef) and E. coli (right) isolates obtained from Paraguay during 8 weeks from April to June
2005. Cluster analysis was performed using the method of Dice with UPGMA (‘unweighted pair group method with arithmetic mean’), with band tolerance set to
1.5%. All isolates were resistant to ampicillin, amoxicillin/clavulanic acid, cefotaxime, ceftazidime, cefazolin and piperacillin. All isolates were sensitive to 
imipenem. IPS, Instituto de Prevision Social; HNA, Hospital Nacional; HCL, Hospital de Clinicas; LCSP, Laboratorio Central de Salud Publica; IMT, Instituto de
Medicina Tropical; IRM, Ineram; CMB, Centro Me´dico Bautista; HPD, Hospital General Pedia´trico; ML, Meyer Lab; CU, Laboratorio Curie; SC, Saint Carla; SA, 
Saint America; CIP, ciprofloxacin; GEN, gentamicin; TZP, piperacillin/tazobactam; TET, tetracycline; SXT, co-trimoxazole. *Non-typeable isolates.
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Supplementary data  
 
Table S1. Primer sequences used for detection of different β-lactamase genes in E. coli and K. 
pneumoniae isolates 
Primer                     Nucleotide sequence (5’-3’)                                Target gene                 Expected size
Bla-1 (fw)                   ATAAAATTCTTGAAGACGAAA                       TEMbla                                          1079
Bla-2 (rev)                  GACAGTTACCAATGCTTAATC     
TEM seq                    TTACTGTCATGCCATCC                                     TEM       
TEM seq                    AGAGAATTATGCAGTGC                     
SHV-1 (fw)                GCCCGGGTTATTCTTATTTGTCGC                  SHV  1017
SHV-2 (rev)               TCTTTCCGATGCCGCCGCCAGTCA       
CTX-M-1m (fw)        AAAAATCACTGCGCCAGTTC                           CTX-M-1 group               415
CTX-M-1m (rev)       AGCTTATTCATCGCCACGTT
CTX-M-2m (fw)        CGACGCTACCCCTGCTATT                               CTX-M-2 group              552
CTX-M-2m (rev)       CCAGCGTCACATTTTTCAGG                          
CTX-M-9m (fw)        CAAAGAGAGTGCAACGGATG                         CTX-M-9 group               205
CTX-M-9m (rev)       ATTGGAAAGCGTTCATCACC 
CTX-M-8m (fw)        TCGCGTTAAGCGGATGATGC                          CTX-M-8 group               666
CTX-M-8m (rev)       AACCCACGATGTGGGTAGC
CTX-M-25m (fw)      GCACGATGACATTCGGG                                  CTX-M-25 group            327
CTX-M-25m (rev)     AACCCACGATGTGGGTAGC
CTX-M-2 (fw)           TTAATGACTCAGAGCATT                                CTX-M-2                         899
CTX-M-2 (rev)          GATACCTCGCTCCATTTATTG                          
I1 (fw)                        CGAAAGCCGGACGGCAGAA                    I1 plasmid                       139                  
I1 (rev)                       TCGTCGTTCCGCCAAGTTCGT            
FIA(fw)                      CCATGCTGGTTCTAGAGAAGGTG                  FIA plasmid                     462
FIA(rev)                     GTATATCCTTACTGGCTTCCGCAG
FIB(fw)                      GGAGTTCTGACACACGATTTTCTG                 FIB plasmid                     702
FIB(rev)                     CTCCCGTCGCTTCAGGGCATT
A/C(fw)                     GAGAACCAAAGACAAAGACCTGGA              A/C plasmid                     465
A/C(rev)                    ACGACAAACCTGAATTGCCTCCTT
FIIS (fw)                     CTGTCGTAAGCTGATGGC                        FIIS plasmid                    270
FIIS (rv)                      CTCTGCCACAAACTTCAGC
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Chapter 4                                                                   Important methodological considerations 
Dear Editor,  
 
The acquisition and expression of β-lactamases by bacteria is a major health concern    
in the treatment of infectious disease, with the increase in carriage of extended-spectrum β-
lactamases (ESBLs) being of particular concern. CTX-M β-lactamases constitute one family 
of the these rapidly disseminating ESBL enzymes, having been identified in numerous 
countries within Africa, Asia, Europe, South America and the USA, also including India [1, 
2]. Phylogenic studies have revealed 5 major groups of acquired CTX-M enzymes, CTX-M-1, 
CTX-M-2, CTX-M-8, CTX-M-9 and CTX-M-25, with CTX-M-15 and CTX-M-28  (the 
subject of this letter) belonging to the CTX-M-1 group [3]. More specifically, CTX-M-15 has 
been frequently isolated from India [4], whilst CTX-M-28 is much less common, only recently 
having been identified in India and Tunisia [5, 6]. Further, these two enzymes only differ by a 
single amino acid substitution, which is present at the C-terminus of the protein (3’-end of the 
CTX-M gene), and it is usual to distinguish between these two CTX-M types (as well as other 
CTX-M types) using nucleotide sequencing (see GenBank accession numbers AY044436 and 
AJ549244).  
In this respect, we would like to caution researchers to use at least one CTX-M 
flanking gene primer (3’-end) in order to obtain sequencing products that accurately 
differentiate between CTX-M-15 and CTX-M-28. In particular, if nucleotide polymorphisms 
exist in the PCR primers used to amplify CTX-M genes, and the resultant PCR products are 
subsequently sequenced, then these nucleotide polymorphisms will be present in any 
subsequent sequence data obtained from the original PCR product. For example, Achour et al. 
[5] used four CTX-M group-specific primer sets to screen for CTX-M genes, and then cloned 
and sequenced the resulting PCR products. However, the use of primers CTX-1F and CTX-1R 
generates a PCR product with 5’- and 3’- termini comprising CTX-M-28-specific sequences 
(Figure 1). Moreover, even if the gene present was actually CTX-M-15, subsequent PCR 
screening, cloning and sequencing would generate a CTX-M-28 sequence, due to the use of 
non-homologous primers. On the other hand, the use of CTX-M-15 specific primers and 
sequencing of subsequent PCR products will mis-identify any CTX-M-28 sequences (Figure 
1). This may have been the case in publications by Moubareck et al. (2005) [6] and Weill et 
al. (2004) [7].  
In fact, the mis-identification of CTX-M-15 and CTX-M-28 enzymes is due to the fact 
that the nucleotide sequences are very similar, with only 2 single nucleotide substitutions. 
Moreover, these sequence differences occur close to the 5’-end (position 21) and 3’-end 
(position 865) of the CTX-M gene, the 5’-end and 3’-end of genes usually being chosen as 
sites to design “specific” PCR screening primers (Figure 1). 
We therefore caution researchers against using CTX-M gene 3’-end PCR screening 
primers to generate PCR product that will be later used in sequencing reactions, especially in 
regions where CTX-M- 15 and CTX-M-28 are present.  
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Figure 1. Problems associated with using non-homologous PCR primers to generate CTX-M 
sequencing products to differentiate between CTX-M-15 and CTX-M-28. CTX-M-15, 
reference CTX-M-15 sequence (GenBank Accession number AY044436). CTX-M28, 
reference CTX-M-28 sequence (GenBank Accession number AJ549244). CTX-1F and CTX-
1R, PCR primers used by Achour et al. (2008) [5]. CTX-M-1-F and CTX-M-15-R, PCR 
primers used by Moubarek et al. (2005) [6] and Weill et al. (2004) [7]. Arrows represent 
direction of PCR amplification. Underlined nucleotides are the stop codon. The cytosine to 
thymidine nucleotide substitution (position 21) is silent. NB: The reverse primers have been 
reverse complemented to match the direction of the gene sequence. 
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Abstract 
 
Background & objective: Extended-spectrum β-lactamase (ESBL)-producing strains of 
Klebsiella pneumoniae continue to cause major problems in hospitals in India. Molecular 
characterization of such ESBL-carrying isolates is essential in allowing hospitals to identify 
the source of these pathogenic bacteria, whilst providing useful information regarding the 
distribution of clonally related ESBL genotypes at both national and international levels. 
Further, monitoring of the spread of individual β-lactamase genes and their associated genetic 
platforms (like plasmids) provides a means to monitor for the appearance of new ESBLs, or 
to establish the dominance of older ESBL enzymes. In this respect, we characterized K. 
pneumoniae isolates associated with serious infections in a tertiary care hospital in 
Pondicherry, India, and compared the results to previous publications, focusing on India. 
 
Methods: A total of 36 ESBL-phenotype and 3 non-ESBL phenotype K. pneumoniae isolates 
were characterized in this study. The isolates were obtained from blood cultures taken from 
39 patients admitted to 8 different wards, at a single tertiary hospital in Pondicherry, India. 
Isolate characterization was performed using pulsed field electrophoresis (PFGE), ESBL 
gene screening, ESBL gene sequencing, and PCR-based plasmid profiling. 
 
Results: Ninety-two percent (36/39) of isolates were positive for blaCTX-M-15, 82% (32/39) for 
blaTEM, 46% (18/39) for blaSHV, and 82% (32/39) for blaOXA. PFGE identified 3 major clusters of 
K. pneumoniae with no relationship between PFGE type and ward. 
 
Interpretation & conclusions: A very high incidence of multiple ESBL-gene carriage was 
detected among the isolates, with the most notable result being the presence of CTX-M-15 in 
92% of isolates. This study emphasizes the major role that CTX-M-15 plays in facilitating 
antimicrobial resistance in Indian hospitals, as well as its rapid spread throughout India, since 
its first identification in 1999. 
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Introduction 
 
Extended-spectrum β-lactamases (ESBLs) are enzymes that confer resistance to all 
penicillins and cephalosporins, including the sulbactam and clavulanic acid combinations and 
monobactams such as aztreonam. ESBL production is seen predominantly in Escherichia coli 
and Klebsiella species (ESBL-EK) but may also be seen in other enterobacteriaceae [1]. 
ESBL producing Klebsiella pneumoniae were first reported in 1983 from Germany and since 
then a steady increase in resistance against cephalosporins has been seen. ESBLs are encoded 
by transferable conjugative plasmids, which also quite often code resistance determinants to 
other antimicrobials [2]. 
Currently, the ESBLs associated with third-generation cephalosporin-resistant (3GC-
resistant) enterobacteriaceae can be divided into the ‘big three’ families of TEM, SHV and 
CTX-M- type β-lactamases. TEM and SHV variants are reliant on key amino acid 
substitutions to increase their substrate profile to include the 3GCs, whereas the CTX-Ms 
have an intrinsic extended-spectrum profile [3]. More than 100 ESBL variants from different 
types are known, the most abundant types are represented by SHV, TEM, OXA and CTX-M 
[4]. Production of these enzymes is either chromosomal or plasmid mediated [5]. The 
plasmid mediated nature of some of these enzymes facilitating their rapid spread among 
bacterial species and isolates, and is important for infection control, clinical and therapeutic 
applications [6].  
      Interestingly, ESBLs are most commonly detected in K. pneumoniae, it being an 
opportunistic pathogen causes severe infections in hospitalized patients, including 
immunocompromised hosts with severe underlying diseases [7]. Bloodstream infections 
associated with K. pneumoniae may arise as a consequence of pneumonia (community- and 
ventilator-acquired), the urinary tract, intra-abdominal pathologies, and central venous line-
related infections. However, though associated with nosocomial infections worldwide, 
relatively little information is currently available regarding the molecular biology of ESBL 
positive K. pneumoniae isolates from India, the second most populated country in the world. 
In order to provide more information from this country, we performed molecular 
characterization of ESBLs from bloodstream isolates of K. pneumoniae collected from a 
tertiary care hospital in Pondicherry, India. 
 
Materials and methods 
Bacterial isolates 
A total of 39 single blood culture isolates of K. pneumoniae were obtained from 39 
patients admitted to 8 different wards at JIPMER (Jawaharlal Institute of Postgraduate 
Medical Education & Research), Pondicherry, India, during the year 2008. Blood culture was 
performed using biphasic medium consisting of Brain Heart Infusion (BHI) agar and BHI 
broth with sodium polyanethol sulphonate as an anticoagulant. K. pneumoniae were identified 
using standard microbiological procedures [8].  
Antimicrobial susceptibility testing 
The antimicrobial resistance profile of K. pneumoniae isolates was obtained using the 
disk diffusion method on Mueller Hinton agar (Hi-Media, Mumbai), following the zone size 
criteria recommended by the Clinical and Laboratory Standards Institute (CLSI) [9]. The 
antibiotics (µg) tested included ampicillin (10), amikacin, gentamicin, piperacillin (100), 
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piperacillin/ tazobactum (100/10), cefoperazone/ sulbactum (75/ 10), cefoxitin (30), 
cefotaxime (30), ceftazidime (30), ceftriaxone, ciprofloxacin (5) and meropenem (10). 
ESBL screening and confirmation by phenotypic methods 
 
Isolates showing resistance to one or more third generation cephalosporins (3GCs) 
were tested for ESBL production by the combination disk method using cefotaxime (CTX) 
(30 µg) cefotaxime / clavulanic acid (10 µg), cefatzidime (CAZ) (30 µg), and 
ceftazidime/clavulanic acid (10 µg). A ≥5mm increase in diameter of the inhibition zone of 
the cephalosporin-plus-clavulanate disc, when compared to the cephalosporin disc alone, was 
interpreted as phenotypic evidence of ESBL production (CLSI guidelines) [9]. K. 
pneumoniae ATCC 700603 was used as positive control and Escherichia coli ATCC 25922 
was used as negative control.  
 
PCR screening and sequence analysis 
 
All the 39 isolates were subjected to molecular analysis. PCR screening and 
sequencing was performed to identify the β-lactamase resistance genes; blaTEM, blaSHV, 
blaOXA-1 group and blaCTX-M as previously described [10-13]. Sequencing was performed 
using both forward and reverse PCR primers and standard methods on a 3130X1 Genetic 
Analyzer (ABI PRISM). The BLASTN program was used for database searching 
(http://www.ncbi.nlm.nih.gov/BLAST/). Additional sequencing primers were required for 
blaTEM PCR product sequencing (Lagging strand 7, 5’-TTACTGTCATGCCATCC-3’ and 
Lagging strand 3, 5’-AGAGAATTATGCAGTGC-3’). PCR primers corresponding to 
sequences downstream (ORF 1) of the blaCTX-M genes (M3 int upp, 5’-
TCACCCAGCCTCAACCTAAG-3’ and ORF1 pol M3, 5’-
GCACCGACACCCTCACACCT-3’ were also used [14]. Finally, PCR products of blaCTX-
M were subjected to sequencing using primers, CTX-M-1 fw multi 5’-
AAAAATCACTGCGCCAGTTC-3’, CTX-M-1 multi (REV) F seq 5’-
AACGTGGCGATGAATAAGCT-3’ and ORF1 pol M3, 5’-
GCACCGACACCCTCACACCT-3’. The presence of individual plasmid types was 
determined by PCR screening of FIA, FIB, FIIs, A/C and I1replicons [15].  
 
Genotyping 
 
Isolate genotyping was performed using pulsed field gel electrophoresis (PFGE) with 
XbaI restriction enzyme. Briefly, isolates were incubated overnight at 370C in 7mL Mueller 
Hinton broth. After incubation, 1mL of bacterial cells were harvested, pelletted and washed 
three times using 1ml EET (Na2EDTA 100mM, EGTA 10mM, Tris HCl 1M) buffer, before 
being adjusted to a cell density of 0.5 at 560nm. A 100µL of cell suspension and 100µL of 
1.4% PFGE grade agarose in EET buffer were mixed and poured into PFGE plug moulds. 
The plugs were incubated at 40C for 30 minutes to harden and 1ml of lysozyme (5mg/ml) was 
added before incubation at 370C for 3 to 4 hours. Lysozyme was removed from the plugs and 
1ml each of deproteinising solution (per plug 3 mg/mL proteinase K and 1 % SDS) was 
added prior to overnight incubation at 370C. Next, the plugs were washed 6 times every 30 
minutes with T10E1 (10mM Tris, 1mM EDTA) buffer, and then soaked in T10E0.1 (10mM Tris, 
0.1mM EDTA) buffer for 30 minutes. Restriction digestion was carried out using 40U of 
XbaI (Fermentas) at 370C. PFGE was performed in 1% agarose gel in a CHEF DR-II system 
(BioRad) with the following conditions 0.5X Tris- Borate EDTA buffer, 140C, 6 V/cm for 22 
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h (with switch times ranging from 5 to 40 s). Lambda ladder PFGE marker (BioRad) was 
used as a molecular weight standard. 
 
Results 
 
Of the 39 isolates investigated, 37 (94.8%) were found to be resistant to at least one of 
the 3GCs. Among these 37 isolates, 36 (97.2%) were found to be ESBL positive by 
phenotypic testing. Antibiotic susceptibility revealed that majority of them was multidrug 
resistance showing 95%, 87%, 92% resistance to gentamicin, ciprofloxacin and ceftriaxone. 
Twenty-one percent showed resistance to amikacin and only 5% to meropenem. 
Among the 39 isolates, 32 (82%) were positive for blaTEM, 18 (46%) for blaSHV, 36 
(92%) for blaCTX-M, and 32 (82%) for blaOXA, respectively. Sequencing of blaCTX-M  
amplicons revealed the presence of blaCTX-M-15 in all isolates.  
Using PCR-based replicon typing, only a single isolate harbored both FIA and FIB 
replicons that carried blaCTX-M-15.  Plasmids harboring FIIs, A/C and I1 replicons types were 
not detected. Finally, PFGE identified 3 major clusters of K. pneumoniae with no relationship 
between PFGE type and ward (Figure 1). 
       
Discussion 
 
 In recent years, a significant increase in ESBL producing Klebsiella spp. has been 
reported in India [16-20], with results from our Indian K. pneumoniae blood culture isolates 
adding extra evidence for this trend. For example, with respect to “classical” ESBL enzymes, 
in one study in north India 67% of Klebsiella isolates possessed both blaTEM and blaSHV 
genes, with 20% possessing a blaTEM gene alone, and 8.4% a blaSHV gene [21]. From our 
study, 44% of K. pneumoniae isolates carried blaTEM and blaSHV genes, 41% a blaTEM gene 
only, and only 5.1% a blaSHV gene. This difference was statistically significant (Chi square 
test P<0.01), though these results do not take into account the added association observed 
between blaTEM, blaSHV and blaCTX-M genes. However, the significance of this finding is not 
yet apparent, though geographical and chronological differences may have played a part in 
the different results obtained. 
 The most notable result from the study was the presence of CTX-M-15 in 92% 
(36/39) of isolates, as well as the combination of CTX-M-15 resistance and OXA resistance 
in 82% (32/39) of isolates. Further, 36% (14/39) of isolates possessed CTX-M, TEM, SHV, 
and OXA resistance. CTX-M-type ESBLs have become increasingly prevalent worldwide in 
the past 15 years [22, 23], with CTX-M-15-positive K. pneumoniae  (first identified in India 
in 1999 [24] being recently found in Portugal [25], Korea [26] and Western Africa [27], as 
well as Bulgaria, Canada, France, Italy, Japan, Poland, Romania, Russia and Turkey [28]. 
Worryingly, 2 of our isolates (5%) possessed TEM, SHV, CTX-M, OXA and meropenem 
resistance genes, which seriously limits treatment options using extended-spectrum β-lactams 
and carbapenem antimicrobials, leaving tigecycline as the only clinically relevant 
antimicrobial agent for these isolates. Taken together, this study emphasizes the major role 
that CTX-M-15 plays in facilitating ESBL-mediated antimicrobial resistance in Indian 
hospitals, and reiterates its association with multiple antibiotic resistance determinants, 
including carbapenem resistance. 
 The K. pneumoniae isolates cultured in this study were found to possess a range of 
genotypes, and were not clonal in nature, though some dendrogram clustering of isolates was 
observed e.g. isolates 79 to 40, 27-86 etc in Figure 1.  However, no relationship was observed 
between clustering and type of infection, or antibiotic resistance profile, except that 3 CTX-
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M-15 positive isolates were genotypically distinct from the remaining (CTX-M-15 positive) 
isolates. The 2 meropenem resistant isolates belonged to the same genotypic cluster and 
hospital ward (NICU), possibly indicating noscomial transmission of this potentially lethal 
multi-antimicrobial resistant K. pneumonia strain. Therefore, surveillance and infection 
prevention measures should be considered as a priority to limit further nosocomial spread. 
 The extensive use of antibiotics has contributed greatly to the emergence of 
multidrug-resistant microbial isolates that possess the ability to cause nosocomial infections. 
The spread of antimicrobial resistance in K. pneumoniae isolates is complicating the 
treatment of serious nosocomial infection in India, not least because resistance in K. 
pneumoniae is typically caused by the acquisition of plasmids containing multiple 
antimicrobial resistances (including genes coding for ESBL resistance) [29]. Further, though 
carbapenems are currently considered to be the preferred agent for the treatment of serious 
infections caused by ESBL-producing Klebsiella strains, our study showed that 5% (2/39) of 
isolates were also resistant to meropenem, which causes great concern with respect to the 
choice of an effective treatment option, and with respect to the spread of combined ESBL and 
carbapenem resistant K. pneumoniae isolates within Indian hospitals. 
 Extended-spectrum β-lactamase (ESBL)-producing strains of K. pneumoniae continue 
to cause major therapeutic concerns in intensive care units, medical wards and surgical wards 
throughout India. Molecular characterization of such ESBL-carrying isolates is essential in 
allowing hospitals to identify the source of these pathogenic bacteria, whilst providing useful 
information regarding the distribution of clonally related ESBL genotypes at both national 
and international levels. Further, monitoring of the spread of individual β-lactamase genes 
and their associated genetic platforms (e.g. plasmids) provide a means to monitor for the 
appearance of new ESBLs, or to establish the dominance of older ESBL enzymes. 
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Figure 1. Relationship between PFGE genotype and antimicrobial susceptibility 
profiles for Klebsiella pneumoniae isolates from Pondicherry. Antimicrobial drugs to 
which isolates were resistant are listed: Cefotaxime (Ce), ceftazidime (Ca), 
ciprofloxacin (Cf), gentamicin (G), amikacin (Ak), ceftriaxone (Ci), meropenem (M) 
and ampicillin (A). NB: new born. Unit: MED = medicine, CAS = casualty, NICU = 
neonatal intensive care unit, SURG = surgery, PAED = paediatrics.  
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Abstract 
 
Objectives: Extended-spectrum cephalosporins and fluoroquinolones are essential 
antimicrobials for treating invasive salmonellosis, though emerging resistance to these 
antimicrobials is of growing concern, especially within India. Therefore, a study was set up to 
characterize the antimicrobial susceptibility phenotypes, types of ESBL genes and plasmids, 
and genotypic relationships of 23 non-typhoidal salmonellae isolated from patients admitted 
to four different hospitals in India.  
 
Methods: Non-typhoidal salmonellae isolates were investigated using serotyping; 
antimicrobial susceptibility testing; PCR screening for β–lactamase genes, qnr genes, aac 
(6’)-Ib and integrons; sequencing for quinolone resistance mutations; and plasmid replicon 
typing. An antimicrobial resistance microarray was used for preliminary screening and 
identification of blaTEM & blaSHV genes. Phenotypic testing for the presence of efflux pumps, 
as well as genotypic characterization, were also performed. 
 
Results: Twelve out of 23 isolates possessed the cephalosporin resistance phenotype, and 
PCR screening revealed that isolates possessed TEM-1, SHV-12, DHA-1, OXA-1-like and 
CTX-M-15 ESBL genes.  FIIS plasmid replicons were detected in the majority of isolates. 
The presence of efflux pumps was detected in 4 isolates resistant to ciprofloxacin. Isolates 
from the same geographical region were genotypically diverse, though some clustering of 
identical serotypes was observed.  
 
Conclusions: A very high proportion (52%) of ESBL producing non-typhoidal salmonellae 
were isolated from 4 hospitals in India. Such pathogens could jeopardize classical antibiotic 
therapy. Continued surveillance for the presence of ESBL producing (non-typhoidal) 
salmonellae in India is essential. 
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Introduction 
 
Non-typhoidal salmonellae are one of the principal pathogens implicated in food-
borne gastroenteritis worldwide. In severe infections such as meningitis and septicemia, 
antibiotic treatment is essential, with extended-spectrum cephalosporins being preferentially 
used to treat for example salmonellosis in children [1, 2]. However, treatment failures due to 
the in-vivo acquisition of extended-spectrum β-lactamase (ESBL) or fluoroquinolone 
resistance genes in salmonellae isolates are now well established [3-5]. Salmonella spp. 
resistant to extended-spectrum cephalosporins have been known since 1988 [6] and may be 
isolated from hospitals in many different continents including Europe [7], North and South 
America [8], North Africa, India and South Korea [9, 10]. Salmonellae have been found to 
possess a wide variety of ESBL enzymes, including TEM, SHV, PER, CTX-M [11-13], as 
well as plasmid mediated AmpC enzymes (e.g. CMY, DHA, ACC-1) [14]. CTX-M enzymes 
are particularly important in facilitating the ESBL resistance phenotype and have been 
described in several Salmonella serotypes [15]. In fact, 12 out of more than 50 currently 
known CTX-M enzymes (which are divided into 5 major phylogenetic groups) have been 
identified in the Salmonella genus [16].  
 Fluoroquinolone resistance is also a growing problem in non-typhoidal salmonellae, 
with the first report of ciprofloxacin resistance in Salmonella enterica infection (eventually 
leading to treatment failure) being published in 1990 [17]. Since then, there have been reports 
of ciprofloxacin resistant isolates being found in many countries, including India, Pakistan, 
Vietnam and Spain [18-26].   
 Combined ESBL and fluoroquinolone resistance are major problems in the effective 
treatment of bacterial infections, both in the community and in the nosocomial setting. This 
problem is greatly increased when bacterial pathogens such as non-typhoidal salmonellae 
acquire both ESBL and fluoroquinolone resistance, as the consequences could be difficult for 
both livestock and in the community [27]. In order to manage and prevent the spread of 
antimicrobial resistance, both governments and clinicians require accurate information as to 
the prevalence and molecular mechanisms of antimicrobial resistance within currently 
circulating bacterial pathogens. At the present moment in time, this information tends to be 
lacking, especially in countries with large populations and unrestricted “over the counter” 
prescription policies, such as India. Therefore, this study was set up to investigate the extent 
of antimicrobial resistance, including ESBL and fluoroquinolone resistance, in non-typhoidal 
salmonellae originating from patients admitted to four hospitals in India. Information was 
also obtained regarding the circulating serotypes and genotypes of non-typhoidal salmonellae 
in order to relate these characteristics to specific antimicrobial phenotypes. 
  
Materials and methods 
 
Bacterial isolates and serotyping 
 
 Twenty-three isolates of non-typhoidal salmonellae were collected from patients 
attending four different hospitals in India (Pondicherry, Bangalore, Mangalore and Delhi) 
during 2007–2008. Non-typhoidal salmonellae were isolated from 19 stool cultures, 3 blood 
cultures and 1 CSF. Isolates were initially identified biochemically [28], followed by 
confirmation using specific antisera. Serovar determination was performed at the 
Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Bilthoven, The Netherlands.  
 
Antimicrobial susceptibility 
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 Antibiotic susceptibility profiles were obtained against 38 antibiotics using the Vitek 
(bioMerieux) system. The MICs of ceftriaxone and ciprofloxacin were determined using the 
E-test (AB Biodisk). Isolates were confirmed as ESBL produces via the combination disk 
method using ceftazidime (30µg) and ceftazidime-plus-clavulanate (30µg plus 10µg) disks. 
A ≥5mm increase in diameter of the inhibition zone of the ceftazidime-plus-clavulanate disc, 
when compared to the ceftazidime disc alone, was interpreted as phenotypic evidence of 
ESBL production. AmpC β-lactamase production was measured using cefoxitin (zone 
diameter <18mm was considered AmpC positive). The AmpC disk test for plasmid mediated 
AmpC β-lactamase detection was carried out according to the procedure previously described 
[29]. For the detection of efflux pumps, a 2-step dilution series of the antibiotics nalidixic 
acid and ciprofloxacin was made to detect minimum inhibitory concentration (MIC) in the 
absence and presence of the efflux pump inhibitor PABN (phenyl-arginine-β-
naphthylamide). MIC values were expressed as the highest dilution to inhibit growth, as 
determined by a lack of opacity in the respective wells of the microtitre plate used. All tests 
were performed according to CLSI guidelines where applicable [30].  
 
PCR screening and sequence analysis 
 
 Isolates were initially screened for the presence of TEM and SHV β-lactamases using 
a commercially available antimicrobial resistance gene microarray (Check-Points BV). PCR 
screening and sequencing was performed to identify the β-lactamase resistance genes; blaTEM, 
blaSHV, blaOXA-1 group, blaCTX-M and ampC as previously described [31-35]. The mechanism 
of quinolone resistance was determined by investigating mutations in the DNA gyrase (gyrA 
and gyrB) and DNA topoisomerase IV (parC or parE) genes [36-38]. Sequencing was 
performed using both forward and reverse PCR primers and standard methods on a 3130X1 
Genetic Analyzer (ABI PRISM). Additional sequencing primers were required for blaTEM 
PCR product sequencing (Lagging strand 7, 5’-TTACTGTCATGCCATCC-3’ and Lagging 
strand 3, 5’-AGAGAATTATGCAGTGC-3’). PCR primers corresponding to sequences 
downstream (ORF 1) of the blaCTX-M genes (M3 int upp, 5’-
TCACCCAGCCTCAACCTAAG-3’ and ORF1 pol M3, 5’-
GCACCGACACCCTCACACCT-3’ were also used [40]. Finally, PCR products of blaCTX-M 
were subjected to sequencing using primers, CTX-M-1 fw multi 5’-
AAAAATCACTGCGCCAGTTC-3’, CTX-M-1 multi (REV) F seq 5’-
AACGTGGCGATGAATAAGCT-3’ and ORF1 pol M3, 5’-
GCACCGACACCCTCACACCT-3’. Plasmid-mediated quinolone resistance, qnr was 
detected as previously described [40]. PCR screening for aac (6’)-Ib was performed 
according to Robicsek et al., 2006 [41]. The presence of individual plasmid types was 
determined by PCR screening of I1, FIA, FIB, FIIs, A/C, HI1, Frep, K/B, and B/0 replicons 
[42]. The presence or absence of integrons was determined using 5’-CS and 3’-CS primers 
specific for the variable regions of integrons as described by Levesque et al. 1995 [43]. 
 
Iso-electric focusing 
 
 Isoelectric focusing of β-lactamase enzymes was performed using the following 
procedure. Briefly, an overnight culture of the relevant isolate was made in 5 mL Brain Heart 
Infusion (BHI) broth with 100 mg/L ampicillin. After overnight incubation the culture was 
diluted 20 times in 5mL fresh BHI and incubated at 370C for 4 hours and with shaking at 
200rpm. The culture tubes were centrifuged for 5 minutes at 4000rpm at 40C, the pellet 
resuspended in 200µL of 50mM tris-HCl, pH 7.4. Five-microlitre lysozyme solution was 
added (40mg/mL), and the mix incubated for 60 minutes at 370C. After 60 minutes, 10 µL of 
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0.5 M EDTA was added and the mix incubated for a further 10 minutes at room temperature. 
The mix was finally centrifuged for 5minutes at 14000 rpm and the supernatant transferred to 
a clean tube [44]. The isoelectric point (pI) of the β-lactamase was determined by isoelectric 
focusing, applying the supernatants of crude cell extracts to Phast gels (GE HealthCare, 
Fairfield, CT, USA) with a pH gradient of 3–9 in a Phast system (GE HealthCare). Extended-
spectrum β-lactamases (ESBLs) with known pI values (TEM-1, SHV-2) were included as pI 
markers. 
 
Genotyping 
 
 Isolate genotyping was performed using pulsed field gel electrophoresis (PFGE) with 
2 restriction enzymes XbaI and SpeI, as well as ERIC PCR. Briefly, isolates were incubated 
overnight at 370C in 7mL Mueller Hinton broth. After incubation, 1mL of bacterial cells were 
harvested, pelletted and washed three times using 1mL EET (Na2EDTA 100mM, EGTA 
10mM, Tris HCl 1M) buffer, before being adjusted to a cell density of 0.5 at 560nm. A 
100µL of cell suspension and 100µL of 1.4% PFGE grade agarose in EET buffer were mixed 
and poured into PFGE plug moulds. The plugs were incubated at 40C for 30 minutes to 
harden and 1mL of lysozyme (5mg/mL) was added before incubation at 370C for 3 to 4 
hours. Lysozyme was removed from the plugs and 1mL each of deproteinising solution (per 
plug 3 mg/mL proteinase K and 1% SDS) was added prior to overnight incubation at 370C. 
Next, the plugs were washed 6 times every 30 minutes with T10E1 (10mM Tris, 1mM EDTA) 
buffer, and then soaked in T10E0.1 (10mM Tris, 0.1mM EDTA) buffer for 30 minutes. 
Restriction digestion was carried out using 40U of XbaI or SpeI (Fermentas) at 370C. PFGE 
was performed in a 1% agarose gel in a CHEF DR-II system (BioRad) with the following 
conditions 0.5X Tris- Borate EDTA buffer, 140C, 6 V/cm for 22h (with switch times ranging 
from 5 to 40 s). Lambda ladder PFGE marker (BioRad) was used as a molecular weight 
standard. ERIC PCR was performed on extracted DNA using PCR primers ERIC-1: 5’-
ATGTAAGCT CCTGGGGATTCAC-3’ and ERIC-2: 5’-
AAGTAATGACTGGGGTGAGCG-3’ as described by Chmielewski et al. 2002 [45].  
 
Results 
 
 The 23 non-typhoidal Salmonella isolates investigated comprised 6 serovars, namely 
Salmonella Agona (48%), Salmonella Typhimurium (26%), Salmonella Enteritidis (13%), 
Salmonella Senftenberg (4%), Salmonella Lexington (4%) and Salmonella Kirkee (4%). 
Serovars were not linked to a particular hospital.  Three of the of 23 (13%) Salmonella 
isolates were determined to be resistant to the following; extended-spectrum cephalosporins 
(cefotaxime, ceftazidime, and ceftriaxone), a monobactam (aztreonam), and a cephamycin 
(cefoxitin), and amoxicillin/clavulanic acid. They exhibited intermediate resistance to 
piperacillin/tazobactam. The three isolates were phenotypically confirmed to be ESBL and 
AmpC producers.  
 Twelve of the 23 (39%) phenotypically confirmed ESBL positive isolates were 
resistant to extended-spectrum cephalosporins, and 4 of these isolates were also resistant to 
ciprofloxacin. Seven of the 23 (30%) isolates were resistant to nalidixic acid, with the MIC of 
2 of the 4 ciprofloxacin resistant isolates (A15 and A13) being >64µg/mL, and the other two 
(B8 and B9) being 32µg/mL. At the species level, 2 of the Salmonella Agona isolates were 
resistant to extended-spectrum cephalosporins and ciprofloxacin. No resistance to 
carbapenems was recorded. Interestingly, 11 (92%) of the 12 ESBL-positive isolates 
belonged to the S. Agona serovar, with 9 (75%) of these 11 S. Agona isolates being 
genotypically clonal, and isolated from 2 different hospitals. ESBL Array analysis (Check-
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Points BV) revealed the presence of 12 TEM and 11 SHV positives within the 23 isolates, 
with all TEM-positive isolates being TEM-1 positive, and all SHV isolates being either 
SHV12 or SHV5 positive. IEF experiments showed that the cell extracts of these isolates 
contained β-lactamases with a corresponding pI of 5.4 (the pI of TEM-1) and 11 β-lactamases 
with a corresponding pI of 8.2 (the pI of SHV-12). Of the 12 ESBL isolates, 12 (100%), 11 
(91.6%), 3 (25.0%), 2 (16.7%) and 1 (8.3%) isolates were found to be TEM-1, SHV-12, 
DHA-1, OXA-1-like and CTX-M-15 positive, respectively. Additionally, 3 ESBL producers 
(25%) were co-producers of plasmid-mediated AmpC β-lactamase (Figure 1). Phenotypic 
evidence for the involvement of efflux pumps was detected in 4 isolates that were 
ciprofloxacin resistant. The range of mutations found in the DNA gyrase (gyrA and gyrB) and 
DNA topoisomerase IV (parC or parE) genes of the ciprofloxacin (quinolone) resistant 
isolates are shown in Table 1. A single ciprofloxacin resistant isolate harbored no mutations 
in the gyrA gene, but contained mutations in the QRDR (quinolone resistance determining 
region) region of the parC gene. All the isolates were negative for qnr gene and all 4 
ciprofloxacin resistant isolates carried the aac (6’)-Ib gene. Plasmids containing FIIS 
replicons were the most frequent plasmid types found (7/23 isolates), with multiple plasmid 
types being observed in 3 isolates only. Twelve isolates were negative for all of the replicons 
tested (Figure 1). There was no correlation between carriage of plasmid types and Salmonella 
serovar. Integrons were detected in 35% (8/23) of the isolates, all ESBL resistant, but were 
not associated with a particular serovar.  
 Though genotypic diversity was observed between the different serovars, some intra-
serovar clonality was observed, particularly among similar serovars isolated from the same 
hospital (Figure 2). The results from the ERIC-PCR tended to correlate with the PFGE 
genotyping results. Finally, antibiotic resistance profiles between ESBL producers tended to 
be similar, with non-ESBL producing isolates being much more susceptible to a range of 
common, clinically useful, antibiotics. In contrast, ESBL producing isolates tended to be 
resistant to most antibiotics tested, except amikacin, ciprofloxacin, meropenem, nalidixic acid 
and piperacillin/tazobactam. 
 
 
Discussion 
 
 In India, non-typhoidal salmonellae constitute approximately 20% of the Salmonella 
serovars currently circulating [46], and dissemination of isolates resistant to extended-
spectrum β-lactamases is frequently observed. Indeed, in this particular study, 52% (12/23) of 
non-typhoidal salmonellae isolated harbored ESBL genes and exhibited an ESBL phenotype, 
representing a very high percentage of isolates. Though several different serovars were 
identified, the great majority of ESBL producers belonged to the Salmonella Agona serovar, 
which also represented the most abundant serovar isolated in this study. In fact, S. Agona was 
reported for the first time in Ghana in 1961 [47], though this particular serovar has since been 
reported in many countries worldwide in both humans and animals [48]. For example, in 
Brazil, S. Agona has been reported as the being the fourth most common Salmonella serotype 
isolated from non-human sources, and among the top 10 serotypes associated with human 
disease [49]. Further, multidrug-resistant S. Agona has been responsible for at least two 
hospital outbreaks in paediatric wards [50, 51]. In both cases, the strains were found to harbor 
large plasmids that conferred resistance to multiple antibiotics. At the current moment in 
time, there are very few publications that have investigated antibiotic resistance in non-
typhoidal salmonellae [52]. From our results, it appears that S. Agona may also play an 
important role in non-typhoidal salmonellae ESBL-mediated resistance in India. More 
importantly, of particular concern is the fact that 2 isolates of S. Agona recovered in this 
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study possessed both ESBL and fluoroquinolone resistance genes, seriously limiting 
antimicrobial treatment options, and possibly providing a reservoir for the spread of this 
combination of antibiotic resistances to other pathogenic bacteria. 
 Eleven of the 23 non-typhoidal Salmonella isolates in this study were found to 
possess the SHV-12, ESBL phenotype and gene. The SHV-12 ESBL enzyme was first 
described in a Klebsiella pneumoniae strain isolated in Switzerland and differs from the 
SHV-1 enzyme by three amino acids substitutions [53]. It is currently one of the most 
common non-CTX-M ESBLs circulating and has been identified in many Gram-negative 
species, including Salmonella species [10, 54]. All of the 12 ESBL producers in our study 
also possessed the TEM-1 (non-ESBL) β-lactamase. TEM-1 is the most commonly 
encountered β-lactamase in the enterobacteriaceae, being able to hydrolyze narrow-spectrum 
penicillins and cephalosporins, such as cephalothin and cephaloridine [8]. 
 Among the isolates studied, 3 were positive for DHA-1, a plasmid-mediated AmpC 
enzyme first identified in Salmonella enteritidis isolates from Saudi Arabia in 1992 [55],  but 
is now reported in several other countries [56, 57]. Finally, a single isolate was positive for 
the CTX-M-15 ESBL enzyme. CTX-M-15 β-lactamase is now the most common CTX-M 
type reported worldwide, being first identified in enterobacterial isolates from India in 1999. 
The carriage of CTX-M-15 ESBL enzymes is a cause of concern for India [58]. 
 The ESBL enzymes that tend to be responsible for cephalosporin resistance in the 
genus Salmonella are TEM and SHV β-lactamase derivatives, though CTX-M type ESBLs 
have recently (though infrequently) been reported. In a study by Rotimi et al., 3.4% of the 
Salmonella spp. studied were found to be CTX-M-15 positive [59]. Further, the association of 
the CTX-M-15 gene with integrons, which can facilitate the rapid spread of resistance, is 
worrying [60], and studies have ascertained that most CTX-M gene-carrying plasmids 
possess replicons belonging to the incompatibility group (Inc) FII, or possess multi replicons 
of Inc FII associated with Inc FIA and FIB [61-65]. 
 Replicon type FIIs plasmids are associated with Salmonella virulence [66]. In this 
study, FIIs replicons plasmids were found in 7 (30.4%), and B/O replicons in 3 (13%), of 
serovars. Both FIA and FIB replicons were positive in 3 (13.0%) of the isolates. Plasmids 
harboring I1, A/C, HI1, Frep, and K/B replicons types were not detected. Plasmids have been 
classified according to their incompatibility (Inc) with other plasmids [67], Inc typing is 
based on the fact that two plasmids sharing common replication and partitioning elements 
meaning that they are unable to proliferate stably within the same bacterium [67]. Sorting of 
plasmids into Inc groups is advantageous because specific plasmid types have been 
associated with virulence and/or antimicrobial resistance [63, 68-73].  
 Integrons are genetic agents known to harbor and spread antibiotic resistance 
determinants in pathogenic bacteria [59]. Interestingly, in our set of non-typhoidal 
salmonellae, all isolates containing integrons were ESBL producing isolates, and integrons 
have previously been associated with the carriage and spread of ESBL enzymes. The 
association of particular β-lactamase genes with class 1 integrons (blaVIM, blaIMP, blaGES, 
blaVEB, blaCTX-M-2/-9, and blaCMY) or by sharing the same plasmid (blaTEM and blaSHV), has 
been reported in enterobacteriaceae [74-81], but the overall occurrence of integrons among 
ESBL-producing isolates has not been thoroughly analyzed [82, 83]. Therefore, the exact role 
of integrons in facilitating non-typhoidal Salmonella antibiotic resistance does require further 
investigation, not least in order to determine the importance of these mobile genetic elements 
in spreading antimicrobial resistance within the Salmonella genus. 
 The antimicrobial resistance ESBL Array (Check-Points BV) is a DNA micro-array 
system that offers accurate and rapid detection of ESBL genes. The use of such DNA micro-
arrays for rapid genotypic detection of β-lactamases could be an important tool for 
monitoring the spread of ESBL resistance genes within the hospital setting of the future [84]. 
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 Genotyping of our non-typhoidal salmonellae revealed variation in PFGE profiles 
within identical serovars, and no conclusive association between hospital and genotype. 
However, it was interesting to note that S. Agona isolates from Delhi were all clonal, 
indicating that this particular S. Agona strain may be endemic within this region of India. 
Further, the fact that this genotype also carries ESBL resistance, means that further studies 
into the current extent of infection with this genotype, as well as its potential to spread into 
surrounding regions, should be more closely investigated.  
 The presence of ESBL and fluoroquinolone antibiotic resistance in non-typhoidal 
Salmonella isolates within resource poor countries is jeopardizing classical antibiotic therapy. 
Continued surveillance of circulating ESBL producing, as well as fluoroquinolone resistant, 
salmonellae is warranted throughout India.  
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Table 1 . Mutations found in the DNA gyrase (gyrA and gyrB) and DNA 
topoisomerase IV ( parC or parE) genes of 4 quinolone resistant non -typhoidal 
salmonellae from India.
All 4 of the above isolates were resistant to ciprofloxacin. Two of the nalidixic acid sensitive 
control strains (included as negative controls) had no mutations (data not shown)
nd = mutations not detected
Isolate No gyrA gyrB parC parE
A15                  Ser 83 → Tyr                  nd Ser 80 → Ile nd 
Asp 87 → Gly 
A13                  Ser 83 → Tyr nd                     Thr 57  → Ser                    nd  
Asp 87 → Gly Ser 80 → Ile 
B8 nd                              nd     Thr 57  → Ser               nd
B9                    Ser 83 →  Le                    nd nd nd
Asp 87 →  Asn
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 83
Chapter 6                                                                        Non-typhoidal salmonellae from India 
 
 
 
 
 
 
 
 
Figure 1. Relationship between PFGE genotype and antimicrobial susceptibility profiles for 
23 non-typhoidal Salmonella isolates from India. Antimicrobial drugs to which isolates were 
resistant are listed: amikacin (Ak), amoxycillin/clavulanic acid (Ac), ampicillin (A), 
cefazolin (Cz), cefepime (Cpm), cefoxitin (Cn), cefpodoxime (Cep), ceftazidime (Ca), 
ceftriaxome (Ci), cefuroxime (Cu), chloramphenicol (C), ciprofloxacin (Cf), meropenem 
(M), nalidixic acid (Na), piperacillin (Pc), piperacillin/tazobacatam (Pc/Tz). T-1 = TEM-1, S-
12 = SHV-12, C-15 = CTX-M-15, O-1= OXA-1 group, A = AmpC (DHA-1). 
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Figure 2. PFGE patterns of 23 non-typhoidal salmonellae obtained from India between 2005 
and 2008, using restriction enzymes XbaI and SpeI. Cluster analysis was performed using the 
method of DICE with UPGMA with band tolerances set to 1.5%. All isolates were cultured 
from stool specimens apart from isolates B4 (CSF), A19, B5 and B13 (blood culture). Place: 
P = Pondicherry, M = Mangalore, B = Bangalore, D = Delhi. T-1 = TEM-1, S-12 = SHV-12, 
C-15 = CTX-M-15, O-1= OXA-1 group, A = AmpC (DHA-1), Ep = Efflux pump positive 
based on antibiotic testing (see methods), Int = Integrons PCR, ERIC = ERIC PCR type, 
Plasmids = Plasmids PCR (Carattoli et al., 2005), FIA, FIB, FIIS, B/O = major plasmids 
incompatibility groups. 
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Abstract 
 
Objectives: The aim of this study was to characterize 34 vancomycin-resistant VanA 
Enterococcus faecium isolates obtained from two hospitals in Saudi Arabia and to assess 
Tn1546 variation within these isolates. 
 
Methods: PFGE and multilocus sequence typing (MLST) genotypes, antibiotic susceptibility 
patterns, the presence of enterococcal surface protein (esp) and hyaluronidase (hyl) genes and 
conjugation frequencies were determined. In addition, Tn1546 elements were characterized. 
 
Results: PFGE and MLST analysis revealed the presence of 31 and 6 different genotypes, 
respectively. Further, three new ST types were discovered. Ninety-seven percent (33/34) of 
the isolates were associated with clonal complex 17 (CC17), with all isolates but one being 
resistant to ampicillin and all isolates being susceptible to linezolid. The esp and hyl genes 
were found in 44% (15/34) and 53% (18/34) of the isolates, respectively. Tn1546 analysis 
revealed that the isolates belonged to five different groups, including two new lineages. The 
IS-element insertions described did not abolish the transfer of VanA resistance. 
 
Conclusions: VanA vancomycin-resistant E. faecium isolates obtained from Saudi Arabian 
hospitals include CC17 MLST types, a clonal cluster associated with E. faecium nosocomial 
infection worldwide. Novel E. faecium MLST types are circulating in Saudi Arabia, as well 
as novel Tn1546 types. It seems likely that CC17 E. faecium isolates may be distributed 
throughout the Middle East as well as Europe, America, Africa and Australia. 
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Introduction 
 
Enterococci and vancomycin-resistant enterococci (VRE) are often found in the 
human and animal gut and have become increasingly responsible for nosocomial infections, 
particularly in the USA. In Europe, however, VRE have tended to be associated with 
community carriage and occasional nosocomial outbreaks, although the incidence of VRE 
infection may be changing [1]. Enterococci often express high-level resistance to 
glycopeptides and aminoglycosides, with vancomycin resistance having been promoted via 
the extensive use of vancomycin in hospitals, as well as the animal growth promoter 
avoparcin. 
Six different vancomycin resistance types have so far been described in enterococci, 
namely VanA, VanB, VanC, VanD, VanE and VanG. The VanA type is characterized by 
both high-level and inducible resistance to vancomycin (MICs 64–1024 mg/L) and 
teicoplanin (MICs 16–512 mg/L) and has been shown to be directly facilitated by the carriage 
of transposon Tn1546, a transposon widely disseminated in humans, animals and the 
environment [2]. 
Currently, there is a distinct lack of data regarding the molecular analysis of VanA 
Enterococcus faecium Tn1546 carriage in VRE isolates originating from the Middle East, 
including Saudi Arabia. Therefore, the aim of this study was to determine E. faecium 
genotypic variation and VanA Tn1546 transposon diversity in VRE isolates recovered from 
the Kingdom of Saudi Arabia. 
 
Materials and methods 
 
Bacterial isolates 
 
Thirty-four vancomycin-resistant E. faecium isolates were cultured from clinical 
specimens obtained from two large tertiary-care hospitals in the Kingdom of Saudi Arabia, 
namely the King Faisal Specialist Hospital and Research Centre, Riyadh (KFSH&RC), and 
the King Fahad National Guard Hospital, King Abdulaziz Medical City, Riyadh (KFNGH). 
Isolates were collected between 2000 and2003. Two pairs of isolates (25/29 and 17/32) were 
isolated from two different patients, but on separate occasions. 
 
PFGE and multilocus sequence typing (MLST) 
 
PFGE was performed using SmaI-digested fragments of bacterial chromosomal DNA, 
with fragment separation achieved in 0.8% agarose. Electrophoresis conditions comprised 
using a constant voltage of 6 V/cm at 148C and pulse times of 3.5–25 s increased linearly 
over 12 h (block 1), followed by 1–5 s increased over 8 h. Gel patterns were analysed using 
BioNumerics software (Applied Maths) with the band tolerance set at 1.0%. MLST was 
performed using internal fragments from seven housekeeping genes. Allele numbers and 
sequence types were assigned after reference to the online E. faecium MLST database at 
http://efaecium.mlst.net/. 
 
Antibiotic susceptibility testing 
 
Antibiotic susceptibility testing was performed using the VITEK 2 automated 
identification and susceptibility system (bioMérieux, Marcy l’Étoile, France) according to the 
manufacturer’s instructions. 
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PCR characterization of Tn1546 elements and screening for virulence genes 
 
Primer pairs used to characterize Tn1546 were based on those published by Miele et 
al. [3]. In addition, primer walking was utilized to define insertion site-specific sequences. 
PCR screening for the enterococcal surface protein (esp) and hyaluronidase (hyl) virulence 
genes used three different primer pairs. For the esp gene, primer pairs esp11 (50-
TTGCTAATGCTAGTCCACGACC-30)/esp12 (50-GCGTCAACACTTGCATTGCCGAA-
30) and 14F (50-AGATTTCATCTTTGATTCTTGG-30)/12R (50-
AATTGATTCTTTAGCATCTGG- 30) were used, and for the hyl gene, primer pair HYL n1 
(50-ACAGAAGAGCTGCAGGAAATG-30)/HYL n2 (50-
GACTGACGTCCAAGTTTCCAA-30). A touchdown PCR protocol was used for all primer 
pairs, comprising an initial annealing temperature of 65ºC, which was initially reduced by 
18C per cycle over 15 cycles, and then followed by 20 cycles of amplification using an 
annealing temperature of 55ºC. All PCRs were performed using Taq DNA polymerase 
(EP0402, Fermentas). 
 
Conjugation frequency 
 
Conjugation frequency was determined using a standard methodology [4], with E. 
faecium GE1 being used as the recipient strain, and antibiotic concentrations of 6 mg/L 
vancomycin, 64 mg/L rifampicin and 10 mg/L fusidic acid being used. Conjugation 
frequencies were calculated with reference to the donor isolate. 
 
Results and discussion 
 
PFGE and MLST genotyping 
 
PFGE identified 18 ‘possibly related’ PFGE genotypes based on a 70% similarity cut-
off value (approximately equivalent to four to six PFGE fragment differences) [5], with all 
isolates being genotypically related at a similarity of 34% (Figure 1). MLST genotyping 
revealed six ST types, with three new ST genotypes (ST 358, 359 and 360) and 59% (20/34) 
of the isolates being ST 17 genotypes. Further, the three new ST types (four isolates) and 
ST 16 (two isolates) were exclusively associated with the KFSH&RC, whereas ST 18 (eight 
isolates) was exclusively associated with the KFNGH. In contrast, ST 17 was recovered 
from both hospitals. Ninety-seven percent (33/34) of the isolates belonged to clonal complex 
17 (CC17), a cluster of E. faecium MLST genotypes previously associated with global 
nosocomial infections [1]. CC17 has been previously associated with ampicillin resistance 
and carriage of the enterococcal surface protein pathogenicity island. In Saudi isolates, 
ampicillin resistance and esp gene carriage were found in 99% and 45% of the isolates, 
respectively, indicating that CC17 isolates from Saudi Arabia possess similar characteristics 
to those obtained from other well documented regions of the world. 
 
Antibiotic susceptibility patterns 
 
All isolates but one were resistant to vancomycin and ampicillin, and all isolates were 
susceptible to linezolid (Figure 1). No pattern was observed with respect to the general 
expression of multiple antibiotic resistances and PFGE genotype. 
 
Characterization of Tn1546 elements 
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In total, five different Tn1546 types were observed within our 34 E. faecium isolates 
(Figure 2). In eight isolates (numbers 2, 4, 5, 6, 12, 34, 35 and 41), the PCR amplicon size 
analysis revealed no major insertions or deletions, compared with theoretical amplicon 
products generated using reference Tn1546 BM4147 sequence. In isolates where Tn1546 
polymorphisms were found, the majority of polymorphic events involved the insertion of 
IS1216V within the intergenic regions of either vans and vanH or vanX and vanY genes, along 
with other less frequent insertions of IS1485 and IS1251. In fact, IS1216V is one of the most 
common insertion sequences found in Tn1546-bearing vancomycin-resistant enterococci 
worldwide. Further, IS1251 has previously been demonstrated to be present in Tn1546 
transposons present within human clinical E. faecium isolates from Brazil, Korea, the USA, 
Norway and Ireland. Our Tn1546 results allowed us to add two new lineages to a previously 
published evolutionary scheme [6], namely lineage III (IS1485 insertion in orf1) and lineage 
IV (IS1216V insertion between vanS and vanH). 
 
Prevalence of esp and hyl virulence genes 
 
Using PCR screening, the enterococcal surface protein (esp) gene was found to be 
present in 44% (15/34) and the hyaluronidase (hyl) gene in 53% (18/34) of the isolates tested. 
esp-positive isolates made up 46% (10/22) of the isolates from the KFNGH and 41% (5/12) 
of the isolates from the KFSH&RC. In contrast, hyl-positive isolates made up 41% (9/22) of 
the isolates from the KFNGH but 75% (9/12) of the isolates from the KFSH&RC. Only four 
esp-positive isolates were also found to be hyl-positive, whereas 14 hyl-positive isolates were 
found to be esp-negative. A significant difference in the prevalence of esp and hyl-positive 
isolates was observed with respect to PFGE clusters (Figure 1), with 71% (10/14) of the esp-
positives belonging to the cluster bordered by isolates 19 and 40 (Fisher’s exact test P = 
0.02), yet 75% (15/20) of the hyl-positives belonging to the cluster bordered by isolates 36 
and 12 (Fisher’s exact test P = 0.004). The distribution of the two hospitals between the 
PFGE clusters defined earlier was not significant (Fisher’s exact test P = 0.066). The 
expression of enterococcal surface protein (Esp) has been associated with both biofilm 
formation and nosocomial infection in E. faecium [7], as well as CC17 isolates [8]. Further, a 
recent publication indicated that clinical E. faecium isolates carrying the esp gene possess an 
increased conjugation frequency with respect to the ability to acquire VanA vancomycin 
resistance [9]. The prevalence of the esp gene within our 33 CC17 isolates was somewhat 
lower than previously reported [1], although all isolates were ampicillin-resistant. However, 
91% (30/33) of the CC17 isolates possessed either the esp or hyl virulence genes. The 
hyaluronidase protein (Hyl) is a virulence trait also associated with clinical E. faecium 
isolates, with a ratio of 2:1 for esp:hyl-positive isolates reported in a sample of 577 isolates 
worldwide [10]. This compares with a ratio of 1:1.2 in our smaller group. 
 
Conjugation frequency 
 
Conjugation frequencies of representative isolates from each transposon group ranged 
from 2.2 x 10-4 to 1.9 x 10-6. These frequencies lie within the range of previously published 
transformation frequencies observed for other global VanA-resistant, Tn1546-carrying E. 
faecium isolates. 
 
Conclusions 
 
In this study, we investigated 34 vancomycin-resistant VanA E. faecium isolates 
cultured from two hospitals situated in Riyadh, Saudi Arabia. The majority of the isolates 
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tested belonged to CC17 and were resistant to ampicillin, suggesting that E. faecium MLST 
types associated with nosocomial infection are also circulating in the Middle East. The 
Tn1546 analysis revealed two new lineages, including two previously undescribed IS1485 
and IS1216V insertions. 
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Figure 1. PFGE patterns obtained from 34 vancomycin-resistant E. faecium isolates from 
Saudi Arabia. Cluster analysis was performed using the method of DICE with UPGMA with 
band tolerances set to 1.0%. Hosp. = hospital, where K = King Faisal Specialist Hospital and 
Research Centre and N = King Fahad National Guard Hospital. esp, enterococcal surface 
protein PCR; hyl, hyaluronidase PCR; AMP, ampicillin; GEN, gentamicin; TET, tetracycline; 
Q/D, quinupristin/dalfopristin; LZD, linezolid; CIP, ciprofloxacin; R, resistant; I, 
intermediate resistance; S, susceptible. 
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Figure 2. Genetic maps of Tn1546 types associated with 34 E. faecium isolates originating 
from Saudi Arabia. The unbroken black lines represent reference Tn1546 sequence BM4147. 
Unfilled block arrows represent the positions of genes and open reading frames (orf1 and 
orf2). Filled boxes represent IS elements and arrows their direction of transcription. Dotted 
lines represent deletions. The unfilled box represents a sequence similar to plasmid pEFNP1 
(Losteinkit et al., 2000; GenBank accession number AB038522, unpublished results). The 
positions of the first nucleotides upstream and downstream of the insertion sequence are 
shown. Group definitions (right-hand side) are based on those published by Schouten et al. 
[6]. Asterisk indicates novel Tn1546 group. Numbers in parentheses indicate how many 
isolates belonged to each Tn1546 grouping. 
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Abstract  
 
Forty infection-associated VanA-type vancomycin-resistant Enterococcus faecium 
(VRE) strains obtained from five collaborating hospitals in Asunción, Paraguay were 
investigated. Genotyping using pulsed-field gel electrophoresis (PFGE) and multilocus 
sequence typing revealed the presence of 17 cluster types and four STs, with 93% (37/40) of 
isolates comprising ST type 78. Other ST types included ST-132, ST-210 and one new ST 
type (ST-438). All but one isolate (ST-438) were associated with clonal complex 17 (CC17), 
and 97% of the total isolates carried the esp gene. Three Tn1546 variants were found, 
including a new lineage containing an ISEfa5 insertion in an existing IS1251 element.  
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Vancomycin-resistant Enterococci (VRE) are nosocomial pathogens widely 
disseminated within hospitals [1], with the vanA genotype being the most common type of 
acquired glycopeptide resistance found in these enterococci. Although the first clinical isolate 
of VRE was detected in Europe in 1986, studies have now shown that clinical VRE may be 
isolated in several world regions [2]. Further, it is currently accepted that a single focal group 
of vanA-type VRE (clonal complex 17 or CC17) is particularly associated with nosocomial 
infections [3]. However, there is some evidence to suggest that this grouping may be 
influenced by the high rates of recombination associated with E. faecium [4]. 
In 1988, French researchers identified a small mobile genetic element in VanA-type 
Enterococcus faecium called Tn1546, which is involved in vancomycin resistance [5], and 
there are currently five other acquired vancomycin resistance genotypes reported in 
enterococci, namely vanB, vanD, vanE, vanG and vanL [5, 6]. 
Currently, there exist limited data regarding the incidence and types of clinical 
vancomycin-resistant E. faecium from countries in South America. Therefore, the objective 
of this study was to investigate the complexity of clinical E. faecium isolates from Paraguay, 
by determining E. faecium genotypes and VanA Tn1546 transposon diversity, and to compare 
the results with isolates from both South America and the rest of the world.  
Two hundred and twenty-one VanA vancomycin-resistant E. faecium isolates were 
collected between January 2005 and March 2007 from five collaborating hospitals in 
Asunción Paraguay. These five hospitals, the Instituto de Previsión Social (IPS), Hospital de 
Clinicas (HCL), Hospital Nacional (HNA), Centro Medico de Bautista (CMB) and Instituto 
de Medicina Tropical (IMT), are representative of the national healthcare system in Paraguay. 
A subset of 40 isolates was chosen for further analysis, based on their site of isolation and 
association with disease. These infection-associated isolates were cultured from abscess 
material, blood, tissue and needle aspirates, representing 7% (7/97), 20% (1/5) and 27% 
(32/117) of the isolates obtained from HCL, HNA, and IPS, respectively. No infection-
associated isolates were obtained from CMB (0/1) and IMT (0/1) hospitals. 
Antibiotic resistance profiling was performed using the VITEK 2 system 
(BioMérieux, Marcy l’Étoile, France) and E-test (amoxicillin/clavulanic acid), according to 
CLSI guidelines. All 40 infection-associated isolates tested in this study were resistant to 
ampicillin, amoxicillin/clavulanic acid, ciprofloxacin, erythromycin, imipenem, penicillin, 
teicoplanin and vancomycin. All isolates were sensitive to linezolid and tetracycline. Forty-
three per cent (17/40) of the isolates were resistant to gentamicin (Figure. 1). 
The enterococcal surface protein gene (esp) was detected by PCR screening [7], revealing 
that all isolates were esp positive with the exception of one isolate (ST132). The prevalence 
of esp in these isolates is higher than previously reported for European CC17 isolates [8]. 
Pulsed-field gel electrophoresis (PFGE) and multi locus sequence typing (MLST) 
genotyping were performed as previously described [9]. PFGE results revealed 17 cluster 
types with no identifiable yearly pattern per cluster. Cluster analysis was performed using the 
method of DICE with UPGMA, with band tolerance set at 1.5% and the threshold cut-off 
value at 80% [10, 11]. The results of MLST genotyping revealed three known (ST-78, ST-
132 and ST-210) and one novel (ST-438) ST type, with 93% (36/40) of isolates comprising 
ST-78 genotypes. These ST-78 isolates comprised 100% of all infection-associated isolates 
from the HCL and HNA hospitals, and 87% (28/32) of the isolates from the IPS. Although 
this ST type has previously been reported in Europe, it has not been reported in South 
America, the USA or Spain, approximately 95% of Paraguayans are of mixed Spanish and 
Amerindian descent. Therefore, the origins of ST-78 in Paraguay remain unexplained, 
although it appears that the ST-78 strain has spread to many hospitals in Asunción.  
In total, 97% (39/40) of the isolates tested belonged to MLST clonal complex 17 
(CC17), which comprises a cluster of E. faecium genotypes previously associated with 
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hospital infections [3, 12]. ST-438 was the only non-CC17 isolate recovered. Further analysis 
revealed no association between the antibiotic resistance profile and PFGE or MLST 
genotypes (Figure. 1). 
Characterization of Tn1546 was performed using previously published primers [13], 
and a touchdown PCR thermocycling protocol [7]. PCR primer walking and sequencing 
were used to define insertion site-specific sequences. The results of Tn1546 characterization 
revealed three different variants (Figure. 2). Two of the isolates did not show any insertion 
or deletion compared with the classic Tn1546 (BM4147) transposon sequence [14]. In 
contrast, 92% (37/40) of the isolates carried a Tn1546 variant containing an insertion of 
IS1216V (and a resultant deletion event) in orf1, coupled to an IS1251 insertion in the 
intergenic region of vanS and vanH (Tn1546 type F1 described by Willems et al. [15]). A 
single isolate with a new MLST genotype (ST-438) carried a novel Tn1546 variant of type F1 
containing an ISEfa5 insertion. This IS element has only previously been described in 
Brazilian E. faecium isolates, where the ISEfa5 was exclusively inserted in the intergenic 
region of vanX and vanY [16]. In this ST-438 Paraguayan isolate the ISEfa5 element was 
inserted in the left flanking region of another insertion element IS1251, which itself was 
situated in the intergenic region between vanS and vanH. Sequencing of the ISEfa5 flanking 
insertion regions showed an inverted repeat of 6 bp (AGAGCC) flanked by an 8 bp direct 
repeat (AGAATAAT) of the IS1251 insertion element. From current evidence, presence of 
the ISEfa5 element in Tn1546 appears to be specific for Enterococcus isolates originating in 
South America. Further, this unusual insertion event indicates that Tn1546 may still be 
evolving in South American E. faecium isolates. 
This is the first report of molecular investigations into vancomycin-resistant E. 
faecium from Paraguay. The results from 40 infection-associated VRE isolates obtained from 
hospitals in Asunción revealed that the majority of isolates were found to be MLST type ST-
78, a genotype associated with MLST clonal complex 17 (hospital-associated) isolates. The 
majority of isolates also carried the same Tn1546 structural variant (type F1), indicating that 
this combination currently represents the majority of infection-associated VanA E. faecium 
isolates currently circulating in hospitals in Asunción, Paraguay [15]. Also, although 
relatively little information is currently available, there appears to be an association between 
Tn1546/ISEfa5 and enterococcal isolates circulating in South America. 
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Figure 1. Pulsed-field gel electrophoresis (PFGE) patterns obtained from 40 infection-
associated vancomycin-resistant Enterococcus faecium isolates obtained from Paraguay 
between 2005 and 2007. Cluster analysis was performed using the method of DICE with 
UPGMA with band tolerance set to 1.5%. 
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Figure 2. PCR and sequence-based characterization of Tn1546 in 40 infection-related 
Enterococcus faecium isolates from Paraguay. Tn1546 reference sequence BM4147 is 
represented by the unbroken black lines. The position of different genes and open reading 
frames (orf1 and orf2) are shown by filled block arrows. IS elements are shown by filled 
boxes and their direction of transcription is represented by arrows. Deletions are represented 
by dotted lines. The positions of the first nucleotides upstream and downstream of the 
insertion sequences are shown. The groups are based on the published results of Willems et 
al. [15]. *A novel F1 variant of Tn1546. Numbers on the left indicate how many isolates 
were found to belong to each Tn1546 variant. 
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Abstract  
 
 Molecular epidemiology of 53 high-level gentamicin resistant (HLGR) E. faecalis 
isolates cultured from 1,686 specimens collected from intensive care and general wards at the 
Erasmus Medical Centre, Rotterdam, The Netherlands, between 2000 and 2003 was studied. 
PFGE and MLST genotyping, antibiotic susceptibility profiling, PCR screening for the 
presence of virulence genes, and assessment of Tn4001 element flanking region variability 
was performed. The MLST analysis revealed the presence of 3 major ST types (ST-2, ST-6 
and ST-16), confirming the importance of these STs in the nosocomial setting. Genotypic 
analysis of 14 serial HLGR isolates obtained from 6 patients revealed that replacement of 
HLGR genotypes did not occur during hospital admission, suggesting that equilibrium exists 
between HLGR genotypes and their host. Among the HLGR E. faecalis isolates tested, the 
majority possessed esp, cob, ccf, cpd, asI and cylM genes. PCR screening for the aac (6’)-Ie-
aph (2”)-Ia gene revealed that all HLGR isolates possessed this 6’-acetyltransferase-2”-
phospho-transferase gene. Most isolates also showed deletions in their Tn4001 flanking 
sequences. Finally, the percentage of patients colonized with HLGR E. faecalis on ICU wards 
was found to be significantly higher than patients on general wards. Our results confirm the 
importance of HLGR E. faecalis ST-2, ST-6 and ST-16 types in the nosocomial environment, 
particularly in ICU wards. Further, the replacement of “indigenous” HLGR E. faecalis 
genotypes, already present in patients at the time of admission to hospital, does not appear to 
occur. This suggests that a balance exists between pathogen and host. 
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Introduction  
 
Enterococcus faecalis is the leading causative agent of human infection among the 
different species of enterococci, being specially associated with nosocomial bacteremia and 
bacterial endocarditis [1-4].  
Treatment options for nosocomial infections, usually involve the use of penicillin or a 
glycopeptide antibiotic in conjunction with an aminoglycoside, a combination that has a 
synergistic effect against many nosocomially acquired enterococcal infections. However, 
these antibiotic treatment therapies are being compromised due to combinations of intrinsic 
and acquired antimicrobial resistance [2]. Indeed, the intrinsic low-level resistance of 
enterococci to many commonly used antimicrobial agents e.g. β-lactams and glycopeptides, 
may have facilitated their survival in hospital environments, allowing them to acquire other 
antibiotic resistance genes involved in, for example, high-level resistance to aminoglycosides 
[5]. In fact, one of the most frequently used aminoglycoside antibiotics is gentamicin, with 
high-level gentamicin resistance (HLGR) being first observed in E. faecalis in1979 [6]. 
Further, HLGR (MIC ≥500 mg/L) may be facilitated by several related aminoglycoside-
modifying enzymes (AMEs) that are expressed from a series of gentamicin resistance genes 
usually carried on transposons, namely aac (6’)-Ie-aph (2”)-Ia, aph (2”)-Ib, aph (2”)-Ic, and 
aph (2”)-Id [7, 8]. 
The ability of enterococci to acquire virulence traits helps them survive in the human 
host [9, 10]. Studies have reported that enterococcal virulence factors such as cytolysins and 
aggregation substance (AS) are among the major factors known to be associated with E. 
faecalis virulence, and have also been associated with enterococcal pathogenicity in animal 
models [2, 11-12]. Additional virulence factors carried by E. faecalis include cell wall 
adhesins e.g. efaAfs [2, 13] and the cell wall-associated cytolysin proteins that are expressed 
by the cylA, cylB and cylM genes, which are involved in immune evasion. Sex pheromone 
genes such as cpd, cob, ccf and cad induce chemotaxis in human leucocytes and induce the 
secretion of lysosomal enzymes in the human host [10, 14-16]. 
The aim of this study was to characterize and compare HLGR E. faecalis isolates 
circulating in both ICU and general wards at a large university medical centre in The 
Netherlands (i.e. Erasmus MC, Rotterdam). We also aimed to provide information regarding 
the prevalence of dominant genotypes, their origin, and enterococcal dynamics during 
hospitalisation and after discharge.  
 
Materials and methods  
 
Bacterial strains 
 
The E. faecalis isolates investigated in this study originated from patients admitted to 
either intensive care wards (surgical and neurological) or general wards (internal medicine, 
neurology and pulmonology) of the Erasmus MC, Rotterdam, The Netherlands, between 
November 2000 and July 2003. All strains were isolated from stool specimens or rectal swabs 
of adults over 18 years of age as part of a simultaneous study investigating the colonization 
and resistance dynamics of Gram-negative bacteria at the Erasmus MC [17]. Stool samples 
and swabs were obtained within 48 hours of admission, during hospital stay (at least 4 days 
after admission and at weekly intervals thereafter), and 1-3 months after discharge. Samples 
were cultured in enterococci-selective esculin enrichment broth containing 75mg/L 
aztreonam (Bristol Myers Squibb) for primary isolation. Subculture was performed using 
Columbia blood agar.  
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Antibiotic susceptibility testing  
 
The determination of antibiotic minimum inhibitory concentrations was performed 
using the VITEK 2 system (bioMerieux) and AST-P524 cards. E. faecalis ATCC 29212 was 
used as a reference isolate. High-level gentamicin resistant E. faecalis isolates were selected 
using the results obtained from VITEK 2 screening such that a single, randomly chosen E. 
faecalis colony (from a maximum of 5) was investigated per patient per time period (i.e. at 
the time of admission, during stay, and at either 1 or 3 months post-discharge). Gentamicin 
susceptible E. faecalis isolates were also analyzed from patients who had been colonized by 
high-level gentamicin resistant E. faecalis in at least 1 sample period and where any of the 
remaining sampling periods had recovered E. faecalis isolates that were gentamicin 
susceptible only.  
 
Multi-locus sequence typing (MLST) 
 
MLST PCR and sequence analysis was performed using internal fragments from 
seven housekeeping genes of E. faecalis as previously described [18]. Allele numbers were 
assigned after reference to the online E. faecalis MLST database situated at 
http://efaecalis.mlst.net/, and sequence types (ST) were then determined based on these allelic 
profiles.  
 
Pulsed-field gel electrophoresis (PFGE) 
 
Pulsed-field gel electrophoresis (PFGE) was performed using SmaI digested 
fragments of genomic chromosomal DNA. Fragments were separated in 0.8% agarose using a 
constant voltage of 6 Vcm-1 at 14oC and pulse times of 3.5 – 25 seconds, which increased 
linearly over 12 hours (block 1). This was followed by a pulse time of 1 – 5 seconds 
increasing over 8 hours. Gel patterns were analyzed using GelCompar software (Applied 
Maths) with gel lanes normalized against a lambda DNA ladder (BIO RAD) with band 
tolerance set at 1.5%.  
 
PCR for virulence-associated genes 
 
PCR screening for the presence of aggregation substance (asI), gelatinase (gelE), 
cytolysins (cylA, cylB and cylM), sex pheromones (cpd, cob and ccf), and enterococcal 
surface protein (esp) genes was performed using primer sequences previously published by 
Eaton and Gasson (2001) [10]. PCR for the hyaluronidase (hyl) gene was performed using 
primers published by Vankerckhoven et al. [19]. A touchdown PCR protocol was used for 
thermocycling [20].  
 
  PCR screening and sequencing of Tn4001 transposon 
 
PCR screening for the presence of Tn4001 containing gentamicin resistant gene aac 
(6’)-Ie-aph (2”)-la and flanking regions was performed using the primers published by 
Vakulenko et al. [8]. A touchdown PCR protocol was used for thermocycling. The primer 
sequences used were: 
aac (6’)-Ie-aph (2”)-la       5’- CAGGAATTTATCGAAAATGGTAGAAAAG – 3’ 
                                            5’- CACAATCGACTAAAGAGTACCAATC – 3’ 
aac (6’)-Ie-aph (2”)-la       5’- CAGAGCCTTGGGAAGATGAAG – 3’ 
                                            5’- CCTCGTGTAATTCATGTTCTGGC – 3’ 
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Results 
 
Bacterial strains 
 
The patient and sample chronology associated with high-level gentamicin E. faecalis 
colonization in ICU and general wards at Erasmus MC between 2000 and 2003 is shown in 
Table 1. In total, 1,686 stool samples or rectal swabs (797 ICU and 889 general wards) were 
obtained from 413 patients (187 ICU and 226 general ward patients), with an enterococcus 
species being cultured from 1,026 (61%) specimens, yielding 5,112 enterococcus colonies for 
investigation. The following enteroccus species were identified: 3,292 (64%) E. faecalis; 
1,034 (20%) E. faecium; 320 (6%) E. cassiflavus /gallinarum; 280 (5%) E. hirae; 98 (2%) E. 
durans and 88 (2%) E. avium. Four hundred and eighty out of 3,292 (15%) E. faecalis 
colonies (368 ICU and 112 general wards), isolated from 57 patients (40 ICU and 17 general 
wards), exhibited high-level resistance to gentamicin. This translates to 20% (40/187) of 
patients from the ICU and 7% (16/226) of patients from general wards were colonized by 
HLGR E. faecalis isolates. Further, a significant difference was observed (Table 2) between 
the percentage of patients colonized with HLGR E. faecalis isolates in the ICU wards 
compared to general wards during stay but not during admission or after discharge [Fisher's 
Exact Test P <0.001]. Fifty-three HLGR E. faecalis isolates were selected for further analysis 
from 39 patients who had been colonized by a HLGR E. faecalis. These 53 isolates included 
12 isolates from admission, 24 isolates from intensive care ward patients, 6 isolates from 
patients exclusively admitted to general wards, and 11 isolates collected between 1 and 3 
months after discharge from hospital. Ten gentamicin susceptible E. faecalis isolates were 
investigated from patients who had also been shown to be colonized by high-level gentamicin 
resistant E. faecalis isolates.  
 
Antibiotic susceptibility patterns for HLGR 
 
Antibiotic susceptibility patterns of 53 HLGR and 10 gentamicin susceptible E. 
faecalis are shown in Tables 3a and 3b, respectively. Among the 53 high-level gentamicin 
resistant isolates tested, 92% (49/53) were resistant to erythromycin, 72% (38/53) resistant to 
tetracycline and 60% (32/53) resistant to streptomycin. All 53-HLGR E. faecalis isolates 
were susceptible to ampicillin, ciprofloxacin, teicoplanin and vancomycin. Of the 10-
gentamicin susceptible E. faecalis isolates, all were susceptible to ampicillin, ciprofloxacin, 
vancomycin and teicoplanin. 
 
Multi-locus sequence typing (MLST) 
 
The results of multi locus sequence typing are shown in Tables 1, 3a and 3b. Three 
major MLST-types (ST-2, ST-6 and ST-16) were isolated, representing 79% of the HLGR 
isolates. In contrast, MLST results for 10 gentamicin susceptible isolates cultured from the 
same patients revealed that all possessed different MLST-types. With respect to the 
relationship between MLST-type and antibiotic profiles, our ST-2 isolates were all 
susceptible to tetracycline, whilst ST-6 and ST-16 were all resistant. Additionally, our ST-16 
isolates were all susceptible to levofloxacin, and a trend towards streptomycin susceptibility 
was observed for our ST-6 isolates. 
 
PFGE results  
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PFGE of 14 serial HLGR isolates from 6 patients revealed that identical genotypes, 
present at the time of admission, could be isolated from the same patient before, during and 
after hospital stay (Figure 1).  
 
PCR for virulence-associated genes 
 
The results of PCR screening of virulence genes in 53 HLGR E. faecalis and 10 
gentamicin susceptible E. faecalis isolates are shown in Tables 3a and 3b, respectively. 
Among HLGR E. faecalis isolates, 51% (27/53), 85% (45/53), 89% (47/53), 100% (53/53), 
94% (50/53), 51% (27/53), 45% (24/53) and 11% (21/53) were positive for esp, cob, ccf, cpd, 
asI, cylM, cylB and cylA genes, respectively. All 53-HLGR isolates were PCR negative for 
hyaluronidase (hyl) and gelatinase (gelE). Comparison with MLST data indicated a negative 
association between carriage of cylM, cylB and cylA genes and ST-2 isolates. Further, there 
was an association between ST-16 isolates and cylA negativity. Finally, both ST-2 and ST-6 
isolates did not harbour the esp gene. 
 
PCR of the Tn4001 transposon 
 
PCR screening results for Tn4001 revealed that all isolates possessed the aac (6’)-Ie-
aph (2”)-Ia gene. In addition, deletions in the IS256 3’flanking region of Tn4001 were 
observed in 68% (36/53) of isolates, and deletions in the 5’flanking region in 51% (27/53) of 
isolates. Twenty-one isolates (40%) possessed deletions in both 3’and 5’flanking sequences. 
All gentamicin susceptible isolates tested were negative for the aac (6’)-Ie-aph (2”)-Ia gene 
as well as for the 5’and 3’flanking IS256 regions.   
 
Discussion  
The reason for the frequent isolation of enterococci from the nosocomial setting is 
that enterococci are prevalent in the human gut and possess the ability to acquire antibiotic 
resistance. Additionally, several factors not associated with the selective pressure of 
antimicrobial use could also facilitate adaptation of enterococci to the hospital environment, 
including factors associated with the patients themselves e.g. the immune status of the 
patient, and factors associated with enterococcal virulence e.g. the possession of virulence 
genes.  
Among the antimicrobial agents currently in use in the nosocomial setting, 
aminoglycosides are particularly important therapeutic agents because of their ability to 
generate synergistic bactericidal activity in combination with other antimicrobial agents, such 
as various β-lactams and vancomycin [7]. However, aminoglycoside resistance genes, which 
encode various aminoglycoside-modifying enzymes e.g. aac (6’)-Ie-aph (2”)-Ia, aph (2”)-Ib, 
aph (2”)-Ic, and aph (2”)-Id, are becoming widespread in the hospital environment, resulting 
in bacterial pathogens that possess high-level resistance to aminoglycosides.  This is now a 
common problem in many hospitals, especially with respect to the HLGR enterococcal 
species E. faecalis and E. faecium, that can readily acquire transposon Tn4001 that possess a 
bifunctional enzyme, 6’-acetyltransferase-2”-phospho-transferase encoded by the fused aac6-
aph2 gene [7, 8]. Further, an association between the emergence of HLGR strains and the use 
of other non-aminoglycoside antimicrobial agents, such as glycopeptides, cephalosporins, 
quinolones and carbapenems, is now well documented [21-23]. Results obtained from Dutch 
HLGR E. faecalis isolates in this study, showed a similar trend in this respect, with all the 
HLGR isolates being resistant to ciprofloxacin and cefuroxime. Though all the HLGR 
isolates in this study were susceptible to ampicillin, the latest 2009 report relating to the 
consumption of antimicrobial agents and antimicrobial resistance among medically important 
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bacteria in The Netherlands (NETHMAP) indicated that there has been an increase in the 
number of β-lactamase positive E. faecalis isolates circulating within The Netherlands, which 
could indicate a recent trend in the evolution of nosocomial E. faecalis isolates. This situation 
requires further monitoring.  
Previous studies have reported that 2 clonal complexes (CC2 and CC9), and the 
singleton ST16 of E. faecalis are especially associated with HLGR in the nosocomial setting, 
with the results from our study being comparable to the results previously reported (Figure 
2). Taken together, the results further verify the importance of CC2 and ST-16 genotypes in 
facilitating nosocomial infection [18, 24, 25]. 
As previously mentioned, antimicrobial resistance may not be the only factor 
associated with the predominance of enterococci (and especially E. faecalis) in the 
nosocomial environment.  For example, several other characteristics could act to enhance the 
virulence of HLGR E. faecalis strains, including the production of extracellular surface 
protein (Esp), cytolysins, aggregation substance, adhesins, extracellular superoxide (ESO), 
and gelatinase. Of these, Esp is perhaps the best-studied example of an enterococcal virulence 
trait. The prevalence of esp gene carriage within our endemic HLGR isolates was 51%, which 
indicates that carriage of the esp gene is not specific for endemic HLGR E. faecalis within 
our hospital isolates. However, a higher level (73%) of esp gene carriage was observed in 
clinical E. faecalis isolates from Swedish hospitals by Hallgren et al. [26], who also reported 
that isolates possessing the esp gene did not show increased adherence compared with esp 
gene negative isolates. Taken together, these results suggest that antimicrobial resistance (and 
possibly the absence of the esp gene) is the most important factor in facilitating E. faecalis 
nosocomial infection. With respect to genotypes, isolates belonging to clonal complex 2 
(which contains ST types 2 and 6) and originating from 7 individual patients were all found 
to be esp negative, which is in contrast to the data published by Kawalec et al. [24], who 
observed an incidence of 48% esp carriage in CC2 isolates. The reason for the difference 
between the two studies could however be related to differences in geographical region or in 
the year of isolation of strains. Other enterococcal virulence factors such as asaI, β-
haemolysins (cylM, cylB and cylA), hyaluronidase and gelatinase have also been shown to be 
important in E. faecalis virulence [2, 11-12]. The majority of HLGR (as well as susceptible 
isolates) tested in our study harbored the sex pheromones cob, ccf and cpd, as well as the 
aggregation substance asaI. In a recent study of Hallgren et al, asaI was detected in 79% of 
94 E. faecalis isolates, respectively, which is a high percentage and similar to our own 
findings. In contrast, no isolates tested possessed the hyaluronidase (hyl) or gelatinase (gelE) 
genes. With respect to the cyl genes, a high degree of diversity was observed in the incidence 
of cylM, cylB and cylA carriage between ST types, though in general, ST16 isolates tended to 
be more frequently positive for one or more of these genes compared to the other ST types 
observed in the study.  However, it is not yet known whether the increased carriage of cyl 
beta-hemolysin genes increases the virulence potential of ST16 E. faecalis isolates. 
The majority of HLGR E. faecalis isolates possess a plasmid that contains the 
transposon Tn4001 [25]. Interestingly, all of the major HLGR E. faecalis ST types in our 
study, possessed deletion events in one or more of the Tn4001 IS256 flanking sequences. 
Casetta et al.[28], suggested that Tn4001 may be stabilized when incorporated into the E. 
faecalis chromosome, with a loss of flanking IS256 insertion sequences being associated with 
carriage on plasmids. This suggests that plasmids may play an important role in facilitating 
high-level gentamicin resistance within our hospital. However, further research is necessary 
to determine whether a single plasmid type or multiple plasmid types are involved in the 
transmission of high-level gentamicin resistance between bacterial species within the 
Erasmus MC or in other hospitals where HLGR E. faecalis is found. 
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Finally, several studies have reported that nosocomial infections are more frequent in 
intensive care units (ICUs) than general hospital wards, with enterococci being reported as 
one of the most common organisms isolated from ICU outbreaks [29-32]. In this study, the 
percentage of patients colonized with HLGR E. faecalis was found to be statistically 
significant when compared to patients who had only been admitted to general wards. The 
increased use of antibiotics on ICU wards is the most likely mechanism facilitating the 
significant incidence of HLGR E. faecalis carriage in ICU patients. Interestingly, we found 
evidence that some patients are colonized with HLGR E. faecalis at the time of admission to 
hospital, and that the same genotype persists within the patient during their hospital stay. 
Hence, replacement of “indigenous” HLGR E. faecalis genotypes, in patients that are HLGR 
E. faecalis positive at the time of admission, by other (hospital-dominant) HLGR E. faecalis 
genotypes does not appear to occur in patients already colonized with (community-acquired) 
HLGR E. faecalis at the time of admission. 
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7 nICU - R (254) ltf
23 nICU * R (16) #
94 nICU - R (16) ltf
106 nICU R (16) - ltf
174 nICU - R (6) !
207 nICU R (16) - !
315 nICU - R (6) ltf
6 sICU - R (21) s (206) 
12 sICU - R (2) ltf
13 sICU s (97) R(2) ltf
19 sICU s (267) R (2) R (2)
20 sICU * R (2) #
22 sICU * R (2) #
59 sICU s (4) s (4) R (253)
64 sICU - R (6) #
67 sICU s (16) R (16) *
131 sICU - R (16) -
142 sICU R (2) R (2) R (2) 
162 sICU s (116) - R (2)
177 sICU R (6) R (6) ltf
182 sICU R (16) R (16) #
188 sICU R (6) R (6) #
210 sICU - R (159) ltf
218 sICU R (159) * ltf
281 sICU - R (6) s (40)
346 sICU - * R (16)
404 sICU R (16) R (16) R (16)
437 sICU s (74) R (16) *
440 sICU * R (6) #
476 sICU - R (6) ltf
44 internal R (16) * *
47 internal * R (16) R (16)
72 neurology - R (21) *
143 neurology R (16) R (16) s (251)
181 neurology R (159) R (159) R (159)
189 neurology R (16) R (16) R (16)
48 pulmonology * * R (16)
69 pulmonology * R (23) !
127 pulmonology - - R (16)
Patient         Ward Type            Adm.               Stay           1-3 months
sICU = surgical intensive care unit. nICU = neurological intensive care. Internal = 
internal medicine. - = no E. faecalis isolated. s = gentamicin sensitive E. feacalis
isolated. * = Enterococcus species isolated not E. faecalis. ltf = lost to follow-up. # = 
died before final specimen could be taken.  ! = refused permission once discharged. 
Numbers in parenthesis = ST type.
Table 1. Chronology of gentamicin resistant E. faecalis isolates  
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Admission  Stay           After Discharge  
ICU 11 (6) 30 (16)* 10 (5)
General Wards 6 (3) 9 (4)* 8 (4)
Table 2. Number of patients colonized by high-level gentamicin resistant 
E. faecalis at a Dutch hospital at different time periods.
() = percentage of patients colonized with high-level gentamicin resistant E. 
faecalis when compared to the total number of patients sampled on ICU (187) 
or general wards (226). * = statistically significant (Fishers Exact Test P 
<0.001 comparing number of patients with and without high-level gentamicin 
resistant E. faecalis isolations between wards at each time period). 
Differences in Admission and After Discharge were not significant using the 
same test (P = 0.09 and P = 0.39, respectively). Patients serially colonized by 
high-level gentamicin resistant E. faecalis isolates were counted at each time 
period.  
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Table 3a. Properties of 53 nosocomial gentamicin resistant E. faecalis isolated from a single Dutch hospital (2000 - 2003)
MLST = ST type; Time = time point when the respective E. faecalis strain was isolated. esp = enterococcal surface protein;  cob, ccf andcpd  = sex pheromones; asI = 
aggregation protein; cylM, cylB, cylA = cytolysin-associated genes M, B and A, respectively. All isolates were PCR negative for hyaluronidase (hyl) and gelatinase (gelE). ERY 
= erythromycin, TET = tetracycline, LVX = levofloxacin, STR = streptomycin. All isolates were sensitive to; ampicillin, nitrofurantoin, penicillin G, teicoplanin, vancomycin, 
and ciprofloxacin.  All isolates were resistant to gentamicin, kanamicin, ciprofloxacin and cefuroxime. aph2.2 = aac (6’)-Ie-aph (2”)-Ia, 5’flank and 3’flank = IS256 on 5’ and
3’ end of aac (6’)-Ie-aph (2”)-Ia respectively.
2 12 ICU - + +     + + - - - R S R R - + +
2 13 ICU - + +     + + - - - R S R R - + +
2 19 ICU - - +     + + - - - R S R R - + +
2 19 (ICU) - - +     + + - - - R S R R - + +
2 20 ICU - - +     + - - - - R S R R - + +
2 22 ICU - - +     + + - - - R S R R + + +
2 142 ADM - - +     + + - - - R S R R + + +
2 142 ICU - - +     + + - - - R S R R + + +
2 142 (ICU) - + +     + + - - - R S R R + + +
2 162 (ICU) - - +     + - - - - I S R S + + +
6 64 ICU - + +     + + + + + R R R S + + -
6 174 ICU - + +     + + - - + R R R S + + -
6 177 ADM - + +     + + - - + R R R S + + -
6 177 ICU - + +     + + - - - R R R S + + -
6 188 ADM - + +     + + - - - R R R S + +  +
6 188 ICU - + +     + + - - - R R R S - +    +
6 281 ICU - + +     + + + - - R R I R + + +
6 315 ICU - + +     + + + + - R R R S - +          +
6 440 ICU - + +     + + + - - R R R S + + -
6 476 ICU - + +     + + - - - R R R S + + +
16 23 ICU + + +     + + + + - R R S R - + -
16 44 ADM + + +     + + + + - R R S R - + -
16 47 GW + + +     + + + + + R R S R - + -
16 47 (GW) - + +     + + + + + R R S R - + -
16 48 (GW) + + +     + + + + + R R S R - + -
16 94 ICU + + +     + + + + - R R S R - + -
16 106 ADM - + +     + + - - - R R S R - + +
16 127 (GW) + + +     + + + + + R R S R + + -
16 131 ICU + + +     + + + + - R R S R - + +
16 143 ADM + + +     + + + + - R R S S - + +
16 143 GW + + +     + + + + - I R S S - + -
16 182 ADM + + +     + + + + - R R S R - + -
16 182 ICU + + +     + + + + - R R S R - + -
16 189 ADM + + +     + + + + - R R S R - + -
16 189 GW + + +     + + + + + R R S R - + -
16 189 (GW) - + - + + + + - R R S R - + -
16 207 ADM - + +     + + + + - R R S S - + -
16 346 (ICU) + + +   +    + + + - R R S S - + -
16 404 ADM + + - + + + - - R R S R - + -
16 404 ICU + + - + + + + - R R S R - + -
16 404 (ICU) + + - + + + + - R R S R - +          -
16 437 ICU - + +     + + - - - R R S R - + -
159 181 ADM + + +     + + - - - S S R S - + +
159 181 GW + + + +     + + - - - S S R S - + +
159 181 (GW) + + +     + + - - - S S R S - + +
159 210 ICU + + +     + + - - - S S R S - + +
159 218 ADM + + - - + + + + R S R S - + +
21 6 ICU + + +     + + + + + R R R R + +        +
21 72 GW + + +     + - - - - R R S R - + -
23 69 GW - + +     + + - - - R R S R + + +
40 67 ICU + - - +     + + - - R R S R - + -
253 59 (ICU) + + +     + + - - + R R S S - + -
254 7 ICU + + +     + + - + - I R R S - + +
MLST    Isolate    Time         esp cob ccf    cpd  asI cylM  cylB    cylA    ERY   TET   LVX    STR     5’ flank aph2.2    3’flank
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206 6 (ICU) - +      + + + - - - S S S S - - -
97 13 ADM - +      + + + + - - I S S I - - -
267 19 ADM - +      + + - - - - I S S S - - -
4 59 ADM - +       - + + - - - S S S S - - -
16 67 ADM + +      + + + + - - S S S S - - -
116 162 ADM - +      + + - - - - I S S S - - -
40 281 (ICU) - - + + - - - - I S S S - - -
74 437 ADM - +      + + + - - - I S S S - - -
267 59 ICU + +      +  + - - - - S S S S - - -
251 143 (GW) - - + + - - - - S S S S - - -
MLST = ST type; Time = time point when the respective E. faecalis strain was isolated. esp = enterococcal surface protein;  cob, ccf andcpd  = 
sex pheromones; asI = aggregation protein; cylM, cylB, cylA = cytolysin-associated genes M, B and A, respectively. All isolates were PCR 
negative for hyaluronidase (hyl) and gelatinase (gelE). ERY = erythromycin, TET = tetracycline, LVX = levofloxacin, STR = Streptomycin, 
Q/D = quinupristin/dalfopristin, SXT = Cotrimoxazole, OFX = Orfloxacin. All isolates were sensitive, toteicoplanin, vancomycin and 
gentamicin, aph2.2 = aac (6’)-Ie-aph (2”)-Ia, 5’flank and 3’flank = IS256 on 5’ and 3’ end of aac (6’)-Ie-aph (2”)-Ia respectively.
Table 3b. Properties of 10 nosocomial gentamIcin sensitive E. faecalis isolated from a single Dutch hospital (2000-2003)
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Figure 1. PFGE patterns of 21 high-level gentamicin resistant isolates obtained from 13 patients. 
Cluster analysis was performed using the method of DICE with UPGMA with band tolerances set 
to 1.5%. Time = time point when the respective E. faecalis strain was isolated (see text for
details). MLST  = multi locus-sequence genotype 
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Figure 2. eburst minimum spanning tree showing clustering of 53 high-level gentamicin reistant and 10 
gentamicin susceptible Enterococcuc faecalis MLST genotypes isolated from patients during admission to a 
Dutch hospital.  ADM = isolated at time of admission; ICU = isolated during stay on ICU ward; GW = 
isolated during an exclusive stay on a general ward; (ICU) = isolated 1 – 3 months after discharge from 
hospital (previous ICU patient); (GW) = isolated 1 – 3 months after discharge from hospital (previous 
general ward patient). Numbers in circles represent MLST types. Single-locus variants are connected by 
thick short solid lines; double-locus variants by thin solid lines,  STs which differ in three loci are connected 
by black dotted lines , and gray dotted lines connect STs that differ in more than three loci. ST distribution 
is indicated by pie charts. 
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Chapter 10                                                                             Summary and concluding remarks 
  The growing problem of antimicrobial resistance involves practically all types of 
pathogens and remains a significant public health concern worldwide [1, 2]. Further, one of 
the most alarming trends is the development of antimicrobial resistance for virtually all 
currently available antimicrobial drugs, sometimes even combined in a single organism. 
Indeed, both the Infectious Diseases Society of America and the European Society of Clinical 
Microbiology and Infectious Diseases have highlighted their concerns regarding the large 
percentage of clinical isolates that are resistant to most antimicrobial agents [3, 4]. In 
particular, the bacterial pathogens Staphylococcus aureus, Enterococcus species, Escherichia 
coli, Acinetobacter species, Pseudomonas species, Streptococcus pneumoniae and Klebsiella 
species are currently most associated with this problem [5-9]. This thesis provides further 
data on the clinical relevance and importance of antimicrobial resistance in six bacterial 
species, including several of the ones mentioned above. 
 
Resistance to β-lactam antibiotics  
 
β-lactam antibiotics are a broad class of antibiotics that include penicillins and their 
derivatives including cephalosporins, monobactams, and carbapenems. They are one of the 
most important groups of antimicrobial agents currently used in the treatment of infectious 
diseases caused by both Gram-negative and Gram-positive bacteria. However, the 
development of resistance to these agents (by both Gram-negative and Gram-positive 
bacterial pathogens) has created great concern among health care professionals.  
The main mechanism of β-lactam resistance, particularly amongst Gram-negative 
bacteria, is the production of β-lactamases, hydrolytic enzymes whose activity causes 
disruption of the amide bond of the four-membered β-lactam ring, leading to hydrolysis of 
the β-lactam ring, and inactivation of the β-lactam antibiotic. In fact, there are several types 
of β-lactamases known that confer resistance to β-lactam antibiotics. A few clinically relevant 
examples of these are discussed in the following section. 
 
The BRO- β-lactamase 
 
Moraxella catarrhalis has been recognized as an important human pathogen, because 
it can cause upper respiratory tract infections (e.g. acute otitis media) in children and lower 
respiratory tract infections (e.g. chronic obstructive pulmonary disease, COPD) in adults with 
pre-existing and chronic pulmonary disease. Although M. catarrhalis strains are generally 
susceptible to most antibiotics used for the treatment of respiratory infections, they tend to be 
resistant to penicillin because of the widespread production of BRO β-lactamase, a unique β-
lactamase first described in Sweden in 1976 [10, 11]. Subsequently, two types of BRO, 
named BRO-1 and BRO-2, coded by the bro-1 and bro-2 genes respectively, have been 
reported. The two BRO enzymes are distinguishable by their level of β-lactamase production 
(BRO-1> BRO-2) and different iso-electric focusing patterns (resulting from a single amino-
acid substitution). Further, the bro-2 gene also has a 21 bp deletion in its promoter region 
compared to bro-1 [12]. Despite some initial confusion, it is now accepted that the bro gene 
is located on the bacterial chromosome [13], and that it may originally have been acquired 
from an unknown Gram-positive bacterium, due to the fact that there is no significant 
sequence similarity between bro and the β-lactamase genes of other Gram-negative bacteria, 
and that the gene possesses an LPXTG signal sequence motif, which is characteristic for 
Gram-positive bacteria [14, 15]. 
Since 1976, there has been a rapid rise in the prevalence of worldwide clinical β-
lactamase resistant M. catarrhalis isolates (which now approaches 90–99% of all clinical 
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isolates), considered to be the fastest dissemination rate of any known bacterial β-lactamase 
gene [15].  
In Chapter 2, we show that more than 90% of a selection of global M. catarrhalis 
isolates appear to be β-lactamase and bro gene positive. With respect to geographical region, 
increased bro-1 β-lactam MICs were observed in M. catarrhalis isolates originating from the 
Far East, and especially Japan, possibly due to differences in geographical antibiotic 
prescribing policies. Additionally, the prevalence of bro positivity between the two-age 
groups (children <5 years and adults > 20 years) was significantly different, which again may 
be due to differences in antibiotic prescribing policies (i.e. differences in age group specific 
prescription). Further, no clonal isolates, linked to a geographical region (including Japan 
and/or the Far East) were found (data not shown). Previous studies have also reported a lack 
of genotypic linkage between M. catarrhalis genotype and bro type, with at least one study 
reporting ampicillin MIC variation in apparently identical M. catarrhalis isolates cultured 
from an otitis media patient in Japan [16]. Further, a recent global survey of 195 M. 
catarrhalis isolates revealed no association between M. catarrhalis genotypes in child or 
adult age groups [17]. However, recent research has identified that mechanisms not 
associated with the bro gene per se may be involved in β-lactamase resistance, which may 
possibly have an effect on the results we obtained from the Far East and between children or 
adults [18]. Further research in this field is necessary. 
The results from our study are worrying, because at the clinical level, β-lactamase 
production by M. catarrhalis has been reported to indirectly benefit other bacterial species 
present within mixed bacterial infections (e.g. S. pneumoniae and H. influenzae), as 
production of BRO β-lactamase may allow β-lactam susceptible bacterial isolates to evade 
antibiotic therapy, possibly facilitating treatment failure [19, 20].  
Interestingly, recent studies have indicated an increase in MIC levels to both 
cefuroxime and cefaclor, as well as an overall decrease in susceptibility to cephems [21-26], 
though in our study, this effect was observed for Far East isolates only. Based on past 
experience, with respect to the rapid dissemination of penicillin resistance in M. catarrhalis, 
it seems logical that the global monitoring of these antibiotic resistances in this bacterial 
species should continue.  
 
Extended spectrum β-lactamases  
 
TEM and SHV-type extended-spectrum β-lactamases (ESBLs) were the most 
prevalent ESBLs in clinical isolates until the 1990s. However, since then CTX-M ESBL 
enzymes have started becoming increasingly prevalent in both clinical and nosocomial 
environments. Initially, clinical problems associated with ESBL-positive bacterial isolates 
tended to be associated with nosocomial outbreaks of. K. pneumoniae, mostly in intensive 
care settings [27]. However, community acquired E. coli has now become the main pathogen 
associated with ESBL-type carriage and infection [28, 29], with recent studies stressing the 
importance of the influx of community-acquired CTX-M-positive bacterial isolates into the 
hospital environment [30]. Further, in contrast to infection caused by ESBL-producing K. 
pneumoniae, approximately one-half of infections caused by ESBL-producing E. coli affects 
non-hospitalized patients [31].  
The presence of ESBL-carrying bacteria, including CTX-M types, has now been 
documented worldwide including in various South American countries such as Argentina, 
Brazil, Uruguay, Peru [32-37], and India [38, 39]. In fact, the prevalence of ESBL producing 
Klebsiella species and E. coli from South America is reported to be amongst the highest in 
the world, estimated to be in the range of approximately 45-52% and 8-18%, respectively 
[40], with reports of high ESBL prevalence in this region dating back to the late 1980s [37]. 
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These statistics match the tendency towards higher infection rates by ESBL producing 
bacteria in countries that are less heavily industrialized. For example, the prevalence of 
ESBL-carrying bacteria in Sweden is approximately 3%, but  >25% in Turkey and Portugal, 
and >30% in South America [40]. Based upon the data currently available on the prevalence 
of ESBL types, it appears that CTX-M is now the most predominant ESBL reported 
worldwide [41], including in the South American continent.  
In Chapter 3, we show the predominance of CTX-M-2 and CTX-M-56 carriage 
(though with no genotypic clonality), in ESBL producing isolates of the enterobacteriaceae K. 
pneumoniaea and E. coli from Paraguay. The prevalence of the CTX-M-2 group has been 
previously reported to be high in South America, with CTX-M-2 group enzymes 
predominating in this continent [34]. Therefore, this study reiterates the current importance of 
CTX-M-2 (as well as CTX-M-56) ESBL enzymes in South America, and indicates that 
urgent action is required to combat the prevalence and spread of ESBL-carrying 
enterobacteriaceae in Paraguay, as well as in South America as a whole. 
Similar to many other countries, ESBL carrying enterobacteriaceae in India are 
becoming a major problem. For example, a study from North India reported the prevalence of 
ESBL as 63.6% in E. coli and 66.7% in K. pneumoniae isolates in 2003 [42]. From India, in 
the past, TEM and SHV type ESBLs were predominant clinical K. pneumoniae and E. coli 
isolates. However, in the recent past CTX-M type ESBLs were reported in several parts of 
India, particularly the comparatively new variant CTX-M-15, which is now the most common 
CTX-M type reported worldwide (reported in Portugal, Korea, Western Africa, Bulgaria, 
Canada, France, Italy, Japan, Poland, Romania, Russia and Turkey [34, 37, 43-48]). Indeed, 
this particular CTX-M ESBL was first identified in enterobacterial isolates from India in 
1999 [49]. The rapid dissemination of the CTX-M-15 gene in enterobacterial isolates is 
enhanced by its plasmid location, and likely, by the insertion sequence ISEcp1 that may act 
as a transposition platform [49].  
In chapter 5, we found a very high incidence of ESBL-gene carriage among K. 
pneumoniae isolates obtained from an NICU and other wards from a single tertiary hospital 
in India, with the most notable result being the presence of CTX-M-15 in 92% of isolates 
(36/39). The isolates in this study were found to possess a range of genotypes, and were not 
clonal in nature, with no relationship between clustering and type of infection, or antibiotic 
resistance profile. This study emphasises the major role that CTX-M-15 plays in facilitating 
antimicrobial resistance in Indian hospitals.  
 
Extended-spectrum β-lactam and fluoroquinolone resistance in Salmonella species 
 
In addition to K. pneumoniae and E. coli, antimicrobial resistance in other 
enterobacterial species such as non-typhoidal salmonellae has become a major problem 
worldwide. Non-typhoidal salmonellae are one of the principal pathogens implicated in food-
borne gastroenteritis worldwide, with treatment failures due to the development of resistance 
to extended-spectrum β-lactams and/or fluoroquinolones in non-typhoidal Salmonella species 
being well documented [50-52]. In India, non-typhoidal salmonellae constitute approximately 
20% of the Salmonella serovars currently circulating [53], and dissemination of isolates 
resistant to extended-spectrum β-lactamases is frequently observed.  
In chapter 6, we observed 52% of non-typhoidal salmonellae isolates harbouring 
ESBL genes and exhibiting an ESBL phenotype. Though several different serovars were 
identified, the great majority of ESBL producers belonged to the Salmonella Agona serovar, 
which also represented the most abundant serovar isolated in this study in different hospitals. 
Further, multidrug-resistant S. Agona has been responsible for at least two hospital outbreaks 
in paediatric wards in Brazil [54, 55]. In both cases, the strains were found to harbour large 
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plasmids that conferred resistance to multiple antibiotics. At the current moment in time, 
there are very few studies that have investigated antibiotic resistance in non-typhoidal 
salmonellae [56], though, from our results, it appears that S. Agona may also play an 
important role in non-typhoidal salmonellae ESBL-mediated resistance in India. More 
importantly, of particular concern is the fact that two isolates of S. Agona recovered in this 
study possessed both ESBL and fluoroquinolone resistance genes, potentially seriously 
limiting antimicrobial treatment options, and possibly providing a reservoir for the spread of 
this combination of antibiotic resistances to other pathogenic bacteria. Additionally, 48% of 
the non-typhoidal Salmonella isolates in this study were found to possess the SHV-12 ESBL 
phenotype and gene. SHV-12 is currently one of the most common non-CTX-M ESBLs 
circulating and has been identified in many Gram-negative species, including Salmonella 
species [57, 58]. The ESBL enzymes that tend to be responsible for cephalosporin resistance 
in the genus Salmonella are TEM and SHV β-lactamase derivatives, though CTX-M type 
ESBLs have recently (though infrequently) been reported. In a study by Rotimi et al., 3.4% 
of Salmonella spp. were found to be CTX-M-15 positive [59]. The presence of ESBL and 
fluoroquinolone antibiotic resistance in non-typhoidal Salmonella isolates within resource 
poor countries is jeopardizing classical antibiotic therapy. Continued surveillance of 
circulating ESBL producing, as well as fluoroquinolone resistant, salmonellae is therefore 
warranted in India.  
 
Vancomycin resistance in Enteroccus faecium 
 
Enterococci are an important group of bacteria especially involved in several types of 
nosocomial infections such as urinary tract infections, bacteremia, intra-abdominal infections, 
skin, soft tissue infections and endocarditis. Enterococci are found in both the “healthy” 
environment and hospital settings, frequently expressing glycopeptide/high-level 
aminoglycoside resistance. The intrinsic low-level resistance of enterococci to many 
commonly used antimicrobial agents e.g. β-lactams and glycopeptides may have allowed 
them to survive in hospital environments and successfully acquire other antibiotic resistance 
genes involved in, for example high-level resistance to glycopeptides (vancomycin and 
teicoplanin in E. faecium), and high-level aminoglycosides (gentamicin resistance in E. 
faecalis).  
In enterococci, seven different vancomycin resistance types have so far been 
described, namely VanA, VanB, VanC, VanD, VanE, VanG and VanL [60]. Though, 
vancomycin resistance is usually more predominant in E. faecium than E. faecalis, with 
VanA type being the most important from the clinical point of view. This is because it is the 
most frequently found type of vancomycin resistance in clinical enterococcal isolates, 
characterized by both high-level and inducible resistance to vancomycin and teicoplanin. 
Vancomycin resistant E. faecium has been reported worldwide, having been promoted via the 
extensive use of vancomycin in hospitals, as well as the animal growth promoter avoparcin 
(an analogue of vancomycin). In E. faecium, VanA type resistance has been shown to be 
directly facilitated by the carriage of transposon Tn1546 [61], a transposon widely 
disseminated in humans, animals and the environment [60].  In fact, significant diversity has 
now been identified within Tn1546-related elements since it was first described by Arthur et 
al. in Enterococcus faecium BM4147 in1993 [61]. This variation, in the form of point 
mutations, insertion sequence (IS) elements, and deletions, has been reported in several 
epidemiological studies [62-65]. Based on these studies, Schouten et al. (2001) proposed an 
evolutionary scheme comprising 2 lineages in Tn1546, based on the nature of these mutations 
and insertion sequences [66].  
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In chapter 7, we describe two extra lineages associated with vanA positive E. faecium 
isolates from hospitals in Saudi Arabia. In the study, we found that the majority of 
polymorphic events in Tn1546 involved the insertion of IS1216V within the intergenic 
regions of either vanS and vanH, or vanX and vanY genes, along with other less frequent 
insertions of IS1485 and IS1251. IS1216V insertions are one of the most common events in 
Tn1546-bearing vancomycin-resistant enterococci worldwide. The IS1485 insertion was first 
described in enterococcus species by Cheng et al. in 1999 [67]. However, the “Saudi isolate 
insertion events” were new to this study.  
In chapter 8, we reported on a novel Tn1546 variant containing an ISEfa5 insertion in 
vanA E. faecium isolates obtained from hospitals in Paraguay. This IS element has only 
previously been described in Brazilian E. faecium isolates, where the ISEfa5 was exclusively 
inserted in the intergenic region of vanX and vanY [64]. In our Paraguayan isolates the ISEfa5 
insertion was found between vanS and vanH genes. Currently, the ISEfa5 insert has been 
described only in South America, and it is interesting to speculate whether this particular 
event is limited to South American vanA E. faecium isolates only. Our results provide further 
evidence for the evolving nature of Tn1546 in vanA E. faecium isolates. Additionally, 
surveillance of vanA type E. faecium and the diversity of Tn1546 resistances is important 
because vancomycin resistant S. aureus isolates have been shown to carry Tn1546 including 
the insertion of IS1251 elements [68], and Tn1546 surveillance will help to trace the 
dissemination of Tn1546 from E. faecium to S. aureus allowing predictions to be made 
regarding the mechanisms on future spread of this important antimicrobial resistance element.  
Finally, in recent years, a clonal complex of vanA type E. faecium isolates (CC17) has 
been identified that is particularly associated with global nosocomial-infections [69] (though 
there is some evidence to suggest that this grouping may be influenced by the high rates of 
recombination associated with the E. faecium species [70]). Our results from Saudi Arabia 
and Paraguay (countries not previously reporting studies on vanA resistance in E. faecium) 
support the high prevalence of “CC17” clonal complex isolates in global nosocomial settings, 
as more than 90% of vanA positive E. faecium isolates from Saudi Arabia and from Paraguay 
belonged to CC17.  
 
High-level aminoglycoside resistance in Enterococcus faecalis 
 
As mentioned above, the intrinsic low-level resistance of enterococci to many 
commonly used antimicrobial agents may have helped them to survive in hospital 
environments and successfully acquire several different antibiotic resistance genes. E. 
faecalis accounts for approximately 75% of all enterococcal infections [71], and this species 
is generally resistant to many commonly used antimicrobial agents, including 
aminoglycosides, aztreonam, cephalosporins, clindamycin, the semi-synthetic penicillins, 
nafcillin and oxacillin, and trimethoprim-sulfamethoxazole. High-level resistance to 
aminoglycosides (e.g. gentamicin) is one possible cause of treatment failure in nosocomial 
infections caused by E. faecalis, as aminoglycosides are usually administered along with 
other groups of antimicrobial agents to generate a synergistic effect and help ensure 
successful antimicrobial therapy. Aminoglycoside resistance in E. faecalis is conferred by 
genes that encode various aminoglycoside-modifying enzymes (AMEs), e.g. aac (6’)-Ie-aph 
(2”)-Ia, aph (2”)-Ib, aph (2”)-Ic, and aph (2”)-Id. These AMEs are becoming widespread in 
the hospital environment, resulting in bacterial pathogens that possess high-level resistance to 
aminoglycosides, especially with respect to the high-level gentamicin resistant (HLGR) E. 
faecalis. E. faecalis readily acquire transposon Tn4001, a transposon that possess a 
bifunctional enzyme, 6’-acetyltransferase-2”-phospho-transferase encoded by the fused aac6-
aph2 gene [72-74]. Further, an association between the emergence of HLGR strains and the 
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use of other non-aminoglycoside antimicrobial agents, such as glycopeptides, cephalosporins, 
quinolones and carbapenems, is now well documented [75-77].  
In chapter 9, results obtained from HLGR positive E. faecalis isolates cultured from 
Erasmus MC showed that all of the HLGR isolates were resistant to ciprofloxacin and 
cefuroxime. Previous studies have reported that 2 clonal complexes (CC2 and CC9) and the 
single ST16 of E. faecalis are especially associated with high-level gentamicin resistance in 
the nosocomial setting, with the results from our study being comparable, further verifying 
the importance of CC2 and ST-16 genotypes in nosocomial infection [78-80]. Of the major 
ST types circulating in Erasmus MC, ST-2 isolates tended to be tetracycline susceptible but 
resistant to levofloxacin and streptomycin, whilst ST-6 isolates tended to be resistant to 
tetracycline and levofloxacin but susceptible to streptomycin. Further, ST-16 isolates tended 
to be susceptible to levofloxacin. The investigation of resistance and susceptibility profiles 
for these antibiotics in the above ST types is important, because these antibiotics are vital in 
the treatment of E. faecalis mediated nosocomial infections. Though all of the HLGR isolates 
isolated at the Erasmus MC were susceptible to ampicillin, the latest NETHMAP report of 
2009 [81], concerning the consumption of antimicrobial agents and antimicrobial resistance 
among medically important bacteria in The Netherlands, showed that there has been an 
increase in the number of β-lactamase positive E. faecalis isolates in Dutch hospitals. Though 
not yet a problem at Erasmus MC, this issue may become a problem in the future and needs 
to be closely monitored.  
Research has shown that the majority of HLGR E. faecalis isolates possess a plasmid 
that contains the transposon Tn4001 [80, 82]. Casetta et al. [83] suggested that Tn4001 may 
be stabilized when incorporated into the E. faecalis chromosome, with a loss of flanking 
IS256 insertion sequences being associated with carriage on plasmids. Interestingly, all of the 
major HLGR E. faecalis ST types in our study, possessed deletion events in one or more of 
the Tn4001 IS256 flanking sequences. This may suggest that plasmids play an important role 
in facilitating high-level gentamicin resistance within Erasmus MC. However, further 
research is necessary to determine whether a single plasmid type or multiple plasmid types 
are involved in the transmission of high-level gentamicin resistance between bacterial species 
within Erasmus MC or in other hospitals where HLGR E. faecalis is found. 
 
Concluding remarks  
 
Antimicrobial resistance is a continuing and increasing threat to both global public 
health and global healthcare systems, meaning that the control of antimicrobial resistance is a 
major issue faced by society today. International surveillance and epidemiological studies of 
antimicrobial resistance are continuing to show increasing resistance against the commonly 
used antimicrobial agents. Further, the fact that globalization is booming, means that it is 
important to understand international patterns of resistance spread, as global travel and the 
concomitant spread of antibiotic resistant microorganisms is becoming much easier. 
Additionally, selective pressure facilitated by the inappropriate and widespread use of 
antibiotics is a major contributor to the problem of antibiotic resistance and should be 
addressed both at the national level (via governmental legislation) and at the local level (via 
hospital prescription guidelines).  
The evolution shown by the different “platforms” involved in antimicrobial resistance 
has significantly reduced the effectiveness of policies adapted for tackling antimicrobial 
resistance. In this respect, another important aspect of antibiotic resistance is to understand 
the mechanisms involved in the spread of antimicrobial resistance on a global scale. This may 
be achieved via the setting up of active surveillance programs, as surveillance programs 
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provide important information on antimicrobial resistance trends, allowing predictions to be 
made.  
Finally, the following steps would be extremely helpful in tackling antimicrobial 
resistance: 
• A reduction in the misuse of antimicrobial agents by designing and implementing 
standard and strict prescription practices. 
• Development of novel antibiotics (10 x '20). [Www.idsociety.org].  
• Using novel antimicrobials selectively, i.e. only when other therapies have failed.  
• The development of rapid, inexpensive, and accurate (point-of-care) diagnostic 
methods to allow rapid decision-making regarding accurate antimicrobial therapy. 
• The improvement of public and healthcare worker education. 
• The improvement of hygiene in hospitals and in the community.  
• A ban on the non-therapeutic use of antimicrobial agents in food and cattle. 
• A reduction in antimicrobial usage via alternative approaches, such as vaccines, 
phages, and probiotics. 
• Development of better alternative methods for anti-infection therapy circumventing 
chemotherapy and thereby preventing the development of resistance. 
 
However, it remains to be seen whether governments, hospitals and individuals are 
able (or willing) to implement these strategies. Only a combined and global effort will 
ultimately limit the spread of antimicrobial resistance and the damaging consequences of a 
lack of action.  
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Nederlandse samenvatting 
Het groeiende probleem van antimicrobiële resistentie is te detecteren in allerlei 
ziekteverwekkers en veroorzaakt wereldwijd een significante belasting van de 
zorginstellingen in de gezondheidszorg [1, 2]. Eén van de meest alarmerende tendensen is de 
ontwikkeling van antimicrobiële resistentie voor vrijwel alle nu verkrijgbare antibiotica. 
Zowel de Amerikaanse vereniging voor infectieziekten als de Europese vereniging van 
Klinische Microbiologie en Besmettelijke Ziekten, hebben allebei hun zorg geuit ten aanzien 
van het grote percentage klinische isolaten dat bestand is geworden tegen de meeste 
antibiotica [3, 4]. Momenteel zijn de Stafylokokken, Enterokokken, Escherchia coli, 
Acinetobacter, Pseudomonas, Streptokok pneumoniae en Klebsiella soorten die het meest 
geassocieerd worden met dit probleem [5-9]. Dit proefschrift bevat studies die data verlenen 
en de klinische relevantie weergeven van 6 verschillende bacteriële soorten die antibiotica 
resistent zijn, met inbegrip van verscheidene van de hierboven vermelde soorten. 
 
De weerstand tegen β-lactam antibiotica  
β-lactam antibiotica is een brede klasse van antibiotica’s en omvatten penicillines en 
hun derivaten met inbegrip van, cephalosporins, monobactams, en carbapenems. Zij zijn één 
van de belangrijkste groepen antibiotica die momenteel in de behandeling van besmettelijke 
ziekten worden gebruikt, zowel veroorzaakt door Gram negatieve als Gram positieve 
bacteriën. De ontwikkeling van resistentie tegen deze antibiotica (door zowel Grampositieve 
als Gramnegatieve bacteriële ziekteverwekkers) heeft tot grote zorg geleid onder 
gezondheidszorgpersoneel.  
Het belangrijkste mechanisme van β-lactam weerstand is de productie van β-
lactamases. Dat zijn hydrolytische enzymen die verstoring van de amideband teweeg brengen 
in de β-lactam ring. Deze verstoring leidt tot het openen van de β-lactam ring wat 
inactivering van het β-lactam antibioticum veroorzaakt. In feite, zijn er verscheidene bekende 
soorten β-lactamases die resistentie tegen β-lactam antibiotica genereren. Een paar klinisch 
relevante voorbeelden hiervan worden besproken in de volgende sectie. 
 
BRO- β-lactamase 
 
Moraxella catarrhalis wordt gezien als een belangrijke menselijke ziekteverwekker, 
omdat het besmettingen veroorzaakt in de bovenste delen van de luchtwegen in kinderen 
(bijvoorbeeld oorontsteking) en onderste delen van de luchtwegen bij volwassenen (b.v. 
chronische obstructieve longziekte, COPD) die al reeds een bestaande of chronische 
longziekte doormaken. Hoewel M. catarrhalis over het algemeen vatbaar is voor de 
antibiotica die gebruikt worden voor luchtweginfectie, neigen zij steeds vaker resistent te 
worden tegen penicilline wegens de steeds wijder verspreide productie van BRO β-
lactamases in deze bacterie. BRO β-lactamase is een unieke lactamase die voor het eerst in 
Zweden in 1976 wordt beschreven [10, 11]. Latere studies melden dat er twee soorten BRO 
zijn, bro-1 en bro-2, gecodeerd door bro-1 en bro-2 genen. De twee enzymen BRO zijn te 
onderscheiden door hun niveau van β-lactamase productie (BRO-1> BRO-2). Daarnaast 
hebben de twee BRO lactamases verschillende iso-electrische patronen (als gevolg van één 
enkele aminozuur substitutie). Verder, heeft gen bro-2 ook een 21 bp deletie in zijn 
promotorgebied in vergelijking met de promotor van bro-1 [12]. 
Ondanks wetenschappelijke discussies, is het nu duidelijk geworden dat het bro gen in 
het bacteriële genoom ligt [13]. Dit gen is zeer waarschijnlijk verkregen via een tot nu toe 
onbekende Gram positieve bacterie, omdat er tot nu toe geen significante vergelijkenissen 
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zijn gevonden tussen het bro gen en verschillende andere β-lactamase genen die aanwezig 
zijn in Gram negatieve bacteriën. Daarnaast bevat het bro gen een LPXTG signaal motief 
voor uitscheiding van eiwitten karakteristiek voor Gram positieve bacteriën [14, 15]. 
Sinds 1976 is er een snelle wereldwijde groei van M. catarrhalis stammen die 
klinische β-lactamase resistentie bezitten. Op dit moment is 90-99% van alle klinische 
isolaten resistent en is bro gecodeerde lactamase daarmee de snelst verspreidde resistentie ten 
opzichte van elke ander bekende bacteriële β-lactamase [15].  
In Hoofdstuk 2, tonen wij aan dat meer dan 90% van een wereldwijde M. catarrhalis 
isolaten collectie, β-lactamase en bro gen positief zijn. Met betrekking tot geografische 
gebieden, werden verhoogde bro-1 β-lactam MICs waargenomen in M. catarrhalis isolaten 
die komen uit het Verre Oosten, en vooral Japan. Deze waarneming kan misschien verklaard 
worden door een ander antibioticum beleid in deze gebieden. Daarnaast, bleek de 
aanwezigheid van het bro gen tussen de twee leeftijdsgroepen (kinderen < 5 jaren en 
volwassenen > 20 jaar) significant te verschillen. Dit is zeer waarschijnlijk opnieuw toe te 
schrijven aan verschillen in het antibioticum beleid (d.w.z. verschillen in antibiotica 
verstrekking in deze leeftijdsgroepen in geografische gebieden). Verder werden er geen 
clonale isolaten gevonden, met betrekking tot een geografisch gebied (met inbegrip van Japan 
en/of het Verre Oosten) (resultaten niet weergegeven). Dit is in overeenstemming met eerdere 
studies die ook geen genotypische (clonale link) tussen M. catarrhalis genotype en bro type 
vonden. Er is echter wel 1 Japanse studie die ampenicilline MIC variatie vond in M. 
catarrhalis stammen, geïsoleerd uit patiënten met een oorontsteking, die ogenschijnlijk 
genotypisch identiek leken te zijn aan elkaar [16]. Verder, blijkt uit een recent overzicht van 
195 M. catarrhalis wereldwijd geïsoleerde stammen dat ook hier geen associatie was tussen 
M. catarrhalis genotypen gevonden in kinderen of volwassen. De stammen collectie is dus 
heterogeen [17]. Niettemin heeft zeer recent onderzoek ook aangetoond dat er mechanismen 
zijn die niet verbonden zijn aan het bro gen, maar wel invloed hebben op β-lactamase 
resistentie. Dit kan van effect zijn op de resultaten die wij hebben verkregen met stammen uit 
het Verre Oosten en het significante verschil van aanwezigheid van het bro gen tussen 
kinderen en volwassenen [18]. Verder onderzoek op dit gebied is dus noodzakelijk. 
De resultaten van onze studie zijn erg verontrustend, omdat op klinisch niveau, β-
lactamase productie door M. catarrhalis indirect invloed heeft op aan andere bacteriële 
soorten. Bijvoorbeeld een M. catarrhalis menginfectie met een Streptokok pneumoniae of 
Haemophilus influenzae bacterie. Met een dergelijke menginfectie kan de productie van BRO 
β–lactamase, β-lactam gevoelige bacteriën laten ontsnappen aan deze antibiotica therapie. 
Hierdoor heeft een behandeling van zo’n infectie een verhoogd risico op mislukking [19, 20].  
Interessant is daarnaast dat recente studies een verhoging van de MIC niveaus in M. 
catarrhalis vonden voor antibiotica cefuroxime en cefaclor. Een algemene daling van 
gevoeligheid tegen cephems werd ook geconstateerd [21-26]. In onze studie werd dit effect 
alleen waargenomen voor de stammen die uit het Verre Oosten zijn geïsoleerd. Gebaseerd op 
ervaringen uit het verleden, met betrekking tot de snelle verspreiding van penicilline 
resistentie in M. catarrhalis, lijkt het niet meer dan logisch dat het wereldwijd monitoren op 
resistentie door moet gaan.  
 
Breed spectrum β -lactamases  
 
TEM en SHV-type breed spectrum β-lactamases (ESBLs) waren de meest 
voorkomende ESBL klinische isolaten uit de jaren '90. Sindsdien is er een toename van de 
enzymen CTX-M ESBL geconstateerd in ziekenhuis omgevingen. Eerst werden de klinische 
problemen gerelateerd aan ESBL-positieve K. pneumoniae op de intensieve zorg afdelingen 
in ziekenhuizen [27]. Ondertussen is nu E. coli de belangrijkste pathogeen geworden die 
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geassocieerd is met ESBL dragerschap en infectie [28, 29]. Recente studies benadrukken het 
probleem van de toevloed via de gemeenschapverworvene CTX-M-positieve bacteriële 
isolaten naar het ziekenhuismilieu [30]. In tegenstelling tot besmetting die door ESBL K. 
pneumoniae veroorzaakt worden, vind ongeveer de helft van besmettingen die door ESBL E. 
coli worden veroorzaakt plaats buiten het ziekenhuis [31].  
 De aanwezigheid van ESBL bevattende bacteriën met daarnaast de CTX-M types 
worden nu wereldwijd gedocumenteerd, met inbegrip diverse Zuid-Amerikaanse landen zoals 
Argentinië, Brazilië, Uruguay, Peru [32-37], en India [38, 39]. In feite, is de aanwezigheid 
van ESBL producerende Klebsiella en E. coli soorten geïsoleerd in Zuid-Amerika een van de 
hoogste in de wereld. De omvang van positieve isolaten wordt geschat op 45-52% en 8-18% 
[40]. Vroegere publicaties geven aan dat ESBL aanwezigheid in dit gebied ook al hoog was 
in de jaren '80 voor ESBLs [37]. Deze statistieken markeren de tendens naar hogere 
infectiegraden door ESBL producerende bacteriën in landen die minder zwaar 
geïndustrialiseerd zijn. Bijvoorbeeld, is de aanwezigheid van ESBL positieve bacteriën in 
Zweden ongeveer 3%, maar > 25% in Turkije en Portugal, en > 30% in Zuid-Amerika [40]. 
Gebaseerd op de huidige gegevens over de aanwezigheid van ESBL, blijkt het dat CTX-M nu 
de meest overheersende ESBL type is [41], inclusief het Zuid-Amerikaanse continent.  
 In Hoofdstuk 3, tonen wij de overheersende aanwezigheid van CTX-M-2 en CTX-
M-56 (hoewel zonder genotypische clonality) aan in ESBL producerend isolaten van 
Enterobacteriaceae, K. pneumoniaea en E.coli soorten geïsoleerd in Paraguay. De hoge 
aanwezigheid van de CTX-M-2 groep is eerder gerapporteerd in Zuid-Amerika [34]. Deze 
studie bevestigt het huidige probleem van CTX-M-2 (evenals CTX-M-56) ESBL enzymen in 
Zuid-Amerika, en wijst erop dat er dringend actie ondernomen moet worden om het 
overwicht en de verspreiding van deze types onder controle te krijgen. Ook in India, lijken 
ESBL positieve bacteriën een belangrijk probleem aan het worden. Als voorbeeld, toonde een 
studie uit 2003 aan, uitgevoerd in Noord-India, dat de aanwezigheid van ESBL in 63.6% in 
E. coli en 66.7% in K. pneumoniae kon worden aangetoond [42]. TEM en SHV was het 
overheersende type ESBLs aanwezig in klinische K. pneumoniae en E. coli isolaten in India. 
Recent is in verschillende delen van India het CTX-M type ESBLs waargenomen, in het 
bijzonder een betrekkelijk nieuwe variant CTX-M-15, die nu wereldwijd het meest gemelde 
type is (gerapporteerd in Portugal, Korea, Westelijk Afrika, Bulgarije, Canada, Frankrijk, 
Italië, Japan, Polen, Roemenië, Rusland en Turkije [34, 37, 43-48]). Dit bepaalde type CTX-
M ESBL werd als eerste geïdentificeerd in Enterobacteriele isolaten vanuit India in 1999 
[49]. De snelle verspreiding van dit CTX-M gen in Enterobacteriele isolaten wordt 
veroorzaakt door de plaats van dit gen op een plasmide met daarbij waarschijnlijk geholpen 
in de verspreiding door de insertie sequentie ISEcp1 die dienst kan doen als transpoase [49].  
In hoofdstuk 5, vonden wij een zeer hoge aanwezigheid van ESBL dragerschap 
onder K. pneumoniae isolaten verkregen uit NICU en andere afdelingen van één enkel tertiair 
ziekenhuis in India, met het opmerkelijke resultaat dat CTX-M-15 in 92% van de isolaten 
aanwezig was (36/39). Genotypisch werd in deze studie aangetoond dat deze stammen 
heterogeen zijn. Er werd geen verband gevonden tussen groeper en type van besmetting, of 
antibiotisch resistentie. Deze studie benadrukt dus de belangrijke rol die CTX-M-15 kan 
spelen in het vergemakkelijken van het verkrijgen van antibiotica resistentie in de Indische 
ziekenhuizen.  
 
Wijdverbreide β-lactam en flouroquinolone resistentie in de soorten van Salmonella's 
 
Naast K. pneumoniae en E. coli, is antibiotica resistentie in andere Enterobacteriële 
soorten zoals niet typhoide Salmonella's wereldwijd een belangrijk probleem geworden. De 
niet typhoide Salmonella's zijn één van de belangrijkste ziekteverwekkers die geïsoleerd 
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worden na voedsel gerelateerde infecties. De huidige behandelingsbelemmeringen voor deze 
infecties zijn op dit moment toe te schrijven aan de ontwikkeling van resistentie tegen breed 
spectrum van β-lactams en/of fluoroquinolones bij de niet typhoide soorten van Salmonella 
[50-52]. In India, vormen de niet typhoide Salmonella's ongeveer 20% van het totaal aantal 
geïsoleerde Salmonella’s serovars  [53], en verspreiding van isolaten resistent tegen breed 
spectrum β-lactamases wordt steeds vaker geobserveerd.  
In hoofdstuk 6, namen wij waar dat 52% van de niet typhoide Salmonella’s ESBL  
genen bevatten, daarnaast werd bij deze stammen ook het ESBL fenotype waargenomen. 
Hoewel verscheidene verschillende serovars werden geïdentificeerd, behoorde de grote 
meerderheid van de ESBLs tot de Salmonella's serovar Agona. Serovar Agona representeert 
het type Salmonella dat ook het meest uit de verschillende ziekenhuizen werd geïsoleerd. 
Verder blijkt dat de Multiresistente S. Agona, ten minste verantwoordelijk blijkt te zijn voor 
twee ziekenhuisuitbraken op kindergeneeskunde afdelingen in Brazilië [54, 55]. In beide 
gevallen werden grote plasmiden gedetecteerd die resistentie tegen veelvoudige antibiotica 
verleenden. Op dit moment zijn er zeer weinig studies die antibiotische resistentie in niet 
typhoide Salmonella’s hebben bestudeerd [56]. Uit onze resultaten blijkt dat S. Agona ook 
een belangrijke bijdrage lijkt te leveren in de niet typhoide Salmonella ESBL-gereguleerde 
resistentie in India. Wat nog belangrijker en een bron van zorg is, is het feit dat twee S. 
Agona isolaten in deze studie genen bevatten van zowel ESBL als van fluoroquinolone 
resistentie. Dit dragerschap kan potentieel ernstige infectie behandelingsopties beperken, en 
daarnaast als een reservoir dienen voor de verdere verspreiding van deze combinatie 
resistentie genen onder andere pathogene bacteriën. Bovendien bleek in deze studie 48% van 
de niet typhoide isolaten van Salmonella's het SHV-12 ESBL gen te bezitten met daarnaast 
het corresponderend fenotype. SHV-12 is momenteel één van de meest voorkomende niet 
CTX-M ESBLs en wordt in vele Gram negatieve soorten geïdentificeerd, met inbegrip van 
Salmonella [57, 58]. De ESBL enzymen die verantwoordelijk lijken te zijn voor 
cephalosporin resistentie in de soort Salmonella zijn TEM en SHV β-lactamase derivaten, 
hoewel CTX-M type ESBLs onlangs ook (niet in grote aantallen) werd gerapporteerd. 
In een studie door Rotimi et al., bleek 3.4% van de Salmonella’s positief te zijn voor CTX-
M-15 [59]. De aanwezigheid van ESBL en fluoroquinolone resistentie in niet typhoide 
Salmonella’s brengt in de arme landen de klassieke antibiotische therapie in gevaar. Het 
voortdurende toezicht op het doorgeven van ESBL, evenals fluoroquinolone resistentie 
aanwezig in Salmonella is daarom ook in India noodzakelijk.  
 
Vancomycin resistentie in Enteroccus faecium 
 
Enterococci is een belangrijke groep bacteriën vooral betrokken bij verscheidene 
soorten ziekenhuis besmettingen zoals urineweg infecties, bacteremia, introabdominale 
infecties, huid, zachte weefselbesmettingen en endocarditis. Enterococci worden gevonden in 
zowel de samenleving als in het ziekenhuis gevonden en hebben vaak een hoge 
glycopeptides/aminoglycosides resistentie. De intrinsiek gevonden lage resistentie van 
Enterococci tegen veel algemeen gebruikte anti-microbiotica bv. β-lactams en glycopeptides 
kunnen eraan hebben bijgedragen dat deze bacterie met succes kan overleven in een 
ziekenhuis omgevingen. De al aanwezige lage resistentie tegen vele antibiotica heeft er zeer 
waarschijnlijk toe bij gedragen dat andere antibiotisch resistentie genen werden verworven, 
bijvoorbeeld resistentie op hoog niveau tegen glycopeptides (vancomycin en teicoplanin in E. 
faecium), en aminoglycosides (gentamicin weerstand in E. faecalis).  
In Enterococcen zijn tot dusver zeven verschillende vancomycine resistentie types 
beschreven, namelijk VanA, VanB, VanC, VanD, Vin, VanG en VanL [60]. Vancomycin 
resistentie gewoonlijk meer aanwezig is in E. faecium dan in E. faecalis, waarbij VanA het 
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belangrijkst gen is vanuit het klinische oogpunt gezien. VanA wordt namelijk het vaakst 
gevonden bij resistenties in klinische Enterococcen isolaten, karakteristiek met hun hoge en 
induceerbare resistentie tegen vancomycine en teicoplanine. Vancomycine resistentie in E. 
faecium wordt wereldwijd gemeld, en wordt geïnduceerd door wijdverbreid gebruik van 
vancomycine in de ziekenhuizen, evenals het dierlijke avoparcin een groeipromotor die 
analoog is aan vancomycine). In E. faecium, wordt VanA resistentie gefaciliteerd door 
transposon Tn1546 [61]. Dit is een transposon die wijdverspreid voorkomt in mensen, dieren 
en het leefmilieu [60]. In feite, is de significante diversiteit gerelateerd aan het Tn1546 
transposon, die voor het eerst werd beschreven door Arthur et al., gevonden in Enterococcus 
faecium BM4147 in 1993 [61]. De variaties in dit transposon gevonden in de vorm van 
puntmutaties, insertie sequentie elementen (IS) en deleties, zijn ook beschreven in 
verschillende andere epidemiologische studies [62-65]. Gebaseerd op deze studies, stelde 
Schouten et a., (2001) een evolutie schema voor bestaand uit 2 lijnen gebaseerd op de aard 
van deze mutaties en insertie sequenties in dit Transposon [66].  
In hoofdstuk 7, beschrijven wij twee extra lijnen geassocieerd met VanA positieve E. 
faecium isolaten, geïsoleerd vanuit de ziekenhuizen in Saudi-Arabië. In deze studie, vonden 
wij dat de meerderheid van de polymorfe veranderingen in Tn1546 veroorzaakt werden door 
de insertie van IS1216V aanwezig binnen een DNA stretch van de genen vanS,  vanH, of 
vanX en vanY genen, samen met ander minder frequente gevonden inserties van IS1485 en 
IS1251. Insertie van IS1216V is één van de meest voorkomende gebeurtenissen in transposon 
Tn1546 gevonden in vancomycin resistente Enterococcen. De insertie IS1485 werd voor het 
eerst beschreven in de Enterococcus soorten door Cheng et al. in 1999 [67], de gevonden 
insertie aanwezig in een isolaat uit Saudi-Arabië was een nieuwe bevinding.  
In hoofdstuk 8, beschrijven wij een nieuwe variant van Tn1546 die een nieuwe 
insertie genaamd ISEfa5 bevat, geïsoleerd uit een VanA postieve E. faeciums aanwezig in  
ziekenhuizen in Paraguay. Dit IS element is slechts alleen eerder beschreven in een 
Braziliaanse E. faecium isolaat, waar ISEfa5 uitsluitend in een DNA stretch gebied van VanX 
en VanY [64] werd gevonden. In onze Paraguayanse isolaten werd de insertie van ISEfa5 
gevonden tussen de VanS en VanH genen. Momenteel, is de insertie ISEfa5 alleen 
beschreven in Zuid-Amerika. Het is dus interessant om te speculeren of deze insertie alleen 
beperkt is tot Zuid-Amerikaanse VanA E. faecium isolaten. Onze studie levert daarnaast meer 
bewijs over de evolutie van Tn1546 in VanA E. faecium positieve isolaten. Daarnaast is het 
belangrijk om de diversiteit van Tn1546 VanA E. faecium te monitoren, omdat er voor 
vancomycin resistente S. aureus isolaten is aangetoond dat deze ook drager zijn van Tn1546 
met inbegrip van het IS1251 element [68]. Het monitoren van de verspreiding van Tn1546 
van E. faecium en overdracht van S. aureus Tn1546 aan E. faecium zal helpen om 
voorspellingen te kunnen doen over de verspreiding, van dit belangrijke resistentie element, 
nu en in de toekomst.  
Tot slot, melden we dat de laatste jaren een clonale vorm van het VanA type 
Enterococcus faecium isolaten (CC17) is geïdentificeerd. Dit type is geassocieerd met 
ziekenhuisinfecties [69]. Voor dit type is er bewijsmateriaal die de suggestie wekt dat deze 
groepering door een hoge recombinatie frequentie, geassocieerd aan de E. faecium soorten, 
wordt bewerkstelligd [70]. Onze resultaten verkregen met stammen uit Saudi-Arabië en 
Paraguay, landen die geen eerder studies hebben gerapporteerd over VanA resistentie in E. 
faecium, ondersteunen de hoge aanwezigheid van het CC17 klonale isolaten in ziekenhuizen. 
Meer dan 90% van de VanA positieve E. faecium VanA isolaten van Saudi-Arabië en 
Paraguay behoord tot het klonale complex CC17.  
 
De aminoglycosideresistentie is op hoog niveau in Enterococcus faecalis 
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Zoals hierboven vermeld, de al aanwezige lage resistentie van Enterococcen tegen 
veel algemeen gebruikte antibiotica helpen deze bacterie om in ziekenhuizen te overleven. En 
verwerft met succes nu ook verschillende andere antibiotica resistentie genen. E. faecalis 
veroorzaakt 75% van alle Enterococcoide besmettingen [71]. Deze soort is over het algemeen 
bestand tegen vele algemeen gebruikte antibiotica, met inbegrip van aminoglycosides, 
aztreonam, cephalosporins, clindamycin, de halfsynthetische penicilline, nafcillin en 
oxacillin, en het trimethoprim -trimethoprim-sulfamethoxazole. Resistentie is op hoog niveau 
tegen aminoglycosides (b.v. gentamicin) is een mogelijke oorzaak van de behandeling- 
belemmeringen in ziekenhuis besmettingen die door E. faecalis worden veroorzaakt. 
Aminoglycosides worden gewoonlijk samen met andere groepen antibiotica’s gegeven om 
een synergetisch effect te produceren om hiermee een succesvol antibiotica therapie te 
verzekeren. De weerstand van Aminoglycoside resistentie in E. faecalis wordt geregeld door 
genen die diverse aminoglycoside-modificerende enzymen (AMEs) coderen, b.v. aac (6') - 
d.w.z. -d.w.z.-aph (2“) - Ia, aph (2“) - Ib, aph (2“) - Ic, en aph (2“)-Id. Deze AMEs wordt 
wijdverspreid in ziekenhuizen gevonden. Dit resulteert in bacteriële ziekteverwekkers die 
zeer resistent zijn tegen aminoglycosides, vooral met betrekking tot gentamicin resistentie in 
E. faecalis. E. faecalis verwerft daarnaast het transposon Tn4001 gemakkelijk, een 
transposon die codeert voor een bifunctional enzyme, 6’-acetyltransferase-2’- 
phosphotransferase, die door het gen aac6-aph2 wordt gecodeerd [72-74]. Verder, is er een 
associatie tussen de aanwezigheid van HLGR stammen en het gebruik van andere niet-
aminoglycoside antibiotica, zoals glycopeptides, cephalosporins, quinolones en carbapenems, 
nu goed gedocumenteerd [75-77]. 
In hoofdstuk 9, worden de resultaten getoond die uit de HLGR positieve E. faecalis 
isolaten werden verkregen, gekweekt in het Erasmus MC. De HLGR positieve E. faecalis 
stammen bleken allemaal bestand te zijn tegen ciprofloxacin en cefuroxime. Eerdere studies 
hebben gerapporteerd dat 2 klonale types (CC2 en CC9) en de enige ST16 type van E. 
faecalis kloon sterk geassocieerd worden met een hoge mate van gentamicin resistentie. Deze 
resistentie wordt voornamelijk gevonden in ziekenhuizen, waarbij onze studie vergelijkbare 
resultaten laat zien. Onze studie bevestigt daarmee de associatie van deze klonale stammen 
CC2/CC9 en ST16 genotypen in ziekenhuis infecties [78-80]. Van de belangrijkste ST types 
die in Erasmus MC circuleren, blijkt ST-2 vatbaar te zijn voor tetracycline, maar daarnaast 
resistent te zijn tegen levofloxacin en streptomycine. Terwijl ST6 resistent blijkt te zijn tegen 
tetracycline en levofloxacin, maar gevoelig is voor streptomycine. Verder blijken ST16 
isolaten vatbaar te zijn voor levofloxacin. Het onderzoek van resistentie en 
gevoeligheidsprofielen voor deze antibiotica in de bovengenoemde ST types is belangrijk, 
omdat deze antibiotica in de behandeling van E. faecalis essentieel zijn. Alhoewel alle HLGR 
isolaten die in het Erasmus MC worden geïsoleerd gevoelig blijken te zijn voor ampicilline, 
blijkt uit het recentste Nethmap- rapport van 2009 [81], betreffende het gebruik van 
antibiotica en resistentie onder medisch belangrijke bacteriën in Nederland, een toename te 
zijn van het aantal van β-lactamase positieve E. faecalis isolaten in de Nederlandse 
ziekenhuizen. Niettemin is dit bij het Erasmus MC nog niet het geval, om te voorkomen dat 
dit ook hier in de toekomst een probleem wordt, moet men dit goed in de gaten houden.  
Onderzoek heeft aangetoond dat de meerderheid van HLGR E. faecalis isolaten een 
plasmide bezitten die een transposon Tn4001 bevat [80, 82]. Casetta et a.l [83], vond dat 
Tn4001 wordt gestabiliseerd wanneer deze wordt opgenomen in het E. faecalis chromosoom, 
waarbij het verlies van flankerende sequenties van IS256 geassocieerd zijn met de 
aanwezigheid op plasmiden. Interessant, alle belangrijke HLGR E. faecalis ST types in onze 
studie, bezaten één of meer deleties van de flankerende Tn4001 IS256 sequenties. Dit kan er 
op wijzen dat plasmiden een belangrijke rol spelen in het verkrijgen van gentamicin 
resistentie binnen het Erasmus MC. Verder onderzoek is noodzakelijk om te bepalen of één 
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enkel plasmide type of meerdere plasmide types betrokken zijn in de transmissie van 
gentamicin resistentie tussen bacteriële soorten binnen Erasmus MC of in andere 
ziekenhuizen waar HLGR E. faecalis geïsoleerd worden. 
 
Conclusie en opmerkingen 
 
Antibiotica resistentie is een toenemende en voortdurende bedreiging voor zowel 
globale volksgezondheid als globale gezondheidszorgsystemen. Controle op antibiotica 
resistentie is daarom een belangrijke kwestie die voor de maatschappij van vandaag onder 
ogen moet worden gezien. Internationaal toezicht en epidemiologische studies tonen aan dat 
antibiotica resistentie een stijgende trend laat zien tegen de algemeen gebruikte antibiotica. 
Verder, betekent het feit dat de globalisering een hoge vlucht neemt, het belangrijk is om de 
internationale patronen van antibiotica resistentie te begrijpen en te volgen. Het internationale 
reizen draagt bij aan het feit dat antibiotica resistentie van micro-organismen steeds 
makkelijker wordt verkregen. 
Bovendien, is de selectieve druk sterk door het vele ongepaste en algemene gebruik 
van antibiotica. Dit is een ander belangrijke bijdrager aan het probleem van antibiotica 
resistentie en zou zowel op het nationale niveau (via de regeringswetgeving) en op het 
plaatselijke niveau (via de richtlijnen van het ziekenhuisvoorschrift) moeten worden 
aangepakt.  
Het ontstaan van verschillende „platforms“ die betrokken zijn bij het monitoren van 
antibiotica resistentie hebben duidelijk de doeltreffendheid van het antibiotica beleid 
aangetast. Een ander belangrijk aspect van antibiotica resistentie is het begrijpen van de 
mechanismen die betrokken zijn bij de verspreiding van resistentie op internationaal niveau. 
Dit kan via het opzetten van actieve toezichtprogramma's worden bewerkstelligd, aangezien 
de toezichtprogramma's belangrijke informatie kunnen verstrekken over de tendensen die er 
zijn in het ontstaan van antibiotica resistentie. Deze informatie zou kunnen worden gebruikt 
om toekomstige voorspellingen te kunnen doen over de verspreiding van antibiotica 
resistentie.  
Tot slot zouden de volgende stappen in het aanpakken van antibiotica resistentie 
uiterst nuttig zijn: 
• Een vermindering van het misbruik van antibiotica door standaard en strikte 
voorschriftpraktijken te ontwerpen en uit te voeren. 
•          Ontwikkeling van nieuwe antibiotica’s (10 x '20). [www.idsociety.org]. 
• Nieuwe antibiotica’s selectief gebruiken, d.w.z. slechts wanneer andere therapie geen 
effect meer heeft.  
• De ontwikkeling van snelle, goedkope, en nauwkeurige diagnostische methodes om 
snelle en nauwkeurige antibiotica therapie toe te staan. 
• De verbetering van scholing van burgers en gezondheidsmedewerkers t.a.v. 
antibiotica gebruik. 
• De verbetering van de hygiëne in ziekenhuizen en in de samenleving.  
• Een verbod op het niet-geneeskundige gebruik van antibiotica in de voedselindustrie 
en veehouderij 
• Een vermindering van antibiotica gebruik via alternatieve benaderingen, zoals 
vaccins, bacteriofagen, en Probiotica. 
•          Ontwikkeling van betere alternatieve methodes voor anti-infectie therapie om hiermee 
de chemotherapy te omzeilen, zodat resistentie voorkomen kan worden. 
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Op dit moment valt het te bezien of overheden, ziekenhuizen en individuen deze 
strategieën kunnen en willen toepassen. Slechts een gezamenlijke en internationale aanpak 
zal uiteindelijk alleen de verspreiding van antibiotica resistentie kunnen voorkomen. 
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